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Abstract 
Malaria is an infectious tropical disease which mostly affects the world’s poorest 
populations and causes above a half million deaths per year. Its eradication is yet an 
unmet goal, mostly, due to the emergence of parasite resistance to classical 
antimalarials and the lack of a commercially available malaria vaccine to prevent the 
disease. In this context, the doctoral project herein reported comprised two main 
research lines for malaria eradication. The first and major work of the project centered on 
the development of dual-action antimalarial drugs. The second research line was 
dedicated to the study of the influence of vaccination with RTS,S, the most clinically 
advanced malaria vaccine candidate, on the immune response of African children 
exposed to the disease. 
This doctoral project initially focused on the development of dual-action drugs potentially 
capable of inhibiting two processes related to the host’s hemoglobin degradation by the 
intraerythrocytic malaria parasite: i) globin degradation by parasite’s cysteine proteases, 
falcipains (FP), and ii) heme detoxification through hemozoin formation (H-f). First 
generation of compounds, HEDICINs, included a cinnamoyl moiety linked to the 4-
amino-7-chloroquinolyl group, the chloroquine (CQ) core, through a dipeptide chain. 
HEDICINs resulted active in the micromolar range (IC50 = 0.83-11 µM) against 
intraerythrocytic CQ-resistant strain W2 of Plasmodium falciparum (Pf), but such activity 
did not correlate with inhibition of FP or H-f. Removal of the hydrophobic dipeptide 
spacer or substitution of the chloroquinoline core by a non-aromatic ring was detrimental 
for the antiplasmodial activity. HEDICINs were further evaluated against another 
protozoal cysteine protease, babesipain-1 (bbspn-1) from Babesia bigemina, whose 
three-dimensional (3D) structure is yet unavailable. Hence, in silico studies were carried 
to build the corresponding 3D structure by homology modeling in order to evaluate the 
interaction of the HEDICINs with bbspn-1. For rationalizing in vitro data at the molecular 
level, a comparative analysis of the compounds’ behavior against FP and bbspn-1 was 
also performed as HEDICINs demonstrated to be more efficient inhibitors of bbspn-1. 
Second generation of compounds, HEFLECINs, were designed as HEDICINs analogues 
where the dipeptide spacer was replaced by a more flexible hydrophobic spacer, an alkyl 
chain. Compounds displayed activities in the nanomolar range (IC50 = 11.0-46.6 nM) 
better than CQ (IC50 = 138 nM), the reference drug against blood-stage Pf CQ-resistant 
strain W2. These compounds were also highly potent (IC50 = 1.1-4.1 µM) in vitro against 
liver-stage P. berghei malaria parasites, and superior to primaquine (IC50 = 7.5 µM), the 
reference drug against the latter stage, thus representing dual-stage antimalarial leads. 
Furthermore, CQ core was respectively replaced by others heteroaromatic core from 
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known antimalarials. Analysis of the structure-activity relationships demonstrated the 
relevance of i) the butyl chain, ii) the CQ core, and iii) the amide functionality, for optimal 
dual-stage antimalarial activity. Two HEFLECINs were further confirmed to be active in 
vivo against blood stage malaria in rodents. Moreover, HEFLECINs were evaluated in 
vitro against the promastigote and amastigote forms of Leishmania infantum, and 
consequently, established as promising anti-leishmanial agents. The mechanism of 
action of these second-generation compounds is yet to be elucidated, as their 
antiplasmodial activities did not correlate with the inhibition of H-f or FP. 
The second part of this doctoral project consisted in the measurement of the antibody 
responses to pre-erythrocytic and erythrocytic Pf antigens in African children vaccinated 
with RTS,S or control vaccine and naturally exposed to malaria, and subsequent 
analysis of the data. According to the results obtained, there seems to be a difference in 
IgG levels, between the RTS,S and vaccine control groups, that drops over time. The 
results of this study contribute to the understanding of a pre-erythrocytic malaria vaccine 
intervention in children. 
 
Keywords: Acridine, antimalarial, babesiosis, chloroquine, cinnamic acid, dual-action, 
leishmaniasis, malaria, Plasmodium, primaquine, vaccine, RTS,S. 
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Resumo 
A malária é uma doença infeciosa que afecta maioritariamente as populações mais 
pobres do mundo e causa mais de meio milhão de mortes por ano. Embora a malária já 
tenha sido erradicada em diversos países, a doença continua presente em cerca de cem 
países, principalmente devido ao aparecimento de estirpes do parasita resistentes aos 
antimaláricos clássicos e, à falta de uma vacina contra a malária comercialmente 
disponível. Neste contexto, o projeto de doutoramento aqui apresentado engloba duas 
linhas de investigação principais contribuindo para a erradicação da malária. O primeiro, 
e principal trabalho do projeto, centrou-se no desenvolvimento de antimaláricos de ação 
dual. O segundo trabalho de investigação dedicou-se ao estudo da influência da 
vacinação com RTS,S, o candidato a vacina da malária clinicamente mais avançado, na 
resposta imune de crianças africanas expostas à doença. 
A primeira parte do projeto iniciou-se com o desenvolvimento de fármacos 
potencialmente capazes de atuar contra dois processos intra-eritrocitários, relacionados 
com a degradação da hemoglobina do hospedeiro pelo parasita da malária: i) 
degradação de globlina pelas falcipaínas (FP), proteases de cisteína do parasita, e ii) 
desintoxicação do heme por formação de hemozoína (H-f). A primeira geração de 
compostos, HEDICINs, consistiu num grupo cinamoílo ligado ao grupo 4-amino-7-
cloroquinolinoílo, o núcleo da cloroquina (CQ), através de uma cadeia dipeptídica. Estes 
compostos resultaram ativos, no ordem do micromolar (IC50 = 0.83-11 µM), contra a 
estirpe resistente à CQ de Plasmodium falciparum (Pf) W2, mas não se verificou 
qualquer correlação entre a atividade antiplasmodial e a inibição de H-f ou FP. A 
remoção do espaçador dipeptídico ou a substituição do núcleo cloroquinolina por um 
anel não aromático demonstrou ser prejudicial à atividade antiplasmodial. 
Adicionalmente, os compostos HEDICINs foram avaliados contra a babesipaína-1 
(bbspn-1), uma protease de cisteína do protozoário Babesia bigemina, cuja estrutura 
tridimensional (3D) não está disponível. Assim, usaram-se técnicas de modelação por 
homologia para construir um modelo 3D da bbspn-1, a fim de avaliar a sua interação 
com os HEDICINs. Com o objetivo de se avançar com uma explicação a nível molecular 
dos resultados in vitro, comparou-se a interação dos compostos com a FP e bbspn-1, 
respectivamente, já que os HEDICINs mostraram ser inibidores mais eficazes da bbspn-
1. 
A segunda geração de compostos, HEFLECINs, corresponde a análogos dos 
HEDICINs, em que a cadeia dipeptídica foi substituída por um espaçador mais flexível e 
hidrofóbico, uma cadeia alquílica. Os compostos apresentaram atividade antiplasmodial 
contra a estirpe de Pf resistente à CQ, W2, na ordem do nanomolar (IC50 = 11.0-
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46.6 nM), atividades superiores às da CQ (IC50 = 138 nM), o farmáco de referência 
contra a fase sanguínea do parasita Pf. Adicionalmente, estes compostos revelaram-se 
mais ativos in vitro (IC50 = 1.1-4.1 µM), contra o parasita P. berghei da fase hepática da 
malária, quando comparados com a primaquina (IC50 = 7.5 µM), o farmáco de referência 
contra esta fase, demonstrando o potencial dos HEFLECINs como antimaláricos de 
ação dual. Posteriormente, substituiu-se o núcleo da CQ por outros núcleos 
heteroaromáticos de antimaláricos conhecidos e investigou-se a influência da natureza 
do espaçador. Este estudo de relação estrutura-atividade demonstrou a relevância i) da 
cadeia de butilica, ii) do núcleo da CQ, e iii) da funcionalidade amida para as ótimas 
atividades dos composto contra ambas fases da malária acima indicadas. Além disso, 
dois HEFLECINs foram confirmados ativos contra a infecção da malária na fase 
sanguínea em roedores. Os HEFLECINs foram ainda testados em culturas de 
promastigotas e amastigotas de Leishmania infantum, revelando-se agentes 
promissores contra da leishmaniose visceral. Uma vez que a atividade antiplasmodial 
dos HEFLECINs não se correlacionou com a inibição de H-F ou FP, o mecanismo de 
ação dos compostos permanece por elucidar. 
A segunda parte do projeto de doutoramento consistiu na medição da resposta de 
anticorpos a antígenos pré-eritrocitários e eritrocitários do Pf em crianças africanas 
vacinados com a vacina RTS,S ou controle e naturalmente expostos à malária, e 
subsequente análise dos dados. Com base nos resultados obtidos, observou-se uma 
diferença nos níveis de IgG, entre o grupo da vacina controle e do RTS,S, que diminui 
ao longo do tempo. Os resultados deste estudo contribuem para a compreensão da 
intervenção da vacinação pré-eritrocitária contra a malária em crianças. 
 
Palavras-chave: Ácido cinâmico, ação dual, acridina, antimalárico, babesiose, 
cloroquina, leishmaniose, malária, Plasmódio, primaquina, vacina, RTS,S. 	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Foreword 
Malaria is an infectious disease responsible for about a half million deaths every year, 
mostly affecting developing countries in tropical areas.1, 2 There are five species of the 
genus Plasmodium which cause malaria in humans, P. malarie, P. ovale, P. knowlesi, P. 
vivax, and P. falciparum (Pf).3 The latter is the most deadly species, mainly among 
children under five years of age, and is predominant in Africa. 
Malaria is transmitted by female Anopheles mosquitoes. Once an infected mosquito bites 
the human skin, it injects sporozoites which penetrate lymph nodes and capillaries (Fig. 
1). The sporozoites that enter the lymph nodes are believed to contribute to the immune 
response. On the other hand, the sporozoites which go into the capillaries travel to the 
liver, where they invade hepatocytes to form a schizont, inside which asexual 
reproduction takes place to produce thousands of merozoites. Subsequently, these 
merozoites are released into the blood stream to invade red blood cells (RBC) and there 
reproduce asexually into more merozoites. When the infected RBC collapse, released 
merozoites are ready to infect other blood cells, thus perpetuating the disease in the 
human host. Occasionally, some intraerythrocytic parasites differentiate into male and 
female gametocytes. The life cycle continues when a mosquito bites the infected human 
and ingests such gametocytes. The sexual reproduction begins within the mosquito gut 
to end with formation of sporozoites. These sporozoites migrate into the salivary glands 
of the mosquito that becomes able to infect other human hosts.4  	  
	  
Figure 1. Life cycle of malaria parasites in humans.(Retrieved from Hill Philos Trans R Soc Lond B Biol Sci 
2011)  
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The Malaria Global Plan from 2011 set the challenge of having, by the end of 2015, i) 
reduced by 75% malaria cases incidence compared to levels in 2000 ii) lowered malaria 
deaths proximate to zero, and iii) eliminated the disease in ten new countries taking into 
account the countries where malaria have been eradicated since 2008.1 Although there 
have been significant advances in malaria containment to meet this global target, such 
progress seems to have slowed down recently making it insufficient to meet worldwide 
needs in this area. Besides, in spite of the fact that the percent of households protected 
with insecticide-treated-net (ITN) and indoor residual spread (IRS) have increased,1 
parasite resistance to ITN continues to emerge. Additionally, concerns have been arisen 
regarding the use of bed nets, since by protecting infants from exposure to the malaria 
parasite, these vector control strategies might be impairing the respective acquirement of 
natural immunity and consequently, the burden of the disease might be shifting to older 
age children resulting in little or none long term benefit for vector control.6 In addition, 
though the number of diagnostic tests and treatments is increasing, millions of people 
continue to lack rapid diagnostics and efficient therapies against malaria.1 Furthermore, 
the malaria parasite has started to show resistance to artemisinins, the key components 
of artemisinin-combination therapies (ACT), which are the current first-line treatments 
against chloroquine (CQ)-resistant malaria. For instance, parasite resistance against 
artemisinins has already been detected in four countries of Southeast Asia.1 
Besides political, social, and economic factors which contribute to the malaria burden on 
the world,7 malaria eradication is yet an unmet goal due to three main reasons: i) lack of 
a large scale ecofriendly way to control the vector, and consequently prevent 
transmission of the disease, ii) widespread parasite resistance to classical antimalarial 
drugs and emerging resistance to current first-line ones, and iii) lack of an effective and 
commercially available antimalarial vaccine to prevent infection.7 Therefore, in order to 
reduce the malaria incidence and death rates, all these boundaries need to be 
eliminated.  
In this dissertation, the work focused on two of the main and complementary approaches 
towards malaria eradication, namely, malaria chemotherapy and prevention. The first 
and major work of the doctoral research, conducted in the area of malaria chemotherapy, 
centered on the development of economically affordable dual action antimalarials, drugs 
capable of acting against two different processes in the malaria life cycle to improve 
efficacy and hinder emergence of parasite resistance. In parallel, work carried in the area 
of malaria prevention contributed to the understanding of whether the low exposure to Pf 
blood stage antigens could influence the immune response of vaccinated children 
against malaria in the long term, by obtaining and partially analyzing the antibody (Ab) 
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response induced by the most clinically advanced pre-erythrocytic antimalarial vaccine, 
RTS,S.8 
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1.0. Introduction 
Nowadays, there are drugs targeting each stage of the malaria asexual reproduction 
cycle within the human host. Chloroquine (CQ, I) and artemisinin (II) both target the 
erythrocytic stage1-3 while primaquine (III) targets the liver stage parasite.4, 5 However, 
most malaria control strategies are in jeopardy due to the emergence of parasite 
resistance. Pf parasites have displayed widespread resistance to one of the safer and 
most affordable drugs, CQ.6, 7 Furthermore, there is growing evidence that Pf is 
developing resistance to the key compounds of the first-line antimalarial medicines for 
CQ-resistant malaria, the artemisinin-combination therapies (ACT), 8 despite the fact that 
ACT have been designed to improve efficacy and hinder emergence of resistance. 
Therefore, there is an increasing need to develop new effective and affordable 
antimalarials capable of delaying parasite resistance. 
 
 
 
The erythrocytic stage is one of the most relevant stages of the malaria life cycle since 
the symptoms of malaria appear in this stage. The symptoms include fever, chill, 
prostration, and anemia and in more severe cases, delirium, metabolic acidosis, cerebral 
malaria, and multi-organ system failure. Therefore, most antimalarial aim to target this 
stage of the malarial life cycle. In this stage, the host’s hemoglobin is endocytosed to the 
parasitophorous vacuole (PV) formed inside the infected RBC, and transported to the 
parasite’s food vacuole (FV) where it is degraded into amino acids required for the 
parasite growth and maturation.9 In addition, hemoglobin degradation 
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allows the modulation of the osmotic stability within the host cell.10 This degradation 
process is believed to occur in a semi-ordered pathway (Fig. 2), where aspartyl 
proteases make the initial cleavage of the hemoglobin. Namely, plasmepsins I (PlmI) and 
II (PlmII) catalyze this first step by breaking down hemoglobin between Phe33 and 
Leu34 of the α-chain to produce globin and free heme (Fig. 2).11 On one hand, globin is 
degraded into small peptide chains by cysteine proteases known as falcipains.12 Once 
falcipains have degraded globin into small peptides, these are following broken into 
oligopeptides of 5 to 10 amino acids by falcilysin.13 Subsequently, dipeptidyl 
aminopeptidase 1 (DPAP1) cleaves these oligopeptides into dipeptides.14 Finally, these 
dipeptides are transported outside the FV into the PV’s cytoplasm where they are 
degraded into amino acids by exopeptidases.15 A comprehensive review regarding 
recent advance towards the development of antimalarial inhibitors of the proteases, 
which participate in the hemoglobin degradation, has been recently published (See 
appendix A). 
 
 
Figure 2. Proteolytic semi-ordered pathway of hemoglobin degradation into amino acids. 
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On the other hand, heme is readily oxidized to ferriprotoporphyrin IX [Fe(III)PPIX]16 
which is toxic to the parasite. [Fe(III)PPIX] is known to cause lipid peroxidation and 
changes in membrane’s permeability.17 The oxidation of membrane components caused 
by free heme promotes cell lysis and subsequent death of the parasite,16 which can’t 
degrade [Fe(III)PPIX] as mammals do (using the enzyme oxygenase) because it lacks a 
mechanism to sequester the free Fe(III) generated.17 Therefore, the main detoxification 
process of [Fe(III)PPIX] involves formation of hemozoin (β-hematin), also known as the 
malaria pigment. Hemozoin is a dark insoluble biocrystal that contains solely monomers 
of [Fe(III)PPIX] and is released into the host RBC every time a parasite completes a 
cycle. Inhibition of hemozoin formation is one of the antimalarial strategies.18 
 
1.1. Targeting inhibition of globin degradation by falcipains 
Other potential target to impair the malaria parasite development constitutes inhibition of 
falcipains, which are one of the most studied families of Pf proteases.19 According to the 
analysis of the Pf genome, there are four cysteine proteases, falcipain 1 (FP1), falcipain 
2 (FP2), falcipain 2’ (FP2’), and falcipain 3 (FP3).20 FP1 has a low sequence identity 
compared to the other falcipains and its role in the malaria life cycle is yet to be 
elucidated. Still reported studies suggest that this protease might participate in the 
generation of oocysts during parasite development in the mosquito midgut.21 FP2, FP2’, 
and FP3 show high sequence identity. For instance, FP2 has been demonstrated to be 
93% similar to FP2’ which is thought to arise by gene duplication.22 FP2 and FP3 present 
a sequence identity of 68% and contribute more or less equally in the digestion of globin. 
In addition, FP2 and FP3 require acidic pH and reducing environment for optimal 
proteolytic activity. Although FP2 concentration in trophozoites is 1.8 times higher than 
that of FP3, the latter cleaves globin two times faster than FP2. Today there are several 
reports in the literature concerning the development of falcipain inhibitors.20 Inhibitors of 
falcipains can be generally classified in peptide-based inhibitors and non-peptidic 
inhibitors. Some of the most active compounds of each family are further below 
presented. The main catalytic residues of falcipains constituted Cys and His, whose side 
chains form an ion pair (thiolate/imidazolium) correctly orientated due to influence of a 
neighboring Asn residue. Molecules bearing electrophilic warheads are generally used to 
inhibit these enzymes because they form irreversible or reversible covalent bond with the 
active site cysteine. Examples of such warhead are α-ketoamide,23 fluoromethyl 
ketone,24 epoxysuccinyl25 or azirine derivatives,25 and the most used, Michael acceptors. 
The crystal structures of FP2 (PDB code = 3BPF) and FP3 (PDB code = 3BPM) reported 
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in complex with known inhibitors of cysteine proteases, such as E64 (IV) and leupeptin 
(V), have facilitated the design of new falcipains inhibitors.12 Accordingly, the 
substituents in the position P1, P2, and P3 of the ligands, E64 and leupeptin, 
respectively interact with residues in the S1, S2, and S3 sites of the active cavity of 
falcipains (Fig. 3). The S2 subsite seems to govern specificity towards FP2 and/or FP3, 
and to prefer substrates with a leucine residue in the corresponding P2 site. In addition, 
the catalytic residues of the FP2 and FP3, cysteines, form a covalent irreversible bond 
with the epoxide moiety of E64 and a covalent reversible bond with the carbonyl motif of 
leupeptin, respectively. 
 
	  
Figure 3. E-64 and leupeptin as inhibitors of falcipains. 
 
One of the most successful examples of the use of Michael acceptor is that of peptidyl-
vinyl sulfones which have to shown to inhibit FP2 in the nanomolar range.26 Inhibition of 
falcipains by such vinyl sulfones has been shown to correlate with the impairment of Pf 
development.19 These compounds include a dipeptide segment for better recognition by 
the parasite’s protease, whereas the vinyl sulfone moiety acts as a Michael acceptor to 
irreversibly alkylate the catalytic Cys residue of the protease (Fig. 4).27 
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Figure 4.  Example of irreversible alkylation of the cysteine residue of falcipains. 
Accordingly to Rosenthal’s studies, the Leucine-homoPhenylalanine (Leu-hPhe) 
dipeptide, has been demonstrated to confer the highest FP inhibitory activity of the 
respective vinyl sulfones. Further studies reported the structural activity relationship 
(SAR) of these and related cysteine inhibitors (Fig. 5).26 In these series, the potency of 
the compounds against FP2 and FP3, respectively, is not an ideal predictor of the 
antiplasmodial activity since SAR against falcipain does not completely correlated with 
the SAR found against the parasite development. For instance, vinyl sulfonamide and 
vinyl sulfonyl derivatives demonstrated to be more potent than vinyl sulfonate ester 
against the parasite, contrary to what was found against FP2. In addition, SAR regarding 
antiplasmodial activity showed that there is a clear preference for -OMe over -H over -F 
substitution in aromatic ring of the vinyl sulfonate esters, opposite to results found 
against falcipains. 
 
	  
Figure 5. Structure of vinyl sulfone inhibitors of FP2/3 developed by Rosenthal and co-workers.26 
 
In addition, other peptide-based inhibitors have been reported to reversibly bind to 
falcipains and inhibit FP2 and FP3 in the nanomolar level, for instance, compounds 
reported by O’Neill and co-workers.28 These compounds possessed the Leu-hPhe 
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dipeptide segment, as the best vinyl sulfone inhibitors reported by Rosenthal’s group, but 
did not include a Michael acceptor moiety; instead, an aldehyde moiety was used in the 
place of the vinyl sulfone warhead. Compounds (VII) and (VIII) displayed IC50 of 1.4 nM 
and 16.3 nM against FP2 and 198.9 nM and 214.6 nM against FP3, correspondingly. 
Also, these compounds (VII) and (VIII) did inhibit the CQ sensitive Pf strain 3D7 with IC50 
of 27.1 nM and 9.3 nM, respectively, and were found to fit well inside the enzyme’s 
active pocket according to docking studies. 
 
 
 
Apart from peptidyl irreversible and reversible inhibitors of FP, non-peptidic compounds, 
known to not be prone to proteolytic degradation, have also shown to inhibit FP in the 
nanomolar range, for instance, compounds reported by Fiandor’s team.29 The most 
potent inhibitors of the series were the 2-cyanopyrimidine derivatives including the 2-
cyano-5-chloropyrimidines and 2-cyano-5-bromopyrimidines. Although these compounds 
were nanomolar inhibitors of FP2 and FP3, they presented antiparasitic activity in the 
micromolar range. Furthermore, Fiandor and co-workers found that introduction of a 
protonable amine read to a significant increase in the antiplasmodial activity. For 
instance, one of the most active compound (IX), which contains a protonable amine, 
displayed an IC50 below 0.5 nM against FP2 and FP3 and an IC50 of 1 nM against the 
CQ-resistant parasite. 
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1.2. Targeting inhibition of hemozoin formation 
As mentioned above, hemozoin formation is a unique process adopted by Plasmodium 
parasites to detoxify free heme. It is a validated target for most of the well-known existing 
antimalarial drugs and considered to be suitable target to developed new antimalarials.30 
There are several families of compounds which impair parasite growth through inhibition 
of hemozoin formation (Fig. 6). The major families are quinolines (X), azoles (XI), 
isonitriles (XII), methylene blue (XIII), and xanthones (XIV).18 For instance, xanthone and 
derivatives inhibit hemozoin formation through the generation of a soluble complex with 
heme. Xanthones presenting a single hydroxyl group displayed IC50 > 50µM against Pf 
clone D6. However, xanthone with multiple hydroxyl substituents, especially on position 
4- and 5-, demonstrated to be more active (IC50 = 0.1-40 µM) against Pf D6.31 In fact, the 
antimalarial activity demonstrated to be positively correlated with the number of hydroxyl 
groups on the compounds. In terms of inhibition of hemozoin formation, xanthones with 
hydroxyl groups in positions 4- and 5- showed the highest activity of the series. Further 
reports in the literature showed that xanthones with an N,N-diethylaminoalkyl side chain 
of 5 or 6 carbons presented significantly higher antimalarial activity against Pf strain D6 
(IC50 = 70-100 nM) exhibiting strong heme affinity. 
 
	  
Figure 6. Known inhibitors of hemozoin formation: amodiaquine (X), clotrimazole (XI), diterpene isonitriles 
derivative (XII), methylene blue (XIII), and xanthone derivative (XIV),against CQ-sensitive Pf. 
 
Other major family of compounds whose SAR against hemozoin formation has been well 
established constitute quinolines and derivatives such as amodiaquine (X) and the 
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widely used CQ. CQ prevents hemozoin growth by capping the growth of the biocrystal, 
thus leading to accumulation of free heme to levels that cause parasite death (Fig. 7).32, 
33 The chlorine atom in position seven of the quinoline ring in CQ has been found 
essential for the drug’s activity against hemozoin formation (Fig. 8).34, 35 In terms of 
optimal antiparasitic activity of antimalarial 4-aminoquinolines, like CQ, i) a halogen in 
position seven (-Cl, -Br, or -I but not -F), ii) a protonable amine at position 1 of the 
quinoline ring, and iii) a dialkylaminoalkylamino side chain are all key structural 
features.36 In addition, a dialkylaminoalkylamino side chain of 2 to 12 carbons leads to 
low nanomolar activities against the CQ-sensitive Pf strain. Moreover, it has been show 
that the protonable amine at position 1 of the quinoline ring and the terminal amine in the 
dialkylaminoalkylamino side chain are important for the accumulation of the compounds 
in the food vacuole and consequent inhibition of its target.37 
 
	  
Figure 7. CQ-heme complex incorporate in the forming biocrystal and inhibits hemozoin formation.32 
 
 
	  
Figure 8. Main characteristics of CQ for the optimal inhibition of hemozoin formation.38 
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Additionally, CQ can accumulate in the FV and subsequently inhibit its target because it 
is a weak base that can diffuse through the parasite’s membrane. Once the drug is 
inside the FV, it is protonated and consequently, trapped in the acidic FV (pH trapping), 
which promotes the inhibition of hemozoin. However, the excessive use of CQ due to its 
high efficacy, low cost, and limited host toxicity led to a gradual decline of the parasite 
sensitivity to this drug,39 despite it aims at a non-proteic (i.e., non-genetically coded) 
target. It has been found that CQ concentrates substantially less in the FV of CQ-
resistant Pf strains. It is widely believed that this lower accumulation is due to a mutant 
transmembrane protein, PfCRT, which promotes CQ efflux from the parasite’s FV, where 
the drug should exert its action.40 
In view of the wide spread parasite resistance to CQ, especially in Africa, nowadays the 
first line of antimalarial treatment for CQ-resistance malaria is based on ACT, where the 
potent artemisinins are combined with other antimalarial to hinder the parasite resistance 
usually associated to monotherapy. However, there has been growing evidence of 
decreasing sensitivity of plasmodial to ACT. Malaria parasite has started to show 
resistance to other antimalarials such as artemisinins, the basis compounds of ACT.41 
New approaches to delay parasite emergence resistance consist on the development of 
dual-action drugs, compounds capable of acting against two processes in the Pf malaria 
life cycle. Hybrid compounds have displayed potent antimalarial activity and no toxicity.42 
Based on their high efficacy and low toxicity, dual-action drugs may constitute the next 
generation of antimalarials.42 
 
1.3. The covalent bitherapy approach against Pf malaria  
The covalent bitherapy approach against malaria refers to the development of hybrid 
drugs that covalently link two antimalarial moieties acting against different processes 
which are essential for parasite survival.43 One of the advantages of hybrid drugs, as 
opposed to multicomponent ones, is that they might diminish the risk of drug-drug 
adverse interactions. An example of hybrid antimalarials is that of trioxaquines, reported 
by Meunier and co-workers, which combine a trioxolane moiety (mimic of the 
artemisinin’s active core) with the CQ’s 4-amino-7-chloroquinoline core.44 The most 
promising trioxaquine (XV) of the series was synthesized from two precursors: i) 4-(N-
aminoethyl)amino-7-chloroquinoline obtained from nucleophilic substitution of ethane-
1,2-diamine on 4,7-dichloroquinoline, and ii) a trioxane-ketone synthesized from α-
terpinene, through photo-oxygenation and subsequent condensation with cyclohexane-
1,4-dione (Scheme 1).45 Trioxaquine (XV) was active in the nanomolar range against the 
asexual intraerythrocytic stage (IC50 = 28 nM) and young (IC50 = 69 nM) or old 
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gametocytes (IC50 = 67 nM) with activities comparable to those presented by the 
respective reference drugs of each tested stage, atovaquone on asexual 
intraerythrocytic forms (IC50 = 4.6 nM), and artesunate that targets both young (IC50 = 72 
nM) and old gametocytes (IC50 = 108 nM). 
	  
Scheme 1. Synthetic route towards trioxaquine (XV), a promising antimalarial built on the covalent bitherapy 
concept.44, 45 
 
In the same year, Bell and co-workers reported a hybrid molecule (XVI) where 
artemisinin was combined with the emblematic antimalarial drug quinine.46 Accordingly, 
artemisinin was reduced to dihydroartemisinin and the vinyl functionality of quinine was 
modified into a carboxylic moiety, so that the two cores were linked to each other through 
an ester bond (Scheme 2). Other functionalities of the respective building blocks could 
not be altered without sacrificing activity. For instance, the potent blood-schizontocidal 
activity of quinine depends on both the quinoline ring and the hydroxyl group. The 
artemisinin-quinine hybrid (XVI) was more active against Pf 3D7 (IC50 = 10.4 nM) than 
artemisinin (IC50 = 45.3 nM), quinine (IC50 = 73.5 nM), or an equimolar mixture of both 
drugs (IC50 = 27.9 nM). 
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Scheme 2. Synthesis route to an antimalarial artemisinin-quinine hybrid (XVI) developed by Bell and co-
workers.46 
 
Other examples of hybrid molecules, which include the artemisinin core, are those 
reported by Capela’s and co-workers.47, 48 In the hope to develop a multi-stage drug 
which did not only target the Pf in the RBC but also the replicative and dormant form in 
the liver stage of the malaria cycle, they decided to join together the ART core and the 
PQ.46 The two synthesized compounds (XVIIa) and (XVIIb) displayed in vitro activities 
against the liver and blood stage comparable to the reference drugs, PQ and ART, 
respectively. Compound (XVIIb) was more active against blood stage (IC50 = 9.1 nM) 
than compound (XVIIa) (IC50 = 12.5 nM). In the liver stage, compound (XVIIa) showed to 
be the most active in vivo, while when testing against blood stage parasite, compound 
(XVIIb) displayed the highest activity in vivo; both results were in agreement with the in 
vitro data. 
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In addition, Capela and co-workers designed and synthesized hybrid compounds (XVIII) 
which join together the vinyl sulfones, previously demonstrated by Rosenthal to be 
potent inhibitor of falcipains,26 to the artemisinin core using a 4-hydroxymethylbenzoic 
acid as a linker. These derivatives displayed activities comparable to those of the 
artemisinin. The synthesis pathway consisted in multiple reaction steps. First, it involved 
the formation of an aldehyde moiety from the respective Boc protected amino acid using 
Weinreb chemistry followed by the Horner–Wadsworth–Emmons reaction. Later, the Boc 
protecting group was removed and the obtained amine was coupled to a second Boc 
protected amino acid to result the dipeptidyl vinyl sulfone. Finally, the corresponding 
amine was deprotected and coupled to the previously obtained artemisinin/4-
hydroxymethylbenzoic acid derivative (Scheme 3). The compounds were evaluated as 
inhibitors of the activity of CQ sensitive malaria parasite and falcipains action. Although 
hybrid compounds displayed activity in the nanomolar range against the parasite, they 
showed to be active only in the micromolar range against FP2 (IC50 = 0.35-16.5 µM), 
suggesting that the main mechanism of action of these derivatives was due to the 
endoperoxide form of the artemisinin core. The most active compound (XVIIIa) of the 
synthesized series against FP2 possessed the dipeptide Leu-hPhe which is in 
agreement with results previously found by Rosenthal’s team.26 
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Scheme 3. a) Synthesis of the vinyl sulfone precursor. b) General synthesis of the hybrid molecules 
designed by Moreira and co-workers. Hybrid molecule  (XVIIIa) is the most active compound against FP2 
that is also active against the parasite.47 
 
O’Neill and co-workers applied a similar concept,28 by synthesizing a series of 
compounds where an endoperoxide was linked to a morpholine urea (Mu-Urea) or to a 
benzyloxycarbonyl protecting group (Cbz) through the dipeptide linker Leu-hPhe. The 
resulting hybrids would expectedly disrupt parasite development through two processes: 
falcipain inhibition and generation of cytotoxic C-radical species. Both the falcipain 
inhibiting moiety and the C-radical species would be released upon hybrid compound 
degradation catalyzed by Fe(II) (Scheme 4). The most active compounds against CQ-
sensitive Pf strain, (XIXa) and (XIXb) with IC50 = 55.5 nM and 35.3 nM, correspondingly, 
were also active against FP2 (IC50 = 425.3 and 510.2 nM for (XIXa) and (XIXb), 
respectively) and FP3 (IC50 = 947 and 332.3 nM, respectively). 
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Scheme 4. a) Most active endoperoxide hybrids ((XIXa) and (XIXb)) reported by O’Neill and co-workers, and 
b) expected mechanism of hybrid degradation by Fe(II).28 
 
Compounds targeting inhibition of both falcipains and hemozoin formation have also 
been reported. For instance, Chibale and co-workers found 4-amino-7-chloroquinoline 
derivatives (XX) containing the isatin scaffold to present activity against three Pf strains, 
CQ-sensitive D10 (IC50 = 0.079−1.33 µM), and CQ-resistant K1 (IC50 = 0.054−1.51 µM) 
and W2 (IC50 = 0.051−1.23 µM) (Fig. 9).49 Also, the compounds displayed activity against 
falcipains in the micromolar range (IC50 > 6.07 µM) though there was no evidence of 
swollen FV in intraerythrocytic parasites, which is a morphological trait of FP inhibition. 
The isatin and the 4-amino-7-chloroquinoline cores were linked through a morpholine or 
alkyl chain, and the isatin core to a ketone or to a thiosemicarbazone warhead meant to 
alkylate the FP catalytic cysteine. Removal of the quinoline moiety resulted in significant 
loss of activity against all Pf strains tested. The most active compounds were those with 
an ethylene spacer between the quinoline and the isatin cores (XX) with a preference for 
a methyl group on the isatin ring’s C-5 (R1). 
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Figure 9. Most active 4-amino-7-chloroquine – isatin conjugates reported by Chibale and co-workers in 
2005.49 
 
Later on, Chibale’s research team reported a series of inhibitors which also included the 
4-amino-7-chloroquinoline core.50 The derivatives were synthesized through multiple 
reaction steps starting from 4,7-dichloroquinoline (Scheme 5). The compounds were 
designed to inhibit FP2 while including the quinoline moiety to promote accumulation of 
the drug in the parasite’s FV. Generally, derivatives lacking the 4-amino-7-
chloroquinoline core showed lower antimalarial activity. In addition, the most active 
compound (XXI) displayed activity against FP2 (IC50 = 3.16 µM) that did not correlate 
with the corresponding activity against Pf CQ-resistant strain W2 (IC50 = 77 nM), 
suggesting that other mechanism(s) could be responsible for the antiplasmodial activity 
of this compound. 
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Scheme 5. a) Synthetic pathway developed by Chibale and co-workers in 2007.50 b) Most active compound 
of the synthesized series. 
 
Following, the same group reported a series of γ- and δ-lactams linked to 4-amino-7-
chloroquinoline through an alkyl chain (XXII) .51 The synthetic pathway involved, first, the 
nucleophilic substitution on 4,7-dichloroquinoline with the relevant alkanediamine. 
Posteriorly, the resulted 4-(N-aminoalkyl)amino-7-chloroquinoline was reacted with 
levulinic acid or 4-acetylbutyric acid and the relevant isocyanide, through a one-pot Ugi 
reaction (Scheme 6). The most active compound (XXIIa) displayed activity in the 
nanomolar range against Pf CQ-resistant W2 strain (IC50 = 96 nM) that did not correlate 
with its ability to inhibit FP2 action (IC50 = 17.6 µM). The lack of correlation between 
antiplasmodial and FP-inhibitory activity and the fact that the compounds presented 
lower IC50 compared to CQ (IC50 = 240 nM) may suggest that these molecules might be 
eluding efflux from the FV. 
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Scheme 6. One-pot Ugi reaction in methanol at room temperature (rt) carried out by Chibale and co-
workers.51 
 
Furthermore, Chibale’s team synthesized a new series of compounds (XXIII) that joined 
chloroquinoline to chalcone through a triazole linker aiming at inhibition of both hemozoin 
formation and FP2 action.52, 53 The synthesis pathway globally involved the previous 
obtainment of suitable precursors, namely, chalcones and 4-azido-7-chloroquinoline, 
followed by an azide-alkyne coupling (Huisgen’s cycloaddition) to yield 1,2,3-triazoles 
(Scheme 7). The most active compound of series (XXIIIa) presented activity (IC50 = 40 
nM) comparable to CQ (IC50 = 17 nM) against the Pf W2 strain. Although the compounds 
showed to inhibit hemozoin formation as CQ did, they only displayed activity in the 
micromolar range against FP2, suggesting that the main mechanism of these series was 
inhibition of hemozoin formation. 
 
	  
Scheme 7. Synthethic pathway developed by Chibale’s team in 2010.53 
 
More recently, Gomes and co-workers developed potential dual-action antimalarials 
(XXIV), expectedly able to also inhibit hemozoin formation and falcipain activity. These 
compounds included the 4-amino-7-chloroquinoline core, meant to impair hemozoin 
formation, linked to an α,β-unsaturated carbonyl moiety expected to act as a Michael
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acceptor, and thus alkylate the catalytic Cys in falcipains.54 The authors believed those 
two moieties should be linked through the Leu-hPhe dipeptide, previously described by 
Rosenthal to enhance inhibitor recognition by falcipains. However, in order to prevent 
premature proteolytic degradation of the dipeptide spacer, the authors used the 
corresponding retro-inverso dipeptide, using the respective D-amino acids (Fig. 10).55, 56 
 
	  
Figure 10. General structure of hybrid compounds (XXIV) designed by Gomes’s team.54 Most promising 
compound (XXIVa) synthesized. 
 
Gomes’s team chose cinnamic acid derivatives motivated by cinnamic acid potential 
ability to act as inhibitor of enzyme catalytic Cys residues,57 due to the α,β-unsaturated 
carbonyl moiety, and by previous reports on the antimalarial properties of cinnamoyl 
derivatives.58-60 One such report, by Schlitzer and co-workers, suggested that the use of 
4-alkoxy-substituted cinnamic acids improved the antiplasmodial activity of identified 
antimalarial leads (Fig. 11).58 Specifically, replacement of the 3-phenylpropionyl moiety 
of the lead structure (XXV) by a 4-propoxycinnamoyl functionality (XXVI) resulted in 
higher activity (IC50 (XXV)= 2.7 µM vs IC50 (XXVI) = 0.20 µM) against the CQ-resistance 
Pf strain Dd2. In addition, they also demonstrated that substitution of the 3-
phenylpropionyl moiety by the 4-phenylcinnamoyl functionality (XXVII) led to significantly 
lower cytotoxicity (IC50 (XXV) < 36.9 µM vs IC50 (XXVII) >180 µM against HeLa) and 5-
fold increase on activity (IC50 (XXV) = 2.7 µM vs IC50 (XXVII) = 0.65 µM) against Pf 
Dd2.59 
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Figure 11. Cinnamic acid derivatives found by Schlitzer research team.58, 59 
 
Gomes et al’s in vitro results demonstrated two of the synthesized derivatives to be 
active in the micromolar range, with the best compound (XXIVa) displaying an IC50 of 1.4 
µM against Pf strain W2. Although the approach showed promising results, further 
studies were required to improve the antimalarial activity of these cinnamic derivatives. 
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2.0. Preamble 
Research work within the area of malaria chemotherapy of the present dissertation 
followed preliminary efforts in the research group towards development of dual-action 
antimalarials (c.f. Fig. 10 in chapter 1) and was supervised by Prof. Paula A. C. Gomes, 
from CIQUP - Departamento de Química e Bioquímica da Faculdade de Ciências da 
Universidade do Porto, in Portugal (DQB-FCUP), and co-supervised by Dr. Cátia A. S. 
Teixeira, from CICECO - Departamento de Química da Universidade de Aveiro, also in 
Portugal.  
The doctoral research work started by the synthesis and evaluation of compounds 
expectedly capable of targeting two essential processes for the malaria parasite survival, 
namely, heme detoxification and globin digestion. Such compounds, called HEDICINs 
(Fig. 12), contained a HEteroaromatic core from a well-known antimalarial (known to 
inhibit hemozoin formation), a DIpeptide spacer (known to promote binding to falcipains), 
and a CINnamoyl group (meant to act as a Michael acceptor by alkylating the catalytic 
cysteine residue of falcipains). D-amino acids instead of L-amino acids were used in the 
dipeptide spacer, in order to prevent premature proteolytic degradation.1, 2 A second 
family lacking the dipeptide spacer, called HECINs (HEteroaromatic-CINnamoyl 
conjugates), was also synthesized and included in the study, to assess the effect of such 
spacer in the compounds’ bioactivity. 
 
	  
Figure 12. General structure of HEDICINs, the first generation of compounds studied in this dissertation. 
 
The doctoral candidate was in charge of the chemical synthesis of the compounds and 
their evaluation as inhibitors of hemozoin or β-hematin (β-H) formation, whereas in vitro 
assessment of their inhibitory activity against both falcipains and development of blood-
stage Pf parasites was carried out by Prof Philip J. Rosenthal’s team at the School of 
Medicine of the University of California – San Francisco, in the United States of America. 
The experimental research work was developed alongside an in silico study against 
falcipains carried out by the thesis co-supervisor, Dr. Cátia Teixeira. 
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2.1. HE[DI]CINs 
HEDICINs were designed according to general structure 1 using 4-amino-7-quinoline as 
the core responsible for inhibition of hemozoin formation, linked to a cinnamoyl moiety as 
the electrophilic warhead eventually able to irreversibly inhibit falcipains, through the 
dipeptide chain. As compared to cinnamoylated derivatives previously synthesized in the 
research group which used D-Leu-D-hPhe as a spacer, HEDICINs included the D-
hPhe−D-Leu as the dipeptide chain instead, since in silico studies in the group have 
suggested that the latter dipeptide chain would allow a better fit into falcipains active site 
and place the α,β-unsaturated system closer to the enzyme’s catalytic cysteine (Fig. 13). 
Moreover, HECINs 2, analogs lacking the dipeptide spacer, were also synthesized to 
assess the relevance of this spacer on compounds’ ability to inhibit both falcipains and 
development of intraerythrocytic Plasmodia in vitro. 
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Figure 13. Structure of HEDICIN in complex with FP2 . 	  
2.1.1. Synthesis of HEDICINs and HECINs 	  
a) HEDICINs 
The synthetic procedure followed to obtain HEDICINs 1 comprised a nucleophilic 
aromatic substitution (SNAr) on 4,7-dichloroquinoline using ammonia in the presence of 
phenol, and subsequent stepwise condensation of the Nα-tert-butoxycarbonyl-protected 
amino acids (Boc-AA-OH) and removal of the Nα-Boc protecting group and finally, 
condensation of the cinnamic acid (Scheme 8). The first SNAr reaction step was a 
straightforward procedure already reported in the literature,3 thus 4-amino-7-
chloroquinoline 2 was easily obtained in good yields (89%). The following coupling 
reactions involved a prior activation of the relevant carboxylic acid with O-(benzotriazol-
1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or benzotriazolyloxy-
tris[pyrrolidino]-phosphonium hexafluorophosphate (PyBOP) in either dichloromethane 
(DCM) or N,N-dimethylformamide (DMF), and in the presence of N-ethyl-N,N-
diisopropylamine (DIEA). These steps resulted in moderate to good yields (40-78%), 
except for the coupling of i) 3 to Boc-D-hPhe-OH (% yield = 35 %), ii) 7 to p-
nitrocinnamic acid (% yield = 17), and iii) 7 to p-(N-tert-butoxycarbonyl)aminocinnamic 
acid (% yield = 13). In regard to Boc removal steps, these were carried out by treatment 
of Boc-protected compounds (4 and 6) with neat trifluoroacetic acid (TFA) at room 
temperature (2 h), and the desired products were obtained in quantitative yield. 
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Scheme 8. Synthesis pathway to obtain HEDICINs 1. 
 
The yield-limiting step in the synthesis pathway to HEDICINs was the coupling of 3 to 
Boc-D-hPhe-OH, probably because of the low nucleophilicity of the amino group in 3. In 
fact, the nitrogen atom at position 1 of 4-amino-7-chloroquinoline 3 withdraws electron 
density from the amino substituent at position 4, making the latter less prone to attack an 
electrophile. Hence, looking for the appropriate reaction conditions to improve yield, 
highly efficient in situ amide coupling reagent were used as: PyBOP, ethyl 
cyano(hydroxyimino)acetato-O2]tri-1-pyrrolidinylphosphonium hexafluorophosphate 
(PyOXIM), (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-
carbenium hexafluorophosphate (COMU), 6-chloro-benzotriazole-1-yloxy-tris-
pyrrolidinophosphonium hexafluorophosphate (PyClock), bromo-tris-pyrrolidino 
phosphonium hexafluorophosphate (PyBrop), and (7-azabenzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) (Fig. 14), still the highest 
yield obtained was 35% (Table 1). The coupling reagent that resulted the best yield in 
this step was TBTU.4 This was an unexpected observation, since PyAOP has been 
described to significantly improve coupling yields when using poor nucleophiles and 
hindered amino acids.4, 5 In addition, increasing the temperature of the reaction up to 50 
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oC and the amount of DIEA base up to 3.3 molar equivalents (eq), even risking the 
possibility of racemization of the desired product,6 did not increase the yield achieved in 
the reaction step. 
 
	  	  
Figure 14. Coupling reagents used to promote in situ coupling of 3 with Boc-hPhe-OH. 
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Table 1. Reaction conditions for the coupling of Boc-D-hPhe-OH to obtain 4. 
Coupling 
Reagent 
DIEA Day(s) 
Temperature 
(oC) 
Solvent % Yield 
PyBOP 
2.2 2 rt 
DMF:DMSO 
(1:1) 
8 
2.2 2 50 6 
3.3 2 50 9 
2.2 2 rt 
DCM + 
Drops of 
DMF 
21 
2.2 1 rt 22 
2.2 1 rt DMF 7 
 COMU 2.2 2 rt DMF 14 
PyOXIM 2.2 2 rt DMF 14 
PyBrop 2.2 
2 rt DMF 29 
3 rt DMF 31 
PyClock 2.2 2 rt DMF 8 
PyAOP 2.2 2 rt DMF 20 
TBTU 2 1 rt DMF 35 
 
Table 1 also shows that when increasing temperature or reaction time, no significant 
difference was observed among the yields obtained. However, a decrease of the amount 
of DMF used as a solvent when using PyBOP as a coupling reagent led to approximately 
two-fold yield increment. This could suggest that the DMF used to synthesize the desired 
compounds possessed water, which could be solvating the nucleophile, and impeding its 
subsequent reaction with the corresponding activated cinnamic acid. 
Moreover, in order to evaluate the influence of the configuration of the amino acid in the 
bioactivity of HEDICINs, an additional HEDICIN (1a’) was synthesized using L-amino 
acids instead of D-amino acids following the synthetic procedure presented in scheme 8. 
Furthermore, to evaluate the effect of chloroquinoline ring on the antiplasmodial activity 
of the compounds, cinnamoylated derivative 8 was also synthesized. Compound 8 was 
obtained following similar procedure to that used for HEDICINs but using as a starting 
material morpholine instead of 4-amino-7-chloroquinoline (Scheme 9). As expected the 
coupling of h-Phe was carried in good yields which confirmed that in the synthetic 
pathway of HEDICINs 1, the coupling of Boc-D-hPhe-OH to obtain compound 4 is limited 
by the poor nucleophilicity of 4-amino-7-choloroquinoline 3. Morpholine was selected 
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based on the structure of the vinyl sulfone reported by Rosenthal’s team and its 
flexibility. The latter could promote a better fit of the ligand into falcipain catalytic site 
although the inhibition of hemozoin formation would be disregarded.  
 
	  
Scheme 9.  Synthetic pathway to obtain morpholine derivative 8. 	  	  
b) HECINs 
In parallel to the synthesis of HEDICINs, HECINs 2a-k were obtained by coupling 
different cinnamic acids, or the respective acyl chlorides, to compound 3 (Scheme 10), 
previously obtained by ammonolysis of 4,7-dichloroquinoline. Initially, PyBOP was used 
as the coupling reagent to couple the respective cinnamic acids. However, the latter 
reaction conditions led to low yields, which encouraged us to try different reaction 
conditions to improve the yields obtained. In this context, the respective acyl chloride, 
when available, and K2CO3 and 18-crown-6 (catalytic amounts) were used to obtain the 
desired HECINs. Accordingly, this reaction conditions provided better results. For 
instance, in the case of the p-metoxy cinnamoyl derivative 2d, when using PyBOP as 
coupling reagents and DMF as solvent, the desired product 2d was obtained with 1% 
yield. However, when using trans-4-methoxycinnamoyl chloride, the desired
product was achieved with an 18% yield (Table 2); a significant increase that facilitates 
the characterization of the desired compound 2d. Additional experimental procedures 
carried out to improve the yields obtained for HECINs demonstrated that, when using
PyBOP as a coupling reagent with DCM and some drops of DMF instead of exclusively 
DMF as a solvent, the yields increased but not higher than 20% which is in agreement 
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with results obtained for HEDICINs when coupling compound 3 to Boc-D-hPhe-OH and 
using the same reaction conditions. 
 
	  
Scheme 10. Synthesis pathways to obtain HECINs. 
 
Table 2. Amide bond formation for HECINs. 
 
X= -Cl, -OH 
Reaction conditions 
PyBOP, DIEA, DMF, rt 
Respective cinnamic 
acid 
K2CO3, 18-Crown-6, 
THF, rt 
% Yield % Yield 
R= H 3 18 
R= -OMe 1 18 
R= -NO2 Not Obtained 5 
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2.1.2. Characterization of HEDICINs and HECINs 
All HEDICINs 1a’, 1a-l, and 8 and HECINs 2a-k were characterized by electrospray 
ionization-ion trap mass spectrometry (ESI-IT MS) as well as by proton (1H-) and carbon 
(13C-) nuclear magnetic resonance (NMR) and high-performance liquid chromatography 
(HPLC). Results were in agreement with the desired structures and are provided in the 
experimental section at the end of this chapter. The HPLC results displayed a peak for 
the relevant sample with a percent of purity that allow further in vitro evaluation. In 
addition, the characteristic signals of the corresponding samples in the ESI-IT MS and 
NMR were observed. As an example for HEDICINs, the relevant NMR and MS spectra of 
the p-methoxycinnamic acid derivative 1d is provided in figures 15−17. 
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Figure 15. 1H-NMR (400 MHz, DMSO-d6) of HEDICIN 1d above 6 ppm (Upper corner) and below 5 ppm 
(bottom corner). 
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Figure 16. 13C-NMR (100 MHz, DMSO-d6) spectrum of the HEDICIN 1d. 
 
 
	  
Figure 17. ES-IT MS of HEDICINs 1d. 
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Fig. 15 shows the protons downfield and upfield in the 1H-NMR spectrum of 1d. The 
downfield region displays the vinyl protons of the α,β-unsaturated carbonyl moiety, the 
proton of the Cα at 6.63 ppm and the proton of the Cβ at 7.38 ppm with coupling 
constant J = 16 Hz which is characteristic of trans-vicinal vinyl protons. Also, the 1H-
NMR spectrum displays the signal of the amide bond attached to the quinoline ring at 
10.34 ppm. In the upfield region (Fig. 15), the 1H-NMR spectrum shows the multiplets of 
the protons of the Cα to the amide functionalities, respectively, at 4.70 ppm and 4.56 
ppm. The singlet at 3.79 ppm represents the three deshielded protons of the methoxy 
substituent in the molecule. In addition, the six shielded protons of the methyl group of 
the leucine isobutyl side chain are also observed. In fig. 16, the 13C-NMR spectrum 
displayed the signals in agreement with the structure of compound 1d, for instance, the 
deshielded signals of the carbonyl groups above 166 ppm and the signal of the methoxy 
group at 55.2 ppm. Please refer to the experimental section of this chapter for a more 
detailed analysis of the spectra of HE[DI]CINs. Moreover, the mass spectrum (Fig. 17) 
shows an intense peak at 613.73 ppm which corresponds to the quasi-molecular ion of 
1d. 
Spectroscopy data of HECINs also correspond with the desired compounds. For 
example, for HECIN 2d, in the upfield region, apart from the respective signal of DMSO 
and water, the signal of protons of the methoxy substituent in the cinnamoyl moiety at 
3.82 ppm (Fig. 18) is displayed. The 1H-NMR spectrum also displays a singlet at 10.34 
ppm that corresponds to the proton of the amide bond and a doublet with a small 
coupling constant of 2 Hz at 8.05 ppm that belongs to the proton of the carbon at position 
8 of the quinoline ring. In addition, a doublet with a coupling constant of 15.6 Hz at 7.12 
ppm was observed, which agrees with the proton of the Cα of α,β-unsaturated carbonyl. 
In fig. 18, the 13C-NMR spectrum displays the number of signal in agreement with the 
desired compounds 2d, for instance, the upfield region shows one signal which 
represents the methoxy group at 55.3 ppm and 16 signals in the downfield region, from 
111 ppm to 165.1 ppm. The most deshielded signal of the spectrum (δC = 165.1 ppm) 
belongs to the carbonyl. In addition, the mass spectrum (Fig. 19) displays the peak 
corresponding to the quasi-molecular ion of 2d at 339.33 and also the corresponding 
dimer at 676.93. 
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Figure 18. 1H-NMR (400 MHz, DMSO-d6) spectrum of HECIN 2d (Top corner) and 13C-NMR (100 MHz, 
DMSO-d6) spectrum of HECIN 2d (Bottom corner). 
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Figure 19. ES-IT MS of HECIN 2d. 
 
2.1.3. Assessment of cinnamoylated derivatives 
Once all cinnamoylated derivatives were synthesized and characterized, they were 
tested in vitro against, β-H formation, falcipain action, and blood stage parasite. The 
ability of the cinnamoylated/quinoline derivatives to inhibit β-H formation was assessed 
following reported procedure.7, 8 Assays to evaluate compounds’ ability to inhibit 
falcipains action and antiplasmodial activity were carried by Rosenthal’s team following 
methodology already described in the literature.9-11 In addition, in silico studies were 
carried out by Dr. Cátia Teixeira. Results are presented in table 3. 
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Table 3. In vitro data of HEDICINs (1 and 8) and HECINs (2). included. 
 
Compound R β-H Inhibition[a] 
IC50 Pf W2[b] 
(µM) 
IC50 FP2[c] 
(µM) 
IC50 FP3 
(µM) logP
[d] 
1a H - 4.89 ±  1.01 19.6 ± 0.4 >50 6.6 
1a’[e] H ND[f] ~8.00 50.0 ND 6.6 
1b p-Me ++ 1.96 ± 0.09 >50 ND 7.1 
1c p-iPr - 0.83 ± 0.08 >50 ND 7.9 
1d p-OMe + 10.8 ± 3.77 >50 ND 6.5 
1e p-NH2 ++ 3.28 ± 0.06 20.3 ± 2.4 >50 5.8 
1f m-F - 5.43 ± 0.63 23.1 ± 1.6 >50 6.8 
1g p-F - 4.67 ± 0.36 50.0 ND 6.8 
1h p-Cl - 2.89 ± 0.08 >50 ND 7.2 
1i p-Br - 2.55 ± 0.02 48.3 ± 2.4 >50 7.4 
1j o-NO2 + 1.66 ± 0.06 >50 ND 6.6 
1k m-NO2 - 2.10 ± 0.09 28.1 ± 3.5 >50 6.6 
1l p-NO2 ++ 1.23 ± 0.12 >50 ND 6.6 
 2a H - >10 >50 ND 4.3 
 2b p-Me - >10 28.5 ± 0.3 >50 4.8 
 2c p-iPr - >10 >50 ND 5.6 
 2d p-OMe - >10 >50 ND 4.2 
 2e m-F - >10 >50 ND 4.5 
2f p-F - >10 >50 ND 4.5 
 2g p-Cl - >10 41.3 ± 1.2 >50 4.9 
 2h p-Br - >10 33.1 ± 3.0 >50 5.1 
         2i o-NO2 - >10 23.6 ± 5.0 >50 4.3 
         2j m-NO2 - >10 14.2 ± 0.4  >50 4.3 
2k p-NO2 - >10 >50 ND 4.3 
8 H[g] - > 10 ND[g] ND  
E64  ND ND 0.0246 ± 0.0012 ND  
ART  ND 0.00876 ND ND  
CQ  ++ 0.0138[h] ND ND  
[a] ability to β-H formation in vitro was calculated as a % of the inhibitory effect displayed by reference drug 
CQ in the same experiment; test compounds were ranked as follows: <50%, not active (-); between 50 and 
75%, moderately active (+); ≥75%, highly active (++); [b] blood-stage antiplasmodial activity was determined 
against the CQ-resistant Pf strain W2, using artemisinin (ART) and CQ as reference drugs; [c] falcipain 
inhibition capacity was evaluated against FP2 using E64 as reference inhibitor and compound with IC50 < 50 
µM were further evaluated against FP3; [d] the logP values were estimated with the MarvinSketch 
software;12 [e] compound 1a’ is the L-amino acid analogue of 1a; [f] ND, not determined; [g] 
Morpholine/cinnamoylated derivative; [h] Retrieved from ref.13 
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a) Inhibition of hemozoin formation 
The β-H formation assays were carried out in 96-wells plates. Briefly, the hemin was 
incubated at 37oC at pH=4.4 for 48 hours with HEDICINs and HECINs, respectively, at 
1mM. Later on, the plates were centrifuged, the supernatant was discarded, and the 
DMSO was used to wash the plates (Fig. 20). The respective absorbance was measured 
once the formed crystals of β-H were hydrolyzed and later dissolved in an aqueous 
solution of NaOH. In this assay, the process of hemozoin formation that takes places in 
the food vacuole was basically simulated using CQ as a positive control and H2O and 
DMSO as negative control of CQ, and the compounds, respectively. 
 
	  
Figure 20. In vitro assay of inhibition of β-H formation. 
 
Results in this assay only enable us to find those compounds able to inhibit β-H 
formation with an activity range similar to the one displayed by CQ in the corresponding 
assay. Although none of HECINs showed activity against β-H     
formation, some HEDICINs were active but no clear SAR could be established between 
inhibition of β-H formation and impairment of the parasite development based on 
HEDICINs results. Furthermore, since chloroquinoline is known to be the core
i) Hemin
ii) pH=4.4
iii)Chloroquine/
    HEDICINs/
    HECINs/
    DMSO/H2O
37oC
48hours
i) Centrifugate (3000x15 min)
    Discard supernatant
ii) Wash with DMSO
    Centrifugate (3000x15 min)
    3 to 4 times
iii) Hydrolisis
     NaOH (0.2M)
iv) Dilution in NaOH (0.1M)
96-well plates
Read
405nM
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responsible for activity of the compounds against hemozoin formation and HECINs did 
not result active against β-H formation, this suggests that coupling directly the cinnamoyl 
moiety to 4-amino-7-chloroquinoline does not promote inhibition of such a process. 
Moreover, the influence of the dipeptide link was assessed by also testing the ability of 
compounds 3, 5, and 7 to inhibit β-H formation (Table 4). Based on the results, coupling 
the first amino acid or the subsequent D-Leu, led to the loss of the activity presented by 
compound 3. However, when coupling p-Me, p-OMe, p-NH2, o-NO2, or the p-NO2 
cinnamic acid resulting compound 1b, 1d, 1e, 1j, 1l, respectively, the corresponding 
derivative displays activity or becomes more active than compound 3. Results 
demonstrate that the later cynnamoyl moieties join together with compound 7 promote 
the activity against β-H formation. However, in order to draw more detailed conclusion 
regarding the inhibition of β-H formation by HEDICINs, a more precise method should be 
carried to evaluate the ability of these compounds to inhibit β-H formation such as the 
one reported by Wright’s team.14 Nevertheless, the latter results suggest the importance 
of the hydrophobic link for the antiplasmodial activity of HEDICINs. 
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Table 4. In vitro results against β-H for compounds 3, 5, and 7. 
Compound 
% inhibition of 
β-H formation 
at 1mM[a] 
 
+ 
3 
 
- 
5 
 
- 
7 
[a] Observed legend of table 3 for compound ranking.   
 
b) Inhibition of falcipain action 
Besides evaluating compounds ability to inhibit β-H formation, cinnamoylated derivatives 
were also assessed as inhibitors of falcipains. In the case of HEDICINs, the most active 
derivatives against falcipains’ action were the non-substituted cinnamoyl derivative 1a 
and the m-NO2 derivative 1k. However, results showed that HECINs were generally 
more active than HEDICINs, which contrast to previous results found against β-H. 
General ability of HECINs to better inhibit falcipain as compared to HEDICINs could be 
explained by in silico results against falcipains carried by Dr. Teixeira. The latter 
demonstrated that the α,β-unsaturated system of HECINs come closer to the cysteine 
residue of the active pocket of the proteases compared to the distance between the beta 
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carbon of the Michael acceptor functionality and catalytic residue of falcipains afforded 
by HEDICINs (Fig. 21). Furthermore as observed in fig. 21, docking results against FP3 
confirmed that the FP3 cavity is too narrow and the cinnamoyl moiety is placed too far 
away from the cysteine residue hindering a possible inhibition of the enzyme (Fig. 21 B). 
Only those compounds which displayed activity against FP2 were evaluated against 
FP3, since FP3’s cavity is narrower,15 therefore, the latter allows lower range of inhibitors 
compared to FP2. Accordingly, none of the derivatives active against FP2 were active 
against FP3 (IC50 > 50 µM). Moreover, the effect of the use of D-amino acids was 
evaluated through the synthesis and assessment of compound 1a’ that contained L-
amino acids instead. Interesting, the use of L-amino acids led to a clear decrease of 
inhibition of FP2. The latter suggests that D-amino acid configuration does not impair 
inhibition of falcipain action, in fact, in HEDICINs case, D-amino acids seem to be 
preferable. 
 	  
	  
Figure 21. Preferred binding modes of the unsubstituted (A and B) and m-NO2 (C and D) cinnamoyl 
derivative 1a and 2j into FP2 and FP3 binding sites, respectively. 	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c) Antiplasmodial assays 
According to antiplasmodial results, all HEDICINs displayed activity in the micromolar 
range against the parasite (IC50 = 0.83-10.8 µM), contrary to HECINs which were not 
active against the parasite (Table 3). Interesting, the most active compound of the series 
1c was the most lipophilic, demonstrating that this property plays a important role in 
antiplasmodial activity as found by Miller and Lin.16 This could also explain the lack of 
activity of HECINs, since HEDICINs are more lipophilic than HECINs due to dipeptide 
spacer use to join the cinnamoyl moiety and the chloroquinoline ring. In addition, there 
was no correlation regarding the activity of the compounds and the electro-donating 
properties of the substituents in the cinnamoyl moiety. Contrary, results suggest that as 
the electronegativity of the para substituent increases, the activity decreases. For 
instance, the p-Br derivative 1i (IC50 = 2.55 µM) and the p-Cl 1h (IC50 = 2.89 µM) were 
more active than the p-F 1g (IC50 = 4.67 µM). Also, para substituent seems 
to be preferable over the meta substituents as demonstrated by the p-F (IC50 = 4.67 µM) 
vs the m-F (IC50 = 5.43 µM) derivatives and the p-NO2 (IC50 = 1.23 µM) vs the m-NO2 
derivative (IC50 = 2.10µM).  Results demonstrated the relevance of the chloroquinoline 
moiety in the antiplasmodial activity of the compounds since compound 8 was not active 
against the malaria parasite (IC50 > 10 µM). Moreover, as in the case of inhibition of 
falcipain action, D-amino acids, in the case of HEDICINs, seems to be promoting 
impairment of parasite growth.  
Results demonstrated that compounds ability to inhibit of hemozoin formation or falcipain 
action does not correlate with compounds ability to impair parasite growth. However, 
HEDICINs displaying antiplasmodial activity below 2µM which were also active against 
 β-H formation, for instance, the p-Me derivative 1b (IC50 = 1.96 µM) and the p-NO2 
derivative 1k (IC50 = 1.23 µM), suggests that inhibition of hemozoin formation might be 
one of the mechanism through which these derivatives exert their activity. In addition, the 
fact that, for instance, the m-NO2 derivative 2j, the most active of HECINs against FP2 
(IC50 = 14.2µM) was not active against the Pf parasite (IC50 > 10 µM), might be 
suggesting that HECINs may not be reaching its corresponding target. The latter could 
be explained by the low basicity of the HECINs which could be impeding the necessary 
accumulation of the molecules in the FV to inhibit the respective target. Overall, the 
relevance of the hydrophobic link and chloroquine moiety to impair parasite growth are 
demonstrated. 
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2.2. Experimental Section 	  
2.2.1. Chemistry  
2.2.1.1. Chemicals and instrumentation 
All solvents and common chemicals were from Sigma Aldrich (Spain), whereas Boc-
protected amino acids were from NovaBiochem (VWR International, Portugal) and TBTU 
was from Bachem (Switzerland). NMR spectra were acquired on a Bruker Avance III 400 
spectrometer from solutions in either deuterated chloroform or deuterated 
dimethylsulfoxide (DMSO-d6) containing tetramethylsilane as internal reference. MS 
spectra were obtained on a Thermo Finnigan LCQ Deca XP Max LC/MSn instrument 
operating with electrospray ionization and ion-trap (ESI-IT) quadrupole detection. HPLC 
analyses were run for target compounds (1-2 and 8) using the following conditions: 30-
100% of B in A (A =H2O with 0.05% of trifluoroacetic acid; B =acetonitrile) in 22 min with 
a flow rate of 1 mL/min on a MerckeHitachi Lachrom Elite instrument equipped with a 
diode-array detector (DAD) and thermostated (Peltier effect) autosampler, using a 
Purospher STAR RP-18e column (150 4.0 mm; particle size, 5 µM). 
 
2.2.1.2. Synthesis of compounds 3-7 	  
4-amino-7-chloroquinoline (3).  
An earlier method by Reitsema and co-workers was followed:3 
4,7-dichloroquinoline (6 g, 0.03 mol) and phenol (30 g, 0.3 mol) 
were mixed at room temperature in a round bottom flask. After 
increasing the temperature to 150oC, ammonia was bubbled into 
the solution for 2 hours. After cooling the mixture back to room 
temperature, a solution of glacial acetic acid (7.5 mL) in water (15 mL) was added with 
stirring, followed by addition of ice-cold ethyl ether (30 mL). The white precipitate formed 
was collected by suction filtration and dissolved in hot water. The pH of the resulting 
solution was adjusted to 11 with 1M NaOH (aq) and, after cooling the mixture, a white 
solid precipitated and was collected, dried and identified as the target 4-amino-7-
chloroquinoline, 2 (4.8g, 89%); mp 110-112 oC; RF (DCM/MeOH 20:1) 0.59; δH (400 
MHz, DMSO-d6) 8.31 (d, J= 5.2 Hz, 1H, Ha), 8.19 (d, J=9.2 Hz, 1H, He), 7.76 (d, J= 2 
Hz, 1H, Hh), 7.40 (dd, J= 8.5 Hz, J= 2 Hz, 1H, Hf), 6.93 (s, 2H, -NH2), 6.55 (d, J= 5.2 Hz, 
1H, Hb); δC (100 MHz, DMSO-d6) 151.6, 151,5, 149.4 (Ca, Cc, Ci), 133.4, 127.3, 124.6, 
123.7 (Ce-Ch), 117.0 (Cd), 102.6 (Cb); ESI-IT MS: m/z (M+H+) 179.33 (C9H7ClN23 
requires 178.03). 
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4-[(2R)-2-(tert-butoxycarbonyl)amino-4-phenylbutanoyl]amino-7-chloroquinoline 
(4) 
Boc-D-homophenylalanine (0.43 g, 1.5 mmol), TBTU (0.49 
g, 1.54 mmol), DIEA (0.36 mL, 2.8 mmol) and 
dimethylformamide (DMF, 7 mL) were mixed in a 
round bottom flask at 0 ºC. After 10 minutes, a solution of 
4-amino-7-chloroquinoline 3 in DMF (7 mL) was added and 
the reaction was allowed to proceed for one day at room temperature. Following, water 
was added to the reaction mixture and the product was extracted with dichloromethane 
(3 times); the organic layers were pooled and sequentially washed with 1% aq. HCl (3 
times) and 5% aq. Na2CO3 (3 times). Finally, the organic layer was dried over anhydrous 
Na2SO4, filtered, and evaporated to dryness under reduced pressure. The crude product 
was purified by column liquid chromatography on silica, using dichloromethane:acetone 
(DCM/Me2CO) 6:1 v/v as eluent. The resulting product was obtained as a white solid and 
corresponded to the target compound 4 (218 mg, 35%); mp 150-152oC; RF 
(DCM/Me2CO 6:1) 0.57; δH (400 MHz, CDCl3) 9.72 (s, 1H, -NH-QN), 8.8 (d, J= 5.2 Hz, 
1H, Ha), 8.29 (d, J= 5.2 Hz, 1H, Hb), 8.05 (d, J= Hz, 1H, Hh), 7.95 (d, J= 8.8 Hz, 1H, 
He), 7.47 (dd, J= 8 Hz, J= 2 Hz, Hf), 7.33-7.29 (m, 2H), 7.24-7.15 (m, 4H)  (-NH-hPhe, 
Ho-Hq), 4.26 (q, J= 7.3 Hz, 1H, Hk), 2.83-2.79 (m, 2H, Hm), 1.50 (s, 9H, Ht), 1.45-1.44 
(m, 2H, Hl); δC (100 MHz, CDCl3); 170.8 (Cj), 157.2, 152.3, 149.3, 141.0, 140.3, 135.3, 
129.1, 128.7, 128.4, 127.2, 126.4, 121.5 (Ca, Cc, Ce-Ci, Cn-r), 118.3 (Cd), 110.4 (Cb), 
81.7 (Cs), 54.7 (Ck), 32.0, 31.3, 28.3 (Cm, Ct, Cl); ESI-IT MS: m/z (M+H+) 440.20 
(C24H26ClN3O3 requires 439.17). 
4-[(2R)-2-amino-4-phenylbutanoyl]amino-7-chloroquinoline (5)  
Compound 4 (0.13 g, 0.3 mmol) was reacted with neat 
trifluoroacetic acid (TFA, 1 mL) for 2 at room temperature, under 
constant stirring. Then, the pH was adjusted to 12 with 30% 
Na2CO3 (aq) and the solution extracted with DCM. The organic 
layer was dried with anhydrous Na2SO4 and evaporated to 
dryness under reduced pressure. Compound 5 was thus 
obtained as a yellow oil (85.3 mg, 85%); RF (DCM/Me2CO 6:1) 0.26; δH (400 MHz, 
CDCl3) 10.89 (s, 1H, -NH-QN), 8.81 (d, J= 5.2 Hz, 1H, Ha), 8.38 (d, J= 5.2 Hz, 1H, Hb), 
8.08 (d, J= 2 Hz, 1H, Hh), 7.77 (d, J=9.2Hz, 1H, He), 7.48 (dd, J= 9Hz, J= 2Hz, 1H, Hf), 
7.33-7.18 (m, 7H, Ho-Hq, -NH2), 3.63-3.59 (m, 1H, Hk), 2.90-2.75 (m, 2H, Hm), 2.01-
1.85 (m, 2H, Hl); δC (100 MHz, CDCl3) 173.3 (Cj), 152.2, 148.9, 140.1, 139.9, 134.8, 
128.9, 128.3, 128.0, 126.8, 126.0, 120.5 (Ca, Cc, Ce-
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Ci, Cn-Cq), 118.0 (Cd), 109.3 (Cb), 55.1 (Ck), 35,7, 31.8 (Cl-Cm); ESI-IT MS: m/z 
(M+H+) 340.33 (C19H18ClN3O requires 339.11). 
 
4-{(2R)-2-[(2R)-2-(tert-butoxycarbonyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (6)  
Boc-D-leucine (0.13 g, 0.38 mmol), PyBOP (0.22 g, 
0.42 mmol), DIEA (0.162 mL, 1.25 mmol) and DCM (2 
mL) were mixed in a round bottom flask at 0 ºC and 
put under stirring for 20 minutes. Then, a solution of 5 
in DCM (2 mL) was added and the reaction allowed to 
proceed for one day at room temperature. Following, 
the reaction mixture was diluted with 14 mL of DCM and sequentially washed with 1% 
aq. HCl (3×18 mL) and 5% aq. Na2CO3 (3×18 mL). Finally, the organic layer was dried 
with anhydrous Na2SO4, filtered, and evaporated to dryness. The crude product was 
purified by column liquid chromatography on silica, using DCM/Me2CO 6:1 v/v as eluent. 
The target compound, 6, was isolated as a yellowish oil (122 mg, 58%); RF (DCM/Me2CO 
6:1) 0.53; δH (400 MHz, CDCl3); 9.75 (s, 1H, -NH-QN), 8.79 (d, J= 5.2 Hz, 1H, Ha), 8.22 
(d, J= 4.8 Hz, 1H, Hb), 8.07 (d, J= 2 Hz, 1H, Hh), 7.95 (d, J= 9.2 Hz, 1H, He), 7.49 (dd, 
J= 8.8 Hz, J= 2 Hz, 1H, Hf), 7.30-7.26 (m, 2H, -NH-Leu, -NH-hPhe), 7.24-7.17 (m, 5H, 
Ho-Hq), 4.60 (q, J= 7.2 Hz, 1H, Hk), 4.16 (b, 1H, Hs), 2.83-2.74 (m, 2H, Hm), 2.22-2.11 
(m, 2H, Hl), 1.81-1.71 (m, 2H, Ht), 1.65-1.55 (m, 1H, Hu), 1.4 (s, 9H, Hy), 0.9 (d, J= 6.8 
Hz, 6H, Hv); δC (100 MHz, CDCl3) 174.5 (Cj), 170.1 (Cr), 155.9 (Cw), 152,1, 149.3, 
141.2, 140.4, 135.3, 129.0, 128.7, 128.4, 127.3, 126.4, 121.9 (Ca, Cc, Ce-Ci, Cn-Cq), 
118.5 (Cd), 110.9 (Cb), 69.7 (Cx), 53.9, 53.1 (Ck, Cs), 40.3, 30.8, 28.2, 24.7, 22.7, 18.8 
(Cl-Cm, Ct-Cv, Cy); ESI-IT MS: m/z (M+H+) 553.27 (C30H37ClN4O4 requires 552.25). 
 
4-{(2R)-2-[(2R)-2-amino-4-methylpentanoyl]amino-4-phenylbutanoyl}amino-7-
chloroquinoline (7)  
Compound 6 (0.122 g, 0.22 mmol) was reacted with 
neat trifluoroacetic acid (TFA, 1 mL) for 2 at room 
temperature, under constant stirring. Then, the pH was 
adjusted to 12 with 30% aq. Na2CO3 
and the desired compound was extracted with DCM. 
The organic layer was dried with anhydrous Na2SO4 
and evaporated to dryness under reduced pressure. 
Compound 6 was thus obtained as a yellowish oil (72 mg, 87%); RF (DCM/Me2CO 6:1) 
0.16; δH (400 MHz, CDCl3) 10.15 (s, 1H, -NH-QN), 8.77 (d, J=5.2Hz, 1H, Ha), 8.28 (b, 
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1H, Hb), 8.11-8.01 (m, 3H, -NH-hPhe, He, Hh), 7.51 (d, J=8.8Hz, 1H, Hf), 7.31-7.13 (m, 
7H, -NH2, Ho-Hq), 4.57 (b, 1H, Hk), 3.52-3.36 (m, 1H, Hs), 2.81-2.78 (m, 2H, Hm), 2.04-
1.84 (m, 2H, Hl), 1.44-1.29 (m, 3H, Hu-Ht), 1.03-0.87 (m, 6H, Hv); δC (100 MHz, CDCl3) 
178.8 (Cj), 171.3 (Cr), 153.1, 150,2, 142.2, 141.4, 136.2, 129.9, 129.6, 129.3, 128.3, 
127.3, 122.9 (Ca, Cc, Ce-Ci, Cn-Cq), 119.3 (Cd), 111.3 (Cb), 54.6, 54.1 (Ck, Cs), 44.5, 
33.0, 25.8, 24.3, 22.2 (Cm-Cl, Ct-Cv); ESI-IT MS: m/z (M+H+) 453.27 (C25H29ClN4O2 
requires 452.20). 
 
2.2.1.3. Synthesis of compounds 1a-l and 1a’ (HEDICINs) 
The relevant cinnamic acid (1.1 eq), PyBOP (1.1 eq), DIEA (2 eq.) and DCM (2 mL) were 
mixed in a round bottom flask and put under stirring for 20 min. Then, a solution of 7 in 
DCM (2 mL) was added and the reaction allowed to proceed for three days. Precipitation 
was observed and the precipitate was collected by suction filtration, washed with ice-cold 
DCM, dried and identified as the pure target compound, except in the case of 1l (p-
nitrocinnamic acid derivative), which was further submitted to liquid chromatography on 
silica, using DCM/Me2CO 6:1 (v/v) as eluent. In the particular case of compound 1e, 
derived from p-aminocinnamic acid, the N-Boc-protected precursor of this cinnamic acid 
derivative was coupled to 7 as described, and the resulting Boc-protected compound 
(1e’) was treated with neat TFA as described for the synthesis of 5 and 7, to give the 
final unprotected compound, 1e. Analytical and spectroscopic data for HEDICINs are 
given below. 
 
4-{(2R)-2-[(2R)-2-(cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1a) 
White solid (29.5 mg, 66%); mp 241-245 oC; 
RF (DCM/Me2CO 6:1) 0.36; δH (400 MHz, 
DMSO-d6) 10.36 (s, 1H, -NH-QN), 8.84 (d, 
J=5.2 Hz, 1H, Ha), 8.59 (d, J=7.6 
Hz, 1H, He), 8.37-8.32 (m, 2H, -NH-Leu, -NH-
hPhe), 8.05-8.04 (m, 2H, Hb, Hh), 7.67 (dd, 
J= 9.28 Hz, J= 2 Hz, 1H, Hf), 7.56 (d, J=7.2 
Hz, 2H), 7.46-7.34 (m, 4H) (Ha’-Hc’, Hy), 7.29-7.15 (m, 5H, Ho-Hq); 6.79 (d, J= 15.6 Hz, 
1H, Hx); 4.72-4.67 (m, 1H), 4.58 (q, J= 7.6 Hz, 1H) (Hk, Hs), 2.85-2.60 (m, 2H, Hm), 
2.19-2.01 (m, 2H, Hl), 1.72-1.61 (m, 1H, Hu), 1.61-1.51 (m, 2H, Ht), 0.90 (dd, J= 16 Hz, 
J= 6.4 Hz, 6H, Hv); δC (100 MHz, DMSO-d6); 172.7, 171.8, 164.9 (Cj, Cr, Cw), 152.2, 
149.1, 141.5, 141.1, 139.0, 134.8, 134.2, 129.5, 128.9, 128.3, 128.3, 128.0, 127.5, 
126.4, 125.9, 124.5, 121.9, 119.4, 112.4 (Ca-Ci, Cn-Cq, Cx-Cc’), 53.5, 51.1 (Ck, Cs), 
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40.9, 33.0, 31.5, 24.2, 23.0, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: m/z (M+H+) 583.47 
(C34H35ClN4O3 requires 582.24); HPLC-DAD: rt = 12.4 min (% Area = 96%). 
 
4-{(2R)-2-[(2R)-2-((p-methyl)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1b) 
 
White solid (30.1 mg, 76%); mp 230-235 
oC; RF (DCM/Me2CO 6:1) 0.24; δH (400 
MHz, DMSO-d6) 10.35 (s, 1H, -NH-QN), 
8.83 (d, J= 5.2 Hz, 1H, Ha), 8.55 (d, J= 
7.6 Hz, 1H, He), 8.36-8.26 (m, 2H, -NH-
Leu, -NH-hPhe), 8.06-8.04 (m, 2H, Hb, 
Hh), 7.66 (dd, J= 9 Hz, J= 2 Hz, 
1H, Hf), 7.46-7.35 (m, 3H, Ha’,Hy), 7.31-7.10 (m, 7H, Ho-q, Hb’), 6.75 (d, J= 16 Hz, 1H, 
Hx), 4.72-4.67 (m, 1H), 4.57 (q, J= 7.7, 1H) (Hk, Hs), 2.81-2.62 (m, 2H, Hm), 2.32 (s, 3H, 
Hd’), 2.20-2.00 (m, 2H, Hl), 1.74-1.50 (m, 3H, Ht-u), 0.90 (dd, J= 16 Hz, J= 6.4 Hz, 6H, 
Hv); δC (100 MHz, DMSO-d6) 172.7, 171.7, 165.0 (Cj, Cr, Cw), 152.2, 149.0, 141.4, 
141.0, 139.2, 134.9, 134.1, 132.0, 129.5, 128.3, 128.2, 127.9, 127.4, 126.3, 125.8, 
124.5, 120.8, 119.3, 112.4 (Ca-Ci, Cn-Cq, Cx-Cc’), 53.4, 51.6 (Ck, Cs), 40.8, 32.9, 31.4, 
24.8, 22.9, 21.6, 20.9 (Cl-Cm, Ct-Cv, Cd’); ESI-IT MS: m/z (M+H+) 597.60 (C35H37ClN4O3 
requires 596.26); HPLC-DAD: rt = 18.3 min (% Area = 98%). 
 
4-{(2R)-2-[(2R)-2-((p-isopropyl)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1c) 
White solid (23 mg, 47%); mp 238-240 
oC; RF (DCM/Me2CO 6:1) 0.44; δH (400 
MHz, DMSO-d6) 10.34 (s, 1H, -NH-QN), 
8.83 (d. J= 5.2 Hz, 1H, Ha), 8.56 (d, J= 
6.8 Hz, 1H, He), 8.36-8.26 (m, 2H, -NH-
Leu, -NH-hPhe), 8.06-8.04 (m, 2H, Hb, 
Hh), 7.67 (d, J= 8.8 Hz, 1H, Hf), 7.50-
7.38 (m, 4H, Ha’-b’), 7.30-7.23 (m, 6H, Ho-q, Hy), 6.73 (d, J= 16 Hz, 1H, Hx), 4.72-4.67 
(m, 2H, Hk, Hs), 2.97-2.62 (m, 3H, Hm, Hd’), 2.20-2.00 (m, 2H, Hl), 1.77-1.51 (m, 3H, Ht-
u), 1.20 (d, J= 6.8 Hz, 6H, He’), 0.90 (dd, J= 16.6 Hz, J= 6.4 Hz, 6H); δC (100 MHz, 
DMSO-d6) 172.7, 171.7, 165.0 (Cj, Cr, Cw), 152.1, 150.0, 149.0, 141.4, 141.0, 138.9, 
134.1, 132.4, 128.3, 128.2, 127.9, 127.5, 126.8, 126.3, 125.8, 124.5, 120.9, 119.36, 
112.4 (Ca-Ci, Cn-Cq, Cx-Cc’), 53.4, 51.0 (Ck, Cs), 40.8, 33.2, 33.0, 31.4, 24.8, 23.6, 
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22.9, 21.6 (Cl-Cm, Ct-Cv, Cd’-Ce’); ESI-IT MS: m/z (M+H+) 625.36 (C37H41ClN4O3 
requires 624.29); HPLC-DAD: rt = 14.5 min (% Area = 93%). 
 
4-{(2R)-2-[(2R)-2-((p-methoxy)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1d) 
White solid (38 mg, 47%); mp 223-241 oC; 
RF (DCM/Me2CO 6:1) 0.35; δH (400 MHz, 
DMSO-d6) 10.34 (s, 1H, -NH-QN), 8.83 
(d, J= 5.2 Hz, 1H, Ha), 8.54 (d, J= 7.6 Hz, 
1H, He), 8.32 (d, J= 8.8 Hz, 1H), 8.24 (d, 
J= 8 Hz, 1H) (-NH-Leu, -NH-hPhe), 8.06-
8.04 (m, 2H, Hb, Hh), 7.66 (d, J= 9.2 Hz, 
J=2 Hz, 1H, Hf), 7.50 (d, J= 8.8 Hz, 2H, Ha’), 7.38 (d, J= 16 Hz, 1H, Hy), 7.29-7.15 (m, 
5H, Ho-q), 6.98 (d, J= 8.8 Hz, 2H, Hb’), 6.63 (d, J= 15.6 Hz, 1H, Hx), 4.72-4.68 (m, 1H), 
4.61-4.52 (m, 1H) (Hk, Hs), 3.79 (s, 3H, OCH3), 2.85-2.62 (m, 2H, Hm), 2.20-2.00 (m, 
2H, Hl), 1.77-1.51 (m, 3H, Ht-u), 0.90 (dd, J= 16.8 Hz, J= 6.4 Hz, 6H, Hv); δC (100 MHz, 
DMSO-d6) 172.8, 171.7, 165.2 (Cj, Cr, Cw), 160.3, 152.1, 149.0, 141.4, 141.0, 138.7, 
134.1, 129.0, 128.3, 128.2, 127.9, 127.3, 126.3, 125.8, 124.5, 120.4, 119.4, 114.3, 112.4 
(Ca-Ci, Cn-Cq, Cx-Cc’), 55.2, 53.4, 51.0 (Ck, Cs, Cd’), 40.8, 33.0, 31.4, 24.2, 22.9, 21.6 
(Cl-Cm, Ct-Cv); ESI-IT MS: m/z (M+H+) 613.73 (C35H37ClN4O4 requires 612.25); HPLC-
DAD: rt = 12.3 min (% Area = 91%). 
 
4-{(2R)-2-[(2R)-2-((p-(tert-butoxycarbonyl)amino)cinnamoyl)amino-4-
methylpentanoyl]amino-4-phenylbutanoyl}amino-7-chloroquinoline (1e’) 
Yellow solid (10 mg, 13%); mp 
(dec.) 238 oC; RF (DCM/Me2CO 
6:1) 0.35; δH (400 MHz, DMSO-
d6) 10.33 (s, 1H, -NH-QN), 9.55 
(s, 1H, -NHBoc), 8.83 (d, J= 4.8 
Hz, 1H, Ha), 8.53 (d, J= 7.2 Hz, 
1H, He), 8.32 (d, J= 9.2 Hz, 
1H), 8.26 (d, J= 8 Hz, 1H) (-NH-
Leu, -NH-hPhe), 8.06-8.04 (m, 2H, Hb, Hh), 7.66 (dd, J= 9.2 Hz, J= 2 Hz, 1H, Hf), 7.50-
7.38 (m, 4H, Ha’-Hb’), 7.34 (d, J= 16 Hz, 1H, Hy), 7.23 (m, 5H, Ho-q), 6.65 (d, J= 15.6 
Hz, 1H, Hx), 4.72-4.68 (m, 1H), 4.61-4.52 (m, 1H) (Hk, Hs), 2.85-2.62 (m, 2H, Hm), 2.20-
2.00 (m, 2H, Hl), 1.77-1.51 (m, 3H, Ht-u), 1.48 (s, 9H, Hf’), 0.90 (dd, J= 17.2 Hz, J= 6.4 
Hz, 6H, Hv’); δC (100 MHz, DMSO- d6) 172.8, 171.8, 165.2 (Cj, Cr, Cw), 152.5, 152.2, 
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149.0, 141.4, 141.0, 140.8, 138.7, 134.1, 128.5, 128.3, 128.2, 128.1, 127.1, 126.4, 
125.9, 124.5, 119.7, 119.4, 118.0, 112.0 (Ca-Ci, Cn-Cq, Cx-Cd’), 79.3 (Ce’), 53.4, 51.1 
(Ck, Cs), 40.7, 33.0, 31.4, 28.0, 24.2, 22.9, 21.6 (Cl-Cm, Ct-Cv, Cf’); ESI- IT MS: m/z 
(M+H+)  698.47 (C39H44ClN5O5 requires 697.30); HPLC- DAD: rt = 16.5 min (% Area = 
97%). 
 
4-{(2R)-2-[(2R)-2-((p-amino)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1e) 
Yellow solid (12 mg, 78%); mp 240-
242 oC; RF (DCM/Me2CO 6:1) 0.11; δH 
(400 MHz, DMSO-d6) 10.32 (s, 1H, -
NH-QN), 8.83 (d, J= 5.2 Hz, 1H, Ha), 
8.49 (d, J= 7.6 Hz, 1H, He), 8.32 (d, 
J= 9.2 Hz, 1H), 8.08 (d, J= 8 Hz, 1H) 
(-NH-Leu, -NH-hPhe), 8.06-8.04 (m, 
2H, Hb, Hh), 7.66 (dd, J= 9 Hz, J=2 
Hz, 1H, Hf), 7.29-7.16 (m, 8H, Ho-q, Hy, Ha’), 6.56 (d, J= 8.4 Hz, 2H, Hb’), 6.43 (d, J= 16 
Hz, 1H, Hx), 5.57 (s, 2H, -NH2), 4.71-4.65 (m, 1H), 4.55-4.49 (m, 1H) (Hk, Hs), 2.80-2.59 
(m, 2H, Hm), 2.20-2.00 (m, 2H, Hl), 1.75-1.50 (m, 3H, Ht-u), 0.90 (dd, J= 18.4 Hz, J= 6.4 
Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 172.9, 171.8, 165.9 (Cj, Cr, Cw), 152.1, 150.5, 
149.0, 141.4, 141.1, 139.9, 134.1, 129.0, 128.3, 128.2, 127.9, 126.4, 125.8, 124.5, 
122.0, 119.4, 115.4, 113.6, 112.4 (Ca-Ci, Cn-Cq, Cx-Ca’, Cc’-Cd’), 53.4, 51.2 (Ck, Cs), 
40.7, 33.0, 31.4, 24.2, 22.9, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: m/z (M+H+) 598.30 
(C34H36ClN5O3 requires 597.25); HPLC-DAD: rt =16.5 min (% Area = 97%). 
 
4-{(2R)-2-[(2R)-2-((m-fluoro)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1f) 
White solid (28 mg, 56%); mp 249-254 
oC; RF (DCM/Me2CO 6:1) 0.35; δH (400 
MHz, DMSO-d6) 10.36 (s, 1H, -NH-
QN), 8.83 (d, J= 4.8 Hz, 1H, Ha), 8.58 
(d, J= 7.2 Hz, 1H, He), 8.37-8.30 (m, 
2H, -NH-Leu, -NH-hPhe), 8.06-8.05 
(m, 2H, Hb, Hh), 7.67 (d, J= 9.2 Hz, J= 
2 Hz 1H, Hf), 7.50-7.38 (m, 4H, Ha’-
d’), 7.31-7.15 (m, 6H, Ho-q, Hy), 6.83 (d, J= 16 Hz, 1H, Hx), 4.73-4.68 (m, 1H), 4.63-4.56 
(m, 1H) (Hs, Hk), 2.82-2.63 (m, 2H, Hm), 2.20-2.00 (m, 2H, Hl), 1.75-1.52 (m, 3H, Ht-u), 
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0.90 (dd, J= 15.4 Hz, J= 6.8 Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 172.6, 171.7, 164.5, 
(Cj, Cr, Cw), 163.6, 161.1, 152.2, 149.0, 141.4, 141.0, 137.6, 137.4, 134.1, 130.9, 128.3, 
128.2, 127.9, 126.3, 125.8, 124.5, 123.5, 119.4, 116.1, 113.8, 112.4 (Ca-Ci, Cn-Cq, Cx-
Ce’), 53.5, 51.1 (Ck, Cs), 40.8, 33.0, 31.5, 24.2, 22.9, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: 
m/z (M+H+)  601.40 (C34H34ClFN4O3 requires 600.23); HPLC-DAD: rt = 11.2 min (% Area 
= 100%). 
 
4-{(2R)-2-[(2R)-2-((p-fluoro)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1g) 
White solid (39 mg, 78%); mp 
246-249 oC; RF (DCM/Me2CO 
6:1) 0.35; δH (400 MHz, DMSO-
d6) 10.35 (s, 1H, -NH-QN), 8.83 
(d, J= 5.2 Hz, 1H, Ha), 8.56 (d, 
J= 7.2 Hz, 1H, He), 8.32 (d, J= 
9.2 Hz, 2H, -NH-Leu, -NH-
hPhe), 8.06-8.04 (m, 2H, Hb, 
Hh), 7.67-7.60 (m, 3H, Ha’, Hf), 7.44 (d, J= 15.6 Hz, 1H, Hy), 7.29-7.14 (m, 7H, Ho-q, 
Hb’), 6.73 (d, J= 15.6 Hz, 1H, Hx), 4.73-4.68 (m, 1H), 4.61-4.55 (m, 1H) (Hk, Hs), 2.82-
2.62 (m, 2H, Hm), 2.20-2.00 (m, 2H, Hl), 1.75-1.52 (m, 3H, Ht-u), 0.90 (dd, J= 16 Hz, J= 
6.4 Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 172.7, 171.7, 164.8 (Cj, Cr, Cw), 
152.2, 149.0, 141.4, 141.0, 137.8, 134.1, 131.4, 129.6, 128.3, 128.2, 127.9, 126.3, 
125.8, 124.5, 121.8, 119.4, 116.0, 115.7, 112.4 (Ca-Ci, Cn-Cq, Cx-Cc’), 53.5, 51.0 (Ck, 
Cs), 40.8, 33.0, 31.5, 24.2, 22.9, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: m/z (M+H+) 601.47 
(C34H34ClFN4O3 requires 600.23); HPLC-DAD: rt= 12.5 min (% Area = 85%). 
 
4-{(2R)-2-[(2R)-2-((p-chloro)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1h) 
White solid (25 mg, 59%); mp 
249-260 oC; RF (DCM/Me2CO 
6:1) 0.35; δH (400 MHz, 
DMSO-d6) 10.35 (s, 1H, -NH-
QN), 8.83 (d, J= 4.8 Hz, 1H, 
Ha), 8.57 (d, J= 7.6 Hz, 1H, 
He), 8.34-8.30 (m, 2H, -NH-
Leu, -NH-hPhe), 8.06-8.04 (m, 
2H, Hb, Hh), 7.66 (dd, J= 9 Hz, J=2, 1H, Hf), 7.58 (d, J= 8.8 Hz, 2H), 7.48 (d, J= 8.4 Hz, 
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2H) (Ha’-b’), 7.42 (d, J= 16 Hz, 1H, Hy), 7.22 (m, 5H, Ho-q), 6.79 (d, J= 15.6 Hz, 1H, 
Hx), 4.73-4.68 (m, 1H), 4.61-4.55 (m, 1H) (Hk, Hs), 2.82-2.62 (m, 2H, Hm), 2.20-2.00 (m, 
2H, Hl), 1.75-1.52 (m, 3H, Ht-u), 0.90 (dd, J= 16 Hz, J= 6.4 Hz, 6H, Hv); 
δC (100 MHz, DMSO-d6) 172.6, 171.7, 164.7 (Cj, Cr, Cw), 152.2, 149.0, 141.4, 141.0, 
137.6, 134.1, 133.8, 133.7, 129.1, 128.9, 128.3, 128.2, 127.9, 126.3, 125.8, 124.5, 
122.7, 119.4, 112.4 (Ca-Ci, Cn-Cq, Cx-Cc’), 53.5, 51.1 (Ck, Cs), 40.8, 33.0, 31.5, 24.2, 
22.9, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: m/z (M+H+) 617.23 (C34H34Cl2N4O3 requires 
616.20); HPLC-DAD: rt = 18.5 min (% Area = 100%) 
 
4-{(2R)-2-[(2R)-2-((p-bromo)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1i) 
White solid (31 mg, 70%); mp 
240-246 oC; RF (DCM/Me2CO 
6:1) 0.35; δH (400 MHz, DMSO-
d6) 10.35 (s, 1H, -NH-QN), 8.83 
(d, J= 4.8 Hz, 1H, Ha), 8.57 (d, 
J= 7.2 Hz, 1H, He), 8.39-8.31 (m, 
2H, -NH-Leu, -NH-hPhe), 8.06-
8.04 (m, 2H, Hb, Hh), 7.71-7.61 
(m, 3H), 7.51 (d, J= 8.4 Hz, 2H) (Ha’-b’, Hf), 7.40 (d, J= 15.6 Hz, 1H, Hy), 7.31-7.14 (m, 
5H, Ho-q), 6.80 (d, J= 16 Hz, 1H, Hx), 4.73-4.68 (m, 1H), 4.61-4.55 (m, 1H) (Hk, Hs), 
2.82-2.62 (m, 2H, Hm), 2.20-2.00 (m, 2H, Hl), 1.74-1.49 (m, 3H, Ht-v), 0.90 (dd, J= 16 
Hz, J= 6.4 Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 172.6, 171.7, 164.6 (Cj, Cr, Cw), 152.2, 
149.0, 141.4, 141.0, 137.7, 134.1, 131.8, 129.4, 128.3, 128.2, 127.9, 126.3, 125.8, 
124.5, 122.8, 122.6, 119.4, 112.4 (Ca-Ci, Cn-Cq, Cx-
Cc’), 53.4, 51.1 (Ck, Cs), 40.8, 33.0, 31.4, 24.2, 22.9, 21.6 (Ct-Cv); ESI-IT MS: m/z 
(M+H+)  663.40 (C34H34BrClN4O3 requires 660.15); HPLC-DAD: rt = 18.6 min (% Area = 
98%). 
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4-{(2R)-2-[(2R)-2-((o-nitro)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1j) 
White solid (25 mg, 40%); mp 260-265 oC; 
RF (DCM/Me2CO 6:1) 0.35; δH (400 MHz, 
DMSO-d6) 10.38 (s, 1H, -NH-QN), 8.83 (d, 
J= 5.2 Hz, 1H, Ha), 8.62 (d, J= 
6 Hz, 1H, He), 8.49 (d, J= 9.2 Hz,1H), 8.32 
(d, J= 7.2 Hz, 1H) (-NH-Leu, -NH-hPhe), 
8.07-8.04 (m, 3H, Hb, Hh, He’), 7.83-7.62 
(m, 5H, Hf, Hy, Hb’-d’), 7.30-7.15 (m, 5H, Ho-q), 6.79 (d, J= 15.6 Hz, 1H, Hx), 4.73-4.68 
(m, 1H), 4.63-4.58 (m, 1H) (Hk, Hs), 2.87-2.63 (m, 2H, Hm), 2.20-2.00 (m, 2H, Hl), 1.73-
1.51 (m, 3H, Ht-u), 0.90 (dd, J= 14.4 Hz, J= 6.4 Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 
172.5, 171.8, 163.9 (Cj, Cr, Cw), 152.2, 149.0, 148.3, 141.4, 141.0, 134.1, 133.8, 133.7, 
130.2, 129.8, 128.5, 128.3, 128.2, 127.9, 126.6, 126.3, 125.8, 124.6, 124.5, 119.4, 112.4 
(Ca-Ci, Cn-Cq, Cx-Ce’), 53.5, 51.0 (Ck, Cs), 40.9, 33.0, 31.5, 24.2, 22.9, 21.6 (Cl-Cm, 
Ct-Cv); ESI-IT MS: m/z (M+H+) 628.47 (C34H34ClN5O5 requires 627.22); HPLC-DAD: rt = 
17.8 min (% Area = 98%). 
 
4-{(2R)-2-[(2R)-2-((m-nitro)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1k) 
White solid (26 mg, 50%); mp 202-221 
oC; RF (DCM/Me2CO 6:1) 0.35; δH (400 
MHz, DMSO-d6) 10.36 (s, 1H, -NH-QN), 
8.83 (d, J= 4.8 Hz, 1H, Ha), 8.60 (d, J= 
7.2 Hz, 1H, He), 8.41-8.40 (m, 2H), 8.33 
(d, J= 8.8 Hz, 1H) (-NH-Leu, -NH-hPhe, 
Hd’), 8.21 (dd, J= 8.2 Hz, J=1.2 Hz, 1H, 
Hb’), 8.07-7.98 (m, 3H, Hb, Hh, Ha’), 7.74-7.67 (m, 2H, Hf, Hc’), 7.56 (d, J= 15.6 Hz, 1H, 
Hy), 7.29-7.14(m, 5H, Ho-q), 6.99 (d, J= 16 Hz, 1H, Hx), 4.73-4.68 (m, 1H), 4.63-4.58 
(m, 1H) (Hk, Hs), 2.87-2.63 (m, 2H, Hm), 2.20-2.00 (m, 2H, Hl), 1.74-1.49 (m, 3H, Ht-u), 
0.90 (dd, J= 14.4 Hz, J= 6.4 Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 172.5, 171.7, 164.3 
(Cj, Cr, Cw), 152.2, 149.0, 148.2, 141.4, 141.0, 136.7, 136.6, 134.1, 133.6, 130.4, 128.3, 
128.2, 127.9, 126.3, 125.9, 124.8, 124.5, 123.7, 121.4, 119.4, 112.4 (Ca-Ci, Cn-Cq, Cx-
Ce’), 53.5, 51.1 (Ck, Cs), 40.8, 33.0, 31.5, 24.2, 23.0, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: 
m/z (M+H+) 628.53 (C34H34ClN5O5 requires 627.22); HPLC-DAD: rt = 11.1 min (% Area = 
100%). 
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4-{(2R)-2-[(2R)-2-((p-nitro)cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1l) 
Yellowish solid (11 mg, 17%); mp 
252-257 oC; RF (DCM/Me2CO 6:1) 
0.35; δH (400 MHz, DMSO-d6) 
10.34 (s, 1H, -NH-QN), 8.82 (d, J= 
5.2 Hz, 1H, Ha), 8.60 (d, J= 7.2 
Hz, 1H, He), 8.49 (d, J= 8 Hz, 1H), 
8.33 (d, J= 9.2 Hz, 1H) (-NH-Leu, -
NH-hPhe), 8.27 (d, J= 8.4 Hz, 2H, 
Hb’), 8.04 (m, 2H, Hb, Hh), 7.81 (d, J= 9.2 Hz, 2H, Ha’), 7.66 (dd, J= 9.2 Hz, J= 2 Hz, 
1H, Hf), 7.53 (d, J= 15.6 Hz, 1H, Hy), 7.29-7.15 (m, 5H, Ho-q), 6.96 (d, J= 16 Hz, 1H, 
Hx), 4.74-4.68 (m, 1H), 4.64-4.57 (m, 1H) (Hk, Hs), 2.87-2.62 (m, 
2H, Hm), 2.20-2.10 (m, 2H, Hl), 1.74-1.52 (m, 3H, Ht-u), 0.90 (dd, J= 15.6 Hz, J= 6.4 Hz, 
6H, Hv); δC (100 MHz, DMSO-d6) 172.6, 171.8, 164.3 (Cj, Cr, Ct), 152.3, 149.1, 147.6, 
141.5, 141.4, 141.1, 136.8, 134.3, 128.6, 128.4, 128.3, 128.0, 126.5, 126.0, 124.6, 
124.2, 122.8, 119.5, 112.6 (Ca-Ci, Cn-Cq, Cx-Cc’), 53.4, 51.2 (Ck, Cs), 40.7, 33.0, 31.4, 
24.2, 22.9, 21.6 (Cl-Cm, Ct-Cv); ESI-IT MS: m/z (M+H+) 628.73 (C34H34ClN5O requires 
627.22); HPLC-DAD: rt = 18.0 min (% Area = 92%). 
 
4-{(2S)-2-[(2S)-2-(cinnamoyl)amino-4-methylpentanoyl]amino-4-
phenylbutanoyl}amino-7-chloroquinoline (1a’)  
The L-amino acid analogues of precursors 
5-7 (5’-7’) were prepared by methods 
similar to those above described for their D-
amino acid counterparts. Compound 7’ was 
subsequently used to synthesize 1a' as 
previously described for 1a, and the target 
product 1a’ was isolated as white solid (10 
mg, 26%); mp 240-242 oC; RF (DCM/Me2CO 6:1) 0.36; δH (400 MHz, DMSO-d6) 10.35 (s, 
1H, -NH-QN), 8.83 (d, J= 5.2 Hz, 1H, Ha), 8.57 (d, J= 7.6 Hz, 1H, He), 8.35-8.31 (m, 2H, 
-NH-Leu, -NH-hPhe), 8.06-8.04 (m, 2H, Hb, Hh), 7.67 (dd, J= 9.2 Hz, J= 2 Hz, 1H, Hf), 
7.49 (d, J= 7.2Hz, 2H), 7.48-7.33 (m, 4H) (Ha’-c’, Hy), 7.32-7.16 (m, 5H, Ho-q), 6.79 (d, 
J= 16 Hz, 1H, Hx), 4.76-4.51 (m, 2H, Hk, Hs), 2.84-2.63 (m, 2H, Hm), 2.20-2.00 (m, 2H, 
Hl), 1.73-1.51 (m, 3H, Ht-u), 0.90 (d, J= 16 Hz, J= 6.4 Hz, 6H, Hv); δC (100 MHz, DMSO-
d6) 172.7, 171.7, 164.9 (Cw, Cr, Ct), 152.2, 149.0, 141.4, 141.0, 138.9, 134.8, 134.1, 
129.4, 128.9, 128.3, 128.2, 127.9, 127.4, 126.3, 125.8, 124.5, 121.9, 119.4, 112.4 (Ca-I, 
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Cn-q, Cx-c’), 53.4, 51.1 (Ck, Cs), 40.8, 33.0, 31.4, 24.2, 22.9, 21.6 (Cl-Cm, Ct-Cv); ESI-
IT MS: m/z (M+H+)  583.60 (C34H35ClN4O3 requires 582.24); HPLC-DAD: rt = 17.1 min 
(% Area = 100%).  
 
(2R)-4-methyl-N-[(1R)-(morpholine-4-carbonyl)-3-phenyl-propyl]-2-[(cinnamoyl) 
amino]pentanamide (8):  
Compound 8 was obtained following a synthetic 
procedure similar to the one described for HEDICINs 
but starting from morpholine instead of 4-amino-7-
chloroquinoline 3 (Scheme 9). In a round bottom at 
0oc, 1eq of the DhPhe-OH (0.2g, 0.72 mmol) was 
activated using 1 eq of TBTU (0.23 g, 0.72 mmol) 
and 2 eq of DIEA in DMF. After 10 min, 1.1 eq of 
morpholine (0.07 g, 0.78 mmol) was added and the reaction ran for a day. To extract the 
desired product 9, 15 mL of DCM were added and the organic layer was washed three 
times with HCl 1% and NaCO3 5%. The organic layer was dried over Na2SO4 anhydrous, 
filtered, and evaporated down. Liquid chromatography was required to obtain the Mu-
hPhe 9 with a 67 % yield. TFA was used to remove the corresponding Boc-protecting 
group and obtained the Mu-DhPhe-NH2 10. Posteriorly, the latter resulted compound 
was coupled to Boc-D-Leu using 1.1 eq of PyBOP as coupling reagent and DIEA in 
DCM. The subsequent Boc protecting group was also removed with TFA. The resulted 
amine (Mu-hPhe-Leu-NH2 12) was coupled to cinnamic acid using again PyBOP as 
coupling reagent, DIEA, and DCM. Liquid chromatography using as eluent DCM/Me2CO 
6:1 v/v was also required to purify compounds 12 and 8. Compound 8 resulted a white 
solid (39mg, 33%); mp 95-100oC; RF (DCM/Me2CO 6:1) 0.2; δH (400 MHz, CDCl3) 7.58 
(d, J= 16 Hz, 1H, Hr), 7.47 (m, 1H, -NHC=O), 7.40-7.38 (m, 2H, Ht), 7.31-7.09 (m, 8H, 
Hh-Hj, Hu-Hv), 6.85-6.76 (m, 1H, -NHC=O), 6.46 (d, J= 15.6 Hz, 1H, Hq), 4.97-4.89 (m, 
1H), 4.80-4.74 (m, 1H) (Hd, Hl), 3.65-3.21 (m, 8H, Ha-Hb), 2.62-2.58 (m, 2H, Hf), 2.01-
1.84 (m, 2H, He), 1.73-1.52 (m, 3H, Hm-Hn), 0.91-0.88 (m, 6H, Ho); δC (100 MHz, 
CDCl3) 172.9, 170.0, 165.7 (Cc, Ck, Cp), 141.5, 140.8, 134.7, 129.6, 128.7, 128.4, 
128.4, 127.8, 126.1, 120.3, (Cg-Cj, Cq-Cv) 66.6 (Ca), 51.9, 48.1, 45.8 (Cb, Cd, Cl), 41.9, 
34.9, 31.3, 24.8, 23.0, 22.1 (Ce-Cf, Cm-Co); ESI-IT MS: m/z (M+H+) 492.27 (C29H37N3O4 
requires 491.28); HPLC-DAD rt = 17.5 (% Area 100). 
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2.2.1.4. Synthesis of compounds 2a-k (HECINs) 	  
2.2.1.4.1. Coupling reaction using the relevant cinnamic acid 
The respective cinnamic acid (1.1 eq), PyBOP (1.1 eq), DIEA (2 eq.) and DCM (2 mL) 
were mixed in a round bottom flask and put under stirring for 20 min. Then, a solution of 
3 (0.250 g, 1.40 mmol) in DMF (2 mL) was added and the reaction allowed to proceed 
for one day at room temperature. Following, the reaction mixture was diluted with 14 mL 
of DCM and sequentially washed with 1% aq. HCl (3×18 mL) and 5% aq. Na2CO3 (3×18 
mL). Finally, the organic layer was dried with anhydrous Na2SO4, filtered, and 
evaporated to dryness. In all cases, the crude product had to be purified by liquid 
chromatography on silica, using DCM/Me2CO 6:1 v/v as eluent. Target compounds were 
isolated as solids, with analytical, and spectral data given below. 
 
2.2.1.4.2. Coupling reaction using the relevant acyl chloride 
In a round bottom flask at room temperature, it was added 1 eq of compound 3, 1.1 eq of 
the respective acyl chloride, 2.5 eq of K2CO3, and catalytic amount of 18-crown-6 in 
tetrahydrofuran (THF). The reaction ran overnight. Later it was added HCl 1% and the 
desired product was extracted with ethyl acetate. The organic layer was washed with 
Na2CO3 15 %, dried over Na2SO4 anhydrous, filtered, and evaporated down. Liquid 
chromatography was required to obtain the corresponding cinnamoylated derivative. The 
eluent used was DCM/Me2CO 3:1. 
 
4-(cinnamoyl)amino-7-chloroquinoline (2a) 
White solid (62 mg, 18%); mp 170-176 oC; RF 
(DCM/Me2CO 3:1) 0.56; δH (400 MHz, DMSO-d6) 
10.42 (s, 1H, -NH-QN), 8.85 (d, J= 5.2 Hz, 1H, 
Ha), 8.48 (d, J= 9.2 Hz, 1H, He), 8.33 (d, J=5.2 
Hz, 1H, Hb), 8.05 (d, J= 2.4 Hz, 1H, Hh), 7.74-
7.68 (m, 4H), 7.51-7.42 (m, 3H, Hf, Hl, Hn-Hp), 
7.27 (d, J=15.6 Hz, 1H, Hk); δC (100 MHz, DMSO-d6) 164.8 (Cj), 152.2, 149.1, 141.9, 
141.7, 134.5, 134.1, 130.1, 129.0, 128.0, 127.9, 126.3, 124.4, 121.5, 119.0, 111.5 (Ca-i, 
Ck-p); ESI-IT MS: m/z (M+H+) 309.33 (C18H13ClN2O requires 308.07); HPLC-DAD: rt = 
8.10 min (% Area = 85%). 
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4-[(p-methyl)cinnamoyl]amino-7-chloroquinoline (2b) 
Beige solid (11 mg, 2%); mp 209-218 oC; RF 
(DCM/Me2CO 3:1) 0.56; δH (400 MHz, DMSO-
d6) 10.38 (s, 1H, -NH-QN), 8.85 (d, J= 5.2 Hz, 
1H, Ha), 8.49 (d, J= 9.2 Hz, 1H, He), 8.33 (d, 
J= 5.2 Hz, 1H, Hb), 8.05 (d, J= 2 Hz, 1H, Hh), 
7.74-7.67 (m, 2H, Hf, Hl), 7.58 (d, J= 8.4 Hz, 
2H, Hn), 7.29 (d, J= 8 Hz, 2H, Ho), 7.21 (d, J= 15.6 Hz, 1H, Hk), 2.35 (s, 3H, Hq); δC 
(100 MHz, DMSO-d6) 164.9 (Cj), 152.2, 149.1, 141.9, 141.8, 140.0, 134.1, 131.8, 129.6, 
128.0, 127.9, 126.3, 124.4, 120.4, 119.0, 111.5 (Ca-Ci, Ck-Cp), 20.9 (Cq); ESI-IT MS: 
m/z (M+H+) 323.40 (C19H15ClN2O requires 322.09); HPLC-DAD: rt = 9.30 min (% Area = 
85%). 
 
4-[(p-isopropyl)cinnamoyl]amino-7-chloroquinoline (2c) 
Beige solid (17 mg, 3%); mp 187-204 oC; RF 
(DCM/Me2CO 3:1) 0.56; δH (400 MHz, DMSO-
d6) 10.40 (s, 1H, -NH-QN), 8.84 (d, J= 5.2 Hz, 
1H, Ha), 8.49 (d, J= 9.2 Hz, 1H, He), 8.33 (d, 
J= 5.2 Hz, 1H, Hb), 8.05 (d, J= 2.4 Hz, 1H, Hh), 
7.74-7.67 (m, 2H, Hf, Hl), 7.61 (d, J= 8.4 Hz, 
2H, Hn), 7.35 (d, J= 8 Hz, 2H, Ho), 7.23 (d, J= 15.6 Hz, 1H, Hk), 2.96-2.90 (m, 1H, Hq), 
1.22 (d, J= 6.8 Hz, 6H, Hr); δC (100 MHz, DMSO-d6) 164.9 
(Cj), 152.2, 150.8, 149.1, 141.9, 141.8, 134.1, 132.1, 128.0, 127.0, 126.7, 126.3, 124.4, 
120.8, 118.9, 111.5 (Ca-i, Ck-p), 33.3, 23.5 (Cq-Cr); ESI-IT MS: m/z (M+H+) 351.27 
(C21H19ClN2O requires 350.12); HPLC-DAD: rt = 11.4 min (% Area = 85%). 
 
4-[(p-methoxy)cinnamoyl]amino-7-chloroquinoline (2d) 
Beige solid (83 mg, 18%); mp 240-242 oC; 
RF (DCM/Me2CO 3:1) 0.56; δH (400 MHz, 
DMSO-d6) 10.34 (s, 1H, -NH-QN), 8.83 (d, 
J= 4.8 Hz, 1H, Ha), 8.49 (d, J= 8.8 Hz, 1H, 
He), 8.33 (d, J= 5.2 Hz, 1H, Hb), 8.05 (d, 
J= 2 Hz, 1H, Hh), 7.73-7.63 (m, 4H, Hf, Hl, 
Hn), 7.12 (d, J= 15.6 Hz, 1H, Hk), 7.04 (d, 
J= 8.8 Hz, 2H, Ho), 3.82 (s, 3H, Hq); δC (100 MHz, DMSO-d6) 165.1 (Cj), 160.8, 152.2, 
149.1, 141.9, 141.7, 134.0, 129.6, 127.9, 127.1, 126.2, 124.4, 118.9, 118.9, 114.5, 111.3 
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(Ca-Ci, Ck-Cp), 55.3 (Cq); ESI-IT MS: m/z (M+H+) 339.33 (C19H15ClN2O2 requires 
338.08); HPLC- DAD: rt= 6.80 min (% Area= 97%). 
 
4-[(m-fluoro)cinnamoyl]amino-7-chloroquinoline (2e) 
Yellow solid (4 mg, 1%); mp 181-190 oC; RF 
(DCM/Me2CO 3:1) 0.56; δH (400 MHz, 
DMSO-d6) 10.45 (s, 1H, -NH-QN), 8.85 (d, 
J= 5.2 Hz, 1H, Ha), 8.47 (d, J= 8.8 Hz, 1H, 
He), 8.32 (d, J= 5.2 Hz, 1H, Hb), 8.06 (d, J= 
2 Hz, 1H, Hh), 7.74-7.69 (m, 2H, Hf, Hl), 
7.54-7.50 (m, 3H, Hn, Hp, Hr), 7.26-7.31 
(m, 2H, Hk, Ho); δC (100 MHz, DMSO-d6) 164.5 (Cj), 163.6, 152.2, 149.1, 141.7, 140.5, 
137.1, 134.1, 131.0, 128.0, 126.4, 124.3, 124.0, 123.1, 119.0, 116.6, 114.4, 111.6 (Ca-
Ci, Ck-Cq); ESI-IT MS: m/z (M+H+) 327.33 (C18H12ClFN2O requires 326.06); HPLC-DAD: 
rt= 8.70 min (% Area = 98%). 
 
4-[(p-fluoro)cinnamoyl]amino-7-chloroquinoline (2f) 
White solid (19 mg, 4%); mp 210-212 oC; 
RF (DCM/Me2CO 3:1) 0.56; δH (400 MHz, 
DMSO-d6) 10.42 (s, 1H, -NH-QN), 8.85 (d, 
J= 4.8 Hz, 1H, Ha), 8.48 (d, J= 9.2 Hz, 1H, 
He), 8.32 (d, J= 4.8 Hz, 1H, Hb), 8.06 (d, J= 
2 Hz, 1H, Hh), 7.78-7.70 (m, 4H, Hf, Hl, 
Hn), 7.33 (t, J= 9 Hz, 2H, Ho), 7.21 (d, J= 
15.6 Hz, 1H, Hk); δC (100 MHz, DMSO-d6) 164.7 (Cj), 152.2, 149.1, 141.7, 140.7, 134.1, 
131.2, 130.1, 128.0, 126.3, 124.4, 121.4, 119.0, 116.1, 115.9, 111.5 (Ca-Ci, Ck-Cp); 
ESI-IT MS: m/z (M+H+) 327.11 (C18H12ClFN2O requires 326.06); HPLC-DAD: rt = 8.50 
min (% Area = 89%). 
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4-[(p-chloro)cinnamoyl]amino-7-chloroquinoline (2g) 
White solid (44 mg, 21%); mp 240-250 
oC; RF (DCM/Me2CO 3:1) 0.56; δH (400 
MHz, DMSO-d6) 10.44 (s, 1H, -NH-QN), 
8.85 (d, J= 5.2 Hz, 1H, Ha), 8.47 (d, J= 
9.2 Hz, 1H, He), 8.32 (d, J= 4.8 Hz, 1H, 
Hb), 8.06 (d, J= 2 Hz, 1H, Hh), 7.72 (m, 
4H, Hf, Hl, Hn), 7.55 (d, J= 8.4 Hz, 2H, 
Ho), 7.26 (d, J= 16 Hz, 1H, Hk); δC (100 MHz, DMSO-d6) 164.6 (Cj), 152.2, 149.1, 141.7, 
140.5, 134.5, 134.1, 133.5, 129.5, 129.1, 128.0, 126.3, 124.3, 122.3, 119.0, 
111.6 (Ca-Ci, Ck-Cp); ESI-IT MS: m/z (M+H+) 343.33 (C18H12Cl2N2O requires 342.03); 
HPLC-DAD: rt = 8.30 min (% Area = 96%). 
 
4-[(p-bromo)cinnamoyl]amino-7-chloroquinoline (2h) 
Green solid (38 mg, 7%); mp (dec.) 190 oC; 
RF (DCM/Me2CO 3:1) 0.56; δH (400 MHz, 
DMSO-d6) 10.44 (s, 1H, -NH-QN), 8.85 (d, 
J= 5.2 Hz, 1H, Ha), 8.47 (d, J= 8.8Hz, 1H, 
He), 8.32 (d, J=4.8 Hz, 1H, Hb), 8.08 (d, J= 
2.4 Hz,1H, Hh), 7.74-7.70 (m, 6H, Hf, Hl, 
Hn-o), 7.27 (d, J= 16 Hz, 1H, Hk); δC (100 MHz, DMSO-
d6) 164.6 (Cj), 152.2, 149.1, 141.7, 140.5, 134.1, 133.8, 132.0, 129.8, 128.0, 126.3, 
124.3, 123.3, 122.4, 118.9, 111.6 (Ca-Ci, Ck-Cp); ESI-IT MS: m/z (M+H+)  387.27 
(C18H12BrClN2O requires 385.98); HPLC-DAD: rt = 8.60 min (% Area = 97%). 
 
4-[(o-nitro)cinnamoyl]amino-7-chloroquinoline (2i) 
Yellow solid (36 mg, 7%); mp 168-200 oC; 
RF (DCM/Me2CO 3:1) 0.56; δH 
(400MHz,DMSO-d6) 10.56 (s, 1H, -NH-QN), 
8.87 (d, J= 5.2 Hz, 1H, Ha), 8.47 (d, J= 8.8 
Hz, 1H, He), 8.32 (d, J= 4.8 Hz, 1H, Hb), 
8.12 (d, J= 8 Hz, 1H, Hq), 8.07 (d, J= 2 Hz, 
1H, Hh), 7.99 (d, J= 15.6 Hz, 1H, Hl), 7.88-
7.86 (m, 2H), 7.76-7.69 (m, 2H, Hf, Hn-p), 7.25 (d, J= 15.6 Hz, 1H, Hk); δC (100 MHz, 
DMSO-d6) 163.9 (Cj), 152.2, 149.0, 148.2, 141.4, 137.0, 134.1, 133.9, 130.7, 129.8, 
128.8, 128.0, 126.4, 126.1, 124.8, 124.3, 119.0, 111.7 (Ca-Ci, Ck-Cr); ESI-IT MS: m/z 
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(M+H+) 354.33 (C18H12ClN3O3 requires 353.06); HPLC-DAD: trt = 7.90 min (% Area= 
97%). 
 
4-[(m-nitro)cinnamoyl]amino-7-chloroquinoline (2j)  
White solid (11 mg, 2%); mp (dec.) 240-247 
oC; RF (DCM/Me2CO 3:1) 0.56; δH (400 MHz, 
DMSO-d6) 10.49 (s, 1H, -NH-QN), 8.86 (d, J= 
4.8 Hz, 1H, Ha), 8.53 (m, 1H, Hr), 8.49 (d, J= 
9.2 Hz, He), 8.34 (d, J= 5.2Hz, 1H, Hb), 8.27 
(dd, J= 8.2 Hz, J= 1.2 Hz, 1H, Hp), 8.11 (d, 
J= 8 Hz, 1H, Hn), 8.07 (d, J= 2 Hz, 1H, Hh), 
7.84 (d, J= 16 Hz, 1H, Hl), 7.80-7.73 (m, 2H, Hf, Ho), 7.46 (d, J= 16 Hz, 1H, Hk); δC (100 
MHz, DMSO-d6) 164.2 (Cj), 152.2, 149.1, 148.2, 141.5, 139.4, 136.3, 134.5, 134.2, 
130.6, 128.0, 126.4, 124.4, 124.3, 121.5, 118.9, 111.5 (Ca-Ci, Ck-Cr); ESI- IT MS: m/z 
(M+H+) 354.53 (C18H12ClN3O3 requires 353.06); HPLC-DAD: rt  = 7.20 min (% Area = 
100%). 
 
4-[(p-nitro)cinnamoyl]amino-7-chloroquinoline (2k) 
Beige solid (9 mg, 5%); mp desc. 205 oC; RF 
(DCM/Me2CO 3:1) 0.56; δH (400 MHz, 
DMSO-d6) 10.58 (s, 1H, -NH-QN), 8.87 (d, J= 
5.2 Hz, 1H, Ha), 8.48 (d, J= 9.2 Hz, 1H, He), 
8.35-8.32 (m, 3H, Hb, Ho), 8.07 (d, J= 2.4 Hz, 
1H, Hh), 7.94 (d, J= 8.8 Hz, 2H, Hn), 7.83 (d, 
J= 16 Hz, 1H, Hl), 7.74 (dd, J= 9 Hz, J= 2 Hz, 1H, Hf), 7.44 (d, J= 15.6 Hz, 1H, Hk); δC 
(100 MHz, DMSO-d6) 164.1 (Cj), 152.2, 149.1, 147.8, 141.5, 141.0, 139.3, 134.2, 128.9, 
128.0, 126.4, 125.8, 124.3, 124.2, 119.0, 111.7 (Ca-CI, Ck-Cp); ESI-IT MS: m/z 
(M+H+)  354.27 (C18H12ClN3O3 requires 353.06); HPLC-DAD: rt = 7.20 min (% Area= 
92%). 
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2.2.2. In vitro assessment of inhibition of β-H formation 
The inhibition of β-H formation assay was performed as previously described.7, 8 Briefly, 
in a 96-microwell plate it was respectively added i) 50 µL of different concentrations (0.1-
1 mM) of test compounds dissolved in DMSO, in triplicate, and ii) 50 µL hemin chloride 
dissolved in DMSO (5.2 mg/mL). Controls contained equal volumes of water or DMSO. 
β-H formation was initiated by the addition of acetate buffer 0.2 M (100 µL, pH 4.4), 
following plates were incubated at 37 oC for 48 h, and subsequently, they were 
centrifuged at 3000 rpm for 15 min (SIGMA 3-30K). After discarding the supernatant, the 
pellet was washed four times with DMSO (3×200 µL), and finally dissolved in 0.2 M aq. 
NaOH (200 µL). The solubilized aggregates were further diluted 1:6 with 0.1 M aq. NaOH 
and absorbances recorded at 405 nm on a Biotek Powerwave XS with software Gen5 
1.07. 
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3.0. Preamble 
HEDICINs and HECINs were also evaluated against another parasitic cysteine protease, 
babesipain-1 from Babesia bigemina, one of the causing agents of babesiosis, a malaria-
like disease that mainly affects cattle and represents a huge economic burden in the 
cattle industry.1, 2 In vitro evaluation of babesipain-1 inhibition by HEDICINs and HECINs 
was carried out by Dr. Ana Domingos’s team at the Instituto de Higiene e Medicina 
Tropical – Universidade Nova de Lisboa. The doctoral candidate performed a parallel 
study in silico, in order to evaluate the interaction of HEDICINs and HECINs with 
babesipain-1 at the atomic level bbspn-1. As such, and given that there was no three-
dimensional (3D) structure available for babesipain-1, a homology model was built and 
validated, followed by the respective molecular docking of the ligands. 
 
3.1. Babesiosis and Babesia parasites – brief overview 
Babesiosis is a worldwide distributed disease caused by protozoans of the genus 
Babesia, which is transmitted by Rhipicephalus (Boophilus) sp. ticks.2 The symptoms of 
babesiosis included fever, anemia, hemoglobinuria, malaise, and anorexia.2 There are 
several species which cause babesiosis, but the two species which cause more 
economical impact are Babesia bovis and Babesia bigemina.2 The reproductive life cycle 
of Babesia is similar to that of Plasmodia parasites. The sporogony and the gamogony 
takes places in the invertebrate host while merogony, the asexual dividing stage, occurs 
within the erythrocyte of the human host (Fig. 22).3, 4  
Vaccines containing live attenuated parasites are the main strategy to control this 
disease but failures of protective immunity provided by vaccination have been observed 
since these vaccines do not offer cross protection against the different variants in the 
field.5, 6 Moreover, chemoprophylaxis is used as short-term protection during epidemics 
when cattle are being relocated, or to treat pregnant cows. Some examples of drugs 
used to treat babesiosis are diminazene aceturate (XXVIII) or imidocarb (XXIX), and in 
clinical cases clindamycin (XXX) and quinine (XXXI), the latter two are also known to 
treat against malaria.4 Nonetheless, there is the need for a more specific, fast acting, and 
safe chemotherapy to combat the disease.7  
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Figure 22. Babesia life cycle: sporozoites (Sz) differentiate into trophozoites (T) when they enter 
into the vertebrate host’s blood stream. Later, T asexually divide into merozoites (M) which exit 
the erythrocyte and invade other cells and continue to replicate. Some M stop division and 
transform into pre-gametocytes (G). When G are taken into the invertebrate host by a tick feeding, 
they differentiate into Strahlenkörper (Sk); Sk fuse and form zigotes (Z), which undergo meiosis 
given rises to kinetes (Ts and To). To represents kinetes which go into the tick’s ovaries and 
eggs, whereas Ts represents kinetes which transform in the salivary glands (Sg) of the tick into 
Sz ready to infect the next vertebrate host.2 
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Like Plasmodia, B. bigemina is a protozoan of the phylum Apicomplexa.4 The 
sequencing of the genome of B. bigemina is a project in active progress8 and the 
information obtained to this point has revealed potential targets that may be useful for 
the development of new chemotherapy strategies against babesiosis. For instance, three 
cysteine proteases from B. bigemina, BbiCPL1 to BbiCPL3, have been identified which 
belong to the same cysteine protease family and share many features with papain.9 
These features include: i)	   20–23 amino acid putative transmembrane domain, ii) the 
ERFNIN and GNFD pro-sequence motifs typical of cathepsin L-like cysteine proteases, 
iii) the main catalytic residues, for instance, histidine, cysteine and asparagine, and iv) 
six cysteine residues predicted to form disulfide bonds in the mature domain of the 
protease.9  
BbiCPL1 (bbspn-1) is the first cysteine protease from a piroplasm described to possess 
proteolytic activity.9 It is believed to act in the cytosol at an optimum acidic pH of 5.5, and 
it is inhibited by leupeptin and E64,7, 9 known inhibitors of cysteine proteases. In this 
context and based on the fact that i) the roles of cysteine proteases in protozoan 
parasites are often associated with cell invasion and rupture10, and ii) it has been found 
that modest falcipain inhibitors11 are more potent inhibitors of bbspn-1 than of FP2,1 
some HEDICINs and HECINs were further evaluated against bbspn-1.  
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3.2. In vitro evaluation of HE[DI]CINs as bbspn-1 inhibitors 
HE[DI]CINs were evaluated following previously described methods.1 Results obtained 
(Table 5) demonstrated that HEDICINs and HECINs are generally more efficient 
inhibitors of bbspn-1 (IC50 = 9.7-35.8 µM and IC50 = 9.8-48.3 µM, respectively) than of 
FP2 (IC50 = 23.1->50 µM and IC50 = 14.2->50 µM, respectively). Close analysis of the 
data shows: 
• HEDICINs and HECINs displayed about the same range of activities IC50 = 9.7-
35.8 µM and IC50  = 9.8-48.3 µM, respectively. 
• Electro-donating substituents in the cinnamoyl moiety seem to be preferred in 
HECINs series. For instance, the p-OMe substituted compound 2d is more active 
(IC50 = 9.8 µM) than the p-Me analogue 2b (IC50 = 13.4 µM), in turn more active 
than the unsubstituted derivative 2a (IC50 = 20.3 µM). Such pattern is not 
observed in HEDICINs series. 
• HEDICINs results suggest that meta substitution is preferred over ortho 
substitution in the cinnamoyl moiety. For instance, m-NO2 derivatives 1k (IC50 = 
10.2 µM) was more active than o-NO2 1j (IC50 = 18.6 µM). Similar results were 
observed against FP2. 
• No significant different was observed between meta and para substitution in 
HEDICINs series. For example, the p-F 1g and the m-F 1f presented IC50 of 28.1 
µM and 29.1 µM, respectively. The same is observed in HECINs series. 
• Contrary to HECINs results, the best inhibitor of HEDICINs displayed electro-
withdrawing group (p-Cl 1h, IC50 = 9.7 µM) and the worst presented an electro-
donating group (p-OMe 1d, IC50 = 35.8 µM) in the para position. 
• No clear correlation was found between the lipophilicity of the compounds (clog 
P; see table 3 in chapter 2)12 or Charton steric parameter (ν)13 of p-alkyl 
substituent on the cinnamoyl moiety (0.0, 0.52 and 0.76 for alkyl substituents of 
compound 1a, 1b, and 1c, respectively), and compounds’ ability to inhibit 
babesipain-1. 
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Table 5. In vitro data on test compounds, HEDICINs 1 and HECINs 2, as bbspn-1 inhibitors. Compounds’ 
activity as FP2 inhibitors (determined as described in chapter 2) is also displayed, for better comparison. 
HEDICINs R bbspn-1 IC50(µM) 
FP2 IC50 
(µM) HECINs R 
bbspn-1 
IC50(µM) 
FP2 IC50 
(µM) 
1a H 30.8 ± 12.7 19.6 ± 0.4 2a H 20.3 ± 3.1 >50 
1b p-Me 31.3 ± 11.2 >50 2b p-Me 13.4 ± 2.3 28.5 ± 0.3 
1c p-iPr 27.7 ± 10.9 >50     
1d p-OMe 35.8 ± 12.2 >50 2d p-OMe 
9.8 ± 0.6 >50 
1f m-F 29.1 ± 5.7 23.1 ± 1.6 2e m-F 20.9 ± 2.2 >50 
1g p-F 28.1 ± 7.6 50.0 2f p-F 17.4 ± 1.5 >50 
1h p-Cl 9.7 ± 3.0 >50 2g p-Cl 17.9 ± 4.2 41.3 ± 1.2 
1i p-Br 11.0 ± 2.3 48.3 ± 2.4  2h p-Br 14.2 ± 5.2 33.1 ± 3.0 
1j o-NO2 18.6 ± 8.8 >50     
1k m-NO2 10.2 ± 3.5  28.1 ± 3.5 2j m-NO2 48.3 ± 14.7 14.2 ± 0.4 
E64[a]  13.7 ± 3.7 24.6 ± 1.2  
 13.7 ± 3.7 24.6 ± 1.2 
[a] E64 values are in the nM level.  
 
3.3. In silico study of bbspn-1 inhibition by HE[DI]CINs 
A better understanding of the distinctive features of FP2 versus bbspn-1, and of their 
respective interactions with compounds 1 and 2, was pursued through an in silico study. 
This study comprised two major tasks: 1) generation of the bbspn-1 model structure by 
homology modeling, and 2) compound-model enzyme docking studies. 
 
3.3.1. Generation and validation of the bbspn-1 model structure by 
  homology modeling 
The number of crystallographic structures available in Protein Data Bank (PDB) 
(http://www.pdb.org/pdb/home/home.do), though high, is not comparable to the huge 
number of sequences entries encountered in the Universal Protein Resource (Uniprot) 
database (http://www.uniprot.org/). The elucidation of the 3D structure of a protein by X-
ray diffraction crystallography is a high-demanding and frequently unsuccessful 
endeavor. In addition, some proteins are too large for NMR analysis or unable to be 
crystallized for X-ray diffraction.14 In those cases where the 3D structure of a protein of 
interest is unavailable, but the protein’s sequence is known, a model structure may be 
predicted by in silico homology modeling, based on the sequence similarity to other 
proteins whose 3D structures are available. Homology modeling thus provides a 3D 
structure of the desired protein that can be used to carry out studies such as structure-
based drug design, analysis of protein functions, ligand-protein interactions, and protein-
protein interactions, among others.14 
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In order to build the 3D structure of bbspn-1, i) the protein’s sequence was obtained, ii) a 
template search was carried out to identify homolog sequences using the mature site of 
bbspn-1, iii) the corresponding homolog structures were aligned with that of bbspn-1 to 
generate several model candidates, and finally, iv) the generated models were validated 
using a toolbox of validation techniques. 
 
i) Obtaining the sequence of bbspn-1 
The complete sequence of bbspn-1 was searched using the Uniprot database. Once the 
entire sequence (458 amino acids) was retrieved, the enzyme’s mature site was 
identified based on results previously reported by Domingos et al., and the prodomain of 
the protein was cleaved off (Fig. 23).9 Accordingly, the mature sequence contained 217 
amino acids starting from residue Ser242. For simplicity purposes, the numbering of the 
mature sequence was started from 1 for the following studies performed. 
Correspondingly, Ser242 and His458 were addressed as Ser1 and His217, respectively. 
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Figure 23. Sequence of bbspn-1 found in Uniprot. Amino acids 1 to 247 respresent the prodomain and 
Amino acids 242 to 458 represent the mature site of the enzyme according to Domingos et al.9 
 
ii) Template search and selection 
A template search using BLAST was conducted, using the sequence of the mature site 
of bbspn-1 and PDB as database. Based on the search results, the only homolog 
sequences selected were the ones which complied with the following set restrictions: a) 
E-value below 10-40; b) query coverage > 90 % and sequence identity > 35% or query 
coverage > 85% and sequence identity > 40%; c) a PDB structure with a resolution < 2.5 
Å without missing residues in the active site and with bound ligand (See table 6). The 
quality of the built model depends on the quality of the sequence alignment and structure 
template chosen, for instance, the closest the E value to zero the highest the level of the 
sequence similarity.15 Therefore, the previous set restrictions would encourage the 
probability of obtaining reliable results in further studies carried to achieve the desired 3D 
structure of bbspn-1 through homology model. 
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Table 6. Homolog sequences identified with BLAST according to the established search criteria. 
PDB 
code 
(chain 
used) 
Uniprot 
code Organism 
Identity 
% 
Coverage 
% 
PDB 
resolution 
(Å) 
E-value 
1EWM 
(A) P25779 
Trypanosoma 
cruzi 43 91 2.00 1 x 10
-41 
1S4V 
 (A) O65039 
Ricinus 
communis 41 87 2.00 2 x 10
-43 
2BDZ 
(C) P84346 
Jacaratia 
mexicana 38 95 2.10 4 x 10
-43 
2OUL 
(A) Q9N6S8 
Plasmodium 
falciparum 41 94 2. 20 1 x 10
-46 
2P7U  
(A) Q95PM0 
Trypanosomo 
brucei 
rhodesiense 
43 90 1.65 2 x 10-42 
3BWK 
(B) Q9NAW4 
Plasmodium 
falciparum 41 94 2.42 3 x 10
-45 
 
 
Multiple sequence alignment performed using PSI-coffee16 of the sequence of bbspn-1 
and the selected templates is presented in Figure 24. For simplicity, the numbering was 
started at 1 for all the alignments performed and the numbering referred in the text 
corresponds to bbspn-1 sequence. Based on their sequences, bbspn-1 and the six 
homologs are classifiable as cysteine peptidases belonging to Clan CA, subfamily C1A. 
These peptidases present the catalytic residues glutamine (Gln19), cysteine (Cys25), 
histidine (His55), and asparagine (Asn177) that follow always the same order.17 
Alignment of bbspn-1 with the corresponding homolog sequences demonstrated strict 
conservation of the catalytic residues, significant similarities amongst the catalytic sites 
of the proteins and low polymorphism in the surrounding areas (Fig. 24). For instance, 
the tryptophan (Trp179) and Gln (Gln19) known to form the “oxyanion hole” are 
preserved.18 In addition, the 6 cysteine residues (Cys22, Cys63, Cys56, Cys95, Cys148, 
Cys201) predicted to form disulfide bonds are also observed. In addition, according to 
table 7 the selected templates present a significant number of residues in the active site 
as compared to bbspn-1. The proteases, which possess the highest similitude to bbspn-
1, are 1S4V and 2P7U.  
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Table 7. Sequence similarity against the active site of bbspn-1. 
bbspn-1 
S1’ S1 S2 S3 
V F T F H W Q G C G F S Y L F Q S S G G 
1 
3 
0 
1 
3 
2 
1 
3 
3 
1 
3 
7 
1 
5 
5 
1 
7 
9 
1 
9 
2 
3 
6 
3 
6 
4 
6 
7 
6 
8 
1 
2 
9 
1 
5 
3 
2 
0 
6 
5 
9 
6 
0 
6 
1 
6 
5 
6 
6 
1EWM 
(A) 
V A S M H W Q G C S L M A L E T D S G G 
1S4V 
 (A) I A G Q H W Q G C N L M A L E Q N Q G G 
2BDZ 
(C) 
T S R Q H W Q G C D Y Q V T S R S H G G 
2OUL 
(A) 
V V S A H W Q G C N L I S L D K N Y G G 
2P7U  
(A) V A T M H W Q G C G L M A L A I D F G G 
3BWK 
(B) 
I A S A H W Q G C Y Y I S P E K N N G G 
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Figure 24. Multiple sequence alignment performed with PSI-coffee mode of T-Coffee of the amino acid 
sequence of bbspn-1 and the selected templates. The boxes indicate the Cys25, His155, and Asn177 
catalytic regions, correspondingly. The arrows show the catalytic residues glutamine (Gln19), cysteine 
(Cys25), histidine (His155) and asparagine (Asn177), respectively. 
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All these described characteristics make the selected 3D structures suitable templates to 
build the 3D model structure of bbspn-1. Moreover, bbspn-1 will present a higher 
probability to fold in the same structure of the selected template if it has a percent 
sequence identity above ~30% and the length of the templates sequence, individually, 
fall below 250 as compared to the homolog protein (See figure 25).14 In other words, the 
higher the sequence similarity between the selected 3D template obtained from the PDB 
and bbspn-1, the more reliable will be the obtained results. However, since BLAST 
search only resulted proteins with identical residues to bbspn-1 closed to the limit but 
within the safe zone (Fig. 25), building the 3D structure of bbspn-1 through homology 
modeling represented a major challenge. 
 
 
	  
Figure 25. The safe zone defined for homology modeling.14 
 
iii) Sequence alignments and homology models generation 
Homology models were built by two different strategies: a) single template: using one 
available 3D structure homolog to bbspn-1, and b) multiple templates: combining up to 
three 3D structures homolog to bbspn-1. Selected templates were carefully aligned with 
bbspn-1 using PSI-coffee.16 Results demonstrated alignment scores, reflecting the 
expected accuracy of the alignment, up to 93%. Homology modeling calculations were 
done using Modeller v.9.11 (http://salilab.org/modeller/about_modeller.html) and PSI-
coffee alignments. One hundred models were generated for each template combination. 
As previous studies reported in the literature, Modeller performed best when using 
combinations of two or three templates as compared to a single template since it can 
utilize information from multiple templates.19 	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Figure 25.1. The two zones of sequence alignments. Two sequences are practically guaranteed
to fold into the same structure if their length and percentage sequence identity fall into the
region marked as ‘‘safe.’’ An example of two sequences with 150 amino acids, 50% of which are
identical, is shown (gray cross).
Imagine that we want to know the structure of sequence A (150 amino acids
long, Figure 25.2, steps 1 and 2). We compar sequenc A to all the seque ces of
known structures stored in the PDB (using, for example, BLAST), and luckily find
a sequence B (300 amino acids long) containing a region of 150 amino acids that
match sequence A with 50% identical residues. As this match (alignment) clearly falls
in the safe zone (Fig. 25.1), we can simply take the known structure of sequence B
(the template), cut out the fragment corresponding to the aligned region, mutate those
amino acids that differ between sequences A and B, and finally arrive at our model
for structure A. Structure A is called the target and is of course not known at the
ti e of modeling. In practice, homology modeling is a multistep process that can be
summarized in seven steps:
1. Template recognition and initial alignment
2. Alignment correction
3. Backbone generation
4. Loop modeling
5. Side-chain modeling
6. Model optimization
7. Model validation
At almost all the steps choices have to be made. The modeler can never be sure to
make the best ones, and thus a large part of the modeling process consists of serious
thought about how to gamble between multiple seemingly similar choices. A lot of
research has been spent on teaching the computer how to make these decisions, so
that homology models can be built fully automatically. Currently, this allows mod-
elers to construct models for about 25% of the amino acids in a genome, thereby
supplementing the efforts of structural genomics projects (Sanchez and Sali, 1999,
Peitsch, Schwede, and Guex, 2000). This average value of 25% differs significantly
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iv) Validating the built 3D structure of bbspn-1  
The quality assessment basically predicts substantial errors in the built model analyzing 
whether energy or structural parameters of the built models are comparable to those 
already reported experimental 3D structures.20 Multiple validations tools were used to 
assess the built 3D structures of babesipain-1 and enhance the probability to find 
possible errors non-detected by a single validation tool. For instance, ProSA 
measurement of model quality highly depends on protein size; the higher the protein 
size, the lowest the ProSA accuracy. Therefore, using multiple validation scores will 
suffice for the lack of accuracy of some validation tools. In this work, resulted homology 
models were assessed not only by Modeller 9.11 Z-score, but also by PROCHECK,21 
ProQ,22 QMEAN,20 and ProSA17, 18 (See tables 8-9) and visualization of the biomolecular 
system of the different models built. In addition, all the structures presenting a Modeller 
Z-DOPE >-1.00 were disregarded. Accordingly, the best models were expected to 
present i) >90 % of the amino acids in the most favorable region of the Ramachandran 
plot as determined by PROCHECK; ii) a Prosa Z-score which agrees with the scores 
obtained for the PDB structures of the templates used to derive the corresponding 
model; iii) an LG score > 5 and a Maxsub score > 0.5 as determined by ProQ; and iv) a 
QMEAN score > 0.75. These validation score restrictions will help in the selection of the 
most accurate model to evaluate the interaction of HEDICINs and HECINs against 
bbspn-1. Furthermore, docking calculations of a well-known inhibitor of cysteine 
protease, namely E64-C, were ran to evaluate whether resulted ligand conformations 
would allow a possible alkylation of the cysteine residue in the active site of bbspn-1 and 
the different functionalities of the ligands, respectively, were to place in the 
corresponding reported subsite of the cavity. Detailed analysis of the results of each 
validation tool is provided below. 
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Table 8. Homology modeling validation scores obtained by Modeller 9.11. 
Model Alignment Alignment score[a] 
Modeller  
(Z-DOPE) 
1 1EWM-1S4V-2BDZ_42 91 -1.06 
2 1S4V-2BDZ_18 93 -1.06 
3 1S4V-2BDZ_54 93 -1.05 
4 1EWM-1S4V-2BDZ_51 91 -1.04 
5 1EWM-1S4V-2BDZ_76 91 -1.04 
6 2BDZ-2P7U_77 89 -1.03 
7 1S4V-2BDZ_51 93 -1.01 
8 1S4V-2P7U_13 89 -1.01 
9 1S4V-2P7U_68 89 -1.00 
[a] Alignment score by Psi-coffee. 
 
Table 9. Additional scoring parameters of models built and selected according to Modeller 9.11 Z-DOPE 
score. 
Model 
ProQ QMEAN 
Score 
PROCHECK 
(%)[a] 
RMSD 
(Å)[b] 
LGscore MaxSub 
1 5.068 0.536 0.773 88.7; 10.2; 1.1; 0.0 
1.14; 
0.80; 
0.64 
2 5.118 0.555 0.742 91.4; 7.0;0.0;1.6 
0.91; 
0.65 
3 5.318 0.560 0.706 91.4; 7.5; 0.0; 1.1 
0.94; 
0.67 
4 5.091 0.508 0.720 87.6; 11.3; 0.5; 0.5 
1.11; 
0.74; 
0.61 
5 5.358 0.547 0.718 89.8; 8.1; 2.2; 0.0 
1.15; 
0.80; 
0.67 
6 5.394 0.575 0.703  
82.3; 14.5; 
1.6; 1.6 
1.08; 
0.87 
7 5.384 0.565 0.751 90.8; 7.0; 1.1; 1.1; 
0.79; 
0.71 
8 5.391 0.543 0.677 88.7; 10.2; 1.1; 0.0 
0.82; 
1.10 
9 5.297 0.538 0.684 90.3; 8.1; 1.6; 0.0 
0.61; 
1.10 
[a] Correspond to the percentage of residues that are located in the most favorable, 
additionally allowed, generously allowed, and disallowed regions, respectively 
according to the Ramachandran Plot. [b] RMSD values of babesipain-1 model 
compared to the 3D structures of the templates used for the alignment 
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VMD visualization 
All models (1-9) built for bbspn-1 were aligned and visualized using the molecular 
visualization program VMD. Accordingly, most structures were quite similar since the 
RMSD between the built models oscillated between 0.37 and 1.20. As expected the main 
differences observed in the binding cavity of bbspn-1 resulted from the phenylalanine 
residues, specifically, Phe132, Phe67, Phe137. Generally, the rest of the residues in the 
main cavity displayed a significantly similar conformation. 
 
PROCHECK 
According to PROCHECK results, model 7 has more than 90% of the amino acids in the 
most favored regions (Table 9) and there are only two amino acids in the disallowed 
region (Asp199, Arg102) of the Ramachandran diagram (Fig. 26). Analysis of the 3D 
structure in VMD shows that these amino acids are outside of the binding pocket of 
bbspn-1. In fact, the closest amino acid, Asp199, is located at ~20 Å of the α−carbon of 
the catalytic cysteine, falling completely out of the region used for docking HEDICINs 
and HECINs against the enzyme. Therefore, these amino acids should not have impact 
on further docking results. Model 5 and model 9 also present ≥ 90% of the amino acids 
in the most favorable regions but a difference from model 7, they do not present any 
amino acid in the disallowed regions. However, model 7 was derived from the alignment 
with the highest PSI-coffee alignment score and it presents the lowest RMSD compared 
to the original structures 1S4V and 2BDZ, which increases the probability that the 
sequence of bbspn-1 folds correctly on the template combination used to build the 
structure. 
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Figure 26. Ramachandran plot of built 3D structure of bbspn-1 for model 7. The different colored areas 
indicate ‘‘disallowed’’ (beige), ‘‘generously allowed’’ (yellow), ‘‘additional allowed’’ (brown), and ‘‘most 
favored’’ (red) regions. 
 
ProSA 
Additionally, ProSA, a diagnostic tool that is based on the statistical analysis of all 
available PDB structures, was used to reveal whether the built structures presented 
misfolded areas. This validation score specifically assesses whether the interactions of 
each residue in the built structure are favorable.23, 24 Accordingly, ProSA Z-score resulted 
for each experimental structure used are presented in Table 10. Comparison of 
ProSA Z-scores of experimental results with those obtained for each built model 
indicates overall good quality of the models since they Z-score are comparable to those 
obtained for the corresponding used templates. The best results are obtained for models 
4, 6, 7, and 9. As example, the overall model quality of model 7 is displayed in fig. 27. Z-
scores are -7.98, -6.48 and –6.85 for 1S4V (A), model 7 of bbspn-1 (B) and 2BDZ (C), 
respectively. Results demonstrated that although the Z-score of model 7 is slightly lower 
than that of template 1S4V, it is in the same range of template 2BDZ and it is a perfect fit 
within the structures in PDB. 
 
 
 
 
118 | Chapter 3  	  
Table 10. ProSA Z-score of experimental structure and build model. 
Model 
ProSA[a] 
Model 1EWM(A) 1S4V(A) 2BDZ(C) 2P7U(A) 
1 -6.43 
-6.85 -7.98 -6.85 -7.14 
2 -6.31 
3 -6.20 
4 -6.58 
5 -6.25 
6 -6.60 
7 -6.48 
8 -6.39 
9 -6.64 
[a] ProSA determined using ProSA-web. 
https://prosa.services.came.sbg.ac.at/prosa.php 
 
 
	  
Figure 27. ProSA analysis for the model structure of bbspn-1 (B) the template structures, 1S4V (A) and 
2BDZ (C).  
 
ProQ  
Models were also validated by ProQ which help to separate correct models from less 
correct models by finding similar fragments between a built model and a native structure. 
In other words, ProQ score allows to determine whether protein folds are not compatible 
with a protein sequence.25 The quality is quantified taking into account indexes 
LGscore22 and MaxSub.26 A model can be qualified as appropriate if LGscore > 1.5 and 
MaxSub > 0.1, good if LGscore > 3 and MaxSub > 0.5, and very good if LGscore > 5 and 
MaxSub > 0.8.27 Accordingly, model 6 and 7 presented the best ProQ 
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scores (Table 9). For instance, model 7 was evaluated as very good and good according 
to the LG score (5.384) and the MaxSub index (0.565), respectively. 
 
QMEAN 
QMEAN score was also used to validate the model. This score corresponds to the global 
score of the whole model, on the basis of a linear combination of six structural 
descriptors, reflecting the predicted model reliability ranging from 0 to 1 with higher 
scores for reliable models.20 In contrast to other validation tools such as ProSA, 
QMEAN’s quality score is not dependable on protein size. Accordingly, model 1 and 7 
presents the best reliability, compared to the rest of the built models, with a global 
QMEAN score of 0.773 and 0.751, respectively (Table 9). Moreover, the quality of the 
model can be further compared to reference structures of high resolution obtained from 
X-ray crystallography analysis through QMEAN Z-score, where a value of 0 is the 
average value for a good model.20 According to Benkert et al, QMEAN Z-score provides 
an estimation of the “degrees of nativeness” of the structural features observed in a 
model and indicates if the model has a quality comparable to experimental structures.20 
Based on results, QMEAN Z-score for babesipain-1 model 7 is -0.22 (Fig. 28), which 
reinforces the good quality of this derived model for babesipain-1. 
 
	  
Figure 28. Graphical representation of the estimation of the absolute quality of bbspn-1 model 7 assessed 
by QMEAN Z-score. Good models are generally located in the dark zone. The red cross represents the 
positioning of model 7. 	  
Docking known cysteine proteases inhibitors 
Docking studies were carried using the docking algorithm GOLD28 and the ligand E64-C, 
a known inhibitor of cysteine proteases. An active site radius of 12 Å centered in the 
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thiolate moiety of Cys25 was established. Docking calculation were run with flexible 
ligands and results obtained were compared with crystallographic structure already 
reported for papain (1PPP).29 Except for results found for model 7 (Fig. 29), most 
docking conformations resulted for each built model located the electrophilic warhead far 
away from Cys25, out of the binding site and into S2 and S3 pocket, or the oxygen of the 
epoxide of E64-C facing the thiolate moiety of Cys25. In the case of model 7, the most 
frequent ligand conformations place the electrophilic warhead of E64-C, respectively, at 
3.7 Å and right over the catalytic cysteine, a distance which could allow a cysteine 
alkylation to take place. Moreover, the docking conformation found for E64-C against 
model 7 significantly match the typical binding mode of the ligand against other cysteine 
protease such as papain (1PPP). Based on all above, model 7 is suitable to evaluate the 
interaction of HEDICINs and HECINs with bbspn-1 since it was the model that presented 
the best generally validation score according to PROCHECK, ProSA, ProQ, Qmean, and 
a known inhibitor of cysteine proteases, E64-C, docked well within the active pocket the 
corresponding built model. Therefore, the respective docking studies of HEDICINs and 
HECINs were carried using the 3D structure of model 7. 	  
	  
Figure 29. Most frequent docking conformation observed for E64-C against model 7, respectively. All within 
15 Å of Cys25 is represented in MSMS, E64-C is represented in Licorice, and the rest of the protein in 
NewRibbons (cyan). 
 
Detailed description of model 7	  
The overall topology of bbspn-1 structure is similar to that of other family members as it 
presents typical papain-like cysteine protease features (Fig. 30-31): 
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i) it displays two domains, an α-helix-rich (L) domain and a β-sheet-rich (R) 
domain, separated by the active site of the protein (Figure 30 (A, C)); the L 
domain is composed of four helices and the R domain is formed by six anti-
parallel β-sheets;30 
ii) it presents six cysteine residues forming disulfide bonds (Cys22-Cys63, 
Cys56-Cys95 and Cys148-Cys201) and one cysteine residue (Cys25) in the 
active site;  
iii) it shows Cys25 close to His155 and Asn177 which may facilitate the 
appropriate orientation for the thiolate/imidazolium ion pair (Fig. 30 (B));  
iv) it locates Gln19 and Trp179 as to allow the possibility of the formation of the 
“oxyanion hole” that stabilizes the tetrahedral adduct during the nucleophilic 
attack of the thiolate anion to the electrophilic warhead of the substrate 
(Figure 30 (A));18  
v) it also demonstrates the presence of a glycine-rich region, comprising mainly 
of Gly65 and Gly66, that has been found to provide additional stability to the 
complex in other papain-like cysteine proteases, by forming a constellation of 
hydrogen bonds with the substrates.31 
vi) the binding cavity of papain-like cysteine proteases are generally constituted 
by four pockets, S1, S1’, S2 and S3, as shown in Figure 31 for bbspn-1. S1 
vii) and S1’ contain Gln19 and Trp179, respectively, the amino acids which form 
the “oxyanion hole,” S2 pocket governs ligand specificity, and S3 pocket 
contains the glycine rich region of the binding site.  
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Figure 30. (A) Modeled structure of babesipain-1 represented in Cartoon, where some conserved catalytic 
residues and the disulfide bonds are shown. (B) Catalytic residues Cys25, His155, Asn177 of babesipain-1 
in Licorice. (C) Predicted secondary structure of bbspn-1 using PDBSum server. The N-terminal domain and 
the C-terminal domain are constituted by α-helixes (red) and anti-parallel β-sheets (pink), respectively. 	  
	  
Figure 31. S1, S1’, S2, and S3 site of bbspn-1. All within 15 Å of Cys25 is represented in MSMS, residue 25 
and His155 are represented in licorice, and the rest of the protein in NewRibbons. 
 
Comparing FP2 and bbspn-1 active pocket, it is possible to notice that the active pockets 
of bbspn-1 and FP2 are significantly different as demonstrated by table 11. The most 
conserved cavity is S1 and the main differences are observed in the S2 pocket 
which is believe to be responsible for substrate specificity.18 Table 11 shows that S2 is 
more hydrophobic for bbspn-1 than for FP2. For instance, S2 cavity of bbspn-1 presents 
Phe206 while the S2 cavity of FP2 Asp234 instead.7 Moreover, S2 cavity of bbspn-1 
seems to be less deep due to the existence of a Tyr129 instead of Ser149 in the case of 
FP2 which could explain the P2 rank order reported for in bbspn-1 Val > Leu > Phe.7 In 
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addition, the higher hydrophobicity of S2 cavity could justify that the highly hydrophobic 
HEDICINs are more efficient inhibitors of bbspn-1. Furthermore, analysis of the S3 
pocket shows that S3 seems to be more basic for FP2 than for bbspn-1, since the former 
presents polar residues and one basic residue (Lys76) and instead, bbspn-1 only 
presents polar residues (Gln59-Ser60-Ser61). In summary, the above-mentioned 
analyses indicate that the model structure is consistent with the current understanding of 
the protein structure. 
 
Table 11. Active site of bbspn-1 and FP2 cysteine proteases. 
Cysteine 
protease S1’ S1 S2 S3 
bbspn-1 
Val130-Phe132-
Thr133-
Phe137-His155-
Trp179 
Gln19-Gly23-
Cys63-Gly64 
Phe67-Ser68-
Tyr129-Leu153-
Phe206 
Gln59-Ser60-
Ser61-Gly65-
Gly66 
Falcipain-2 
Val150-Val152-
Ser153-Ala157-
His174-Trp206 
Gln36-Gly40-
Cys80-Asn81 
Leu84-Ile85-
Ser149-Leu172-
Asp234 
Lys76-Asn77-
Tyr78-Gly82-
Gly83 
Bold letter highlights the main difference between the cavities 
 
3.3.2. Docking studies  
 
HEDICINs 
Model 7, the 3D structure of bbspn-1 obtained from the alignment of bbspn-1, with 1S4V, 
and 2BDZ, allowed to perform the respective in silico studies to evaluate the interactions 
of HEDICINs and HECINs with the protein and draw conclusions regarding SAR against 
bbspn-1. These results were compared to those previously obtained by Dr. 
Cátia Teixeira for falcipains. In silico results demonstrated that the most preferred 
conformation for HEDICINs against bbspn1 is similar to the one 
previously obtained for FP2. The chloroquinoline is located in S2’, and the cinnamoyl 
moiety, Leu, and hPhe are placed in the S2 site, S1, S1’, respectively (Fig. 32). 
However, the steric hindrance caused by Phe137 impeded the chloroquinoline moiety to 
form a π-π stacking interaction with Trp179 as seen in FP2. Instead, in FP2, there is Ala 
in place of Phe, thus such a steric impediment does not occur. Moreover, docking results 
against bbspn-1 suggest strong hydrophobic interactions between the aromatic ring of 
the cinnamoyl functionality and residues Phe67 and Tyr129 placing the beta carbon 
between 3.8 and 5.8 Å of the cysteine residue which makes possible in some cases that 
a covalent interaction takes place. However, since the cinnamoyl moiety is too rigid, the 
approximation of the β-carbon is impeded. In addition, hPhe forms a π−π stacking 
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interaction with Phe 137 and other non-covalent interactions with residues Asn154, 
His155, and Gln19 are also observed. Furthermore, S2 cavity seems to accommodate 
better apolar groups due to the hydrophobic side chains of the residues Phe67, Leu153 
and Phe206. The latter is in agreement with in vitro data since the polar p-OMe 
cinnamoyl derivative 1d displayed the worst activity of the series  (IC50 = 35.8 µM). 
 
 
	  
Figure 32. Most frequent conformation of ligand 1a against bbspn1. All within 15 Å of Cys25 is represented 
in MSMS, Ligand 1a is represented in Licorice, the residues of the S1, S1’, S2, and S3 pocket are 
represented in CPK. 
 
HECINs 
In the case of HECINs, all ligands, except the m-NO2 analogue 2j, displayed the same 
preferred conformation (Fig. 33). This result is in agreement with in vitro data which 
shows that compound 2j (IC50 = 48.3 µM) is at least two times less active than the rest of 
the compounds of the series (IC50 = 9.8-20.9 µM). Docking results of compounds 2a-b 
and 2d-h indicate that the chloroquinoline ring is located between the S2 and S3 pockets 
building non-covalent interactions with residues Phe67, Tyr129, Phe206 and Leu153. 
Further results suggest that the amide functionality of the respective ligands interact with 
residues Ser205 and His155 except for p-OMe conjugate 2d which only interacts with 
the former residue. The beta carbon of the vinyl bond of the cinnamoyl functionality is 
located within ~4.5 Å from Cys25. Additional trends observed regarding 
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the electrondonating properties of cinnamoyl substituent could be explained by atomic 
Fukui indices for HECINs calculated by Dr. Teixeira. These fukui indices were used as a 
measure of the electrophilicity of the β-carbon of the vinyl bond. Accordingly, electron-
donating substituent favors electron-delocalization towards the carbonyl group, 
consequently, promoting the alkylation of the β-carbon by the catalytic cysteine and 
explaining that the best inhibitor of the series was the p-OMe (IC50 = 9.8 µM). 
	  
Figure 33. Most frequent conformation of ligand 2a and 2j against bbspn-1, respectively. All within 15 Å of 
Cys25 is represented in MSMS, ligand 2a and 2j are represented in Licorice, residue Cys25 and His155 are 
displayed in CPK, and the rest of the protein in NewRibbons (cyan). 	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3.4. In silico protocol 
 
Homology modeling 
The bbspn-1 sequence was obtained from Uniprot database. Only the mature sequence 
from residue 242 to 458 was considered to do the homology model studies. Templates 
search was performed on BLAST using default parameters. Templates matching the 
following requirements: i) E-value below 10-40; ii) query coverage > 90 % and sequence 
identity > 35% or query coverage > 85% and sequence identity > 40%; iii) PDB structure 
with a resolution < 2.5 Å, without missing residues in the active site, and with bounded 
ligand were chosen for these analysis. PDB structures were downloaded from 
www.pdb.org.	   The templates and the target sequences were aligned using the PSI-
coffee mode of T-Coffee v.9.03.32 The bbspn-1 models were constructed based on 
different alignments, single and multiple. For each alignment, 100 models were 
generated using the standard “automodel” routine of Modeller v.9.11.33 The best built 
models were validated by PROCHECK, ProQ, ProSA, and QMEAN, and by docking a 
known inhibitor of papain-like cysteine proteases.  
 
Docking of the inhibitors  
Dockings were performed using GOLD28 version 5.01 allowing the full flexibility of the 
ligand but keeping the protein fixed. The built 3D structure of bbspn-1 (model 7) was 
prepared and used for docking. Basically, the acid and basic residues of the protein were 
protonated at pH=5.5. The protein was then minimized with the AMBER 11 program34 by 
500 steps of steepest descent followed by 2000 steps of conjugate gradient to remove 
bad contacts using a generalized-Born solvent model. The biomolecular force field ff03 
was used.35 On the other hand, the inhibitors were minimized using gaff force field and 
Born solvation. The active site was established as 15 Ȧ from the Cys 25 while the 
docking exploration consisted of 500 conformation runs independent for each inhibitor 
based on the default genetic algorithm (GA) search parameters, which were then ranked 
according to the GOLDScore scoring function. 
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HEFLECINs  
Second generation of heterocyclic-cinnamic acid conjugates 
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4.0. Rationale 
Following synthesis, in vitro and in silico evaluation of HEDICINs and HECINs, as 
described in the previous chapters, a second generation of potential dual-action 
antimalarials was envisioned. Second generation compounds, called HEFLECINs 
(HEterocyclic-FLExible spacer-CINnamic acid conjugates), were designed to also join in 
the same molecular construct a heterocyclic core from a classical antimalarial drug and a 
cinnamoyl moiety, but this time linked together through a flexible alkyl chain (Fig. 34). 
The choice of this spacer was based on earlier reports on the favorable role of alkyl 
chains linked to the heterocyclic core of antimalarial aminoquinolines.1 The substitution 
of the rigid dipeptide spacer in HEDICINs by the flexible and more lipophilic ones in 
HEFLECINs might improve antimalarial properties of the corresponding compounds. 
Finally, HEFLECINs were predicted to have a basicity closer to that of reference 
antimalarial drug chloroquine (pKa~7) than HEDICINs (pKa~4),2 which might favor their 
accumulation in the FV of intraerythrocytic Pf . 
 
 
	  
	  
Figure 34. General structure of HEFLECINs. 
 
As in the case of HE[DI]CINs the doctoral candidate was in charge of the chemical 
synthesis and characterization of HEFLECINs and their evaluation as inhibitors of β-H 
formation, whereas assessment of their inhibitory activity against both falcipains (in vitro) 
and development of blood-stage Pf parasites (in vitro and in vivo) was carried out by 
Prof. Philip J. Rosenthal’s team. The experimental research work was developed 
alongside an in silico study carried out by the thesis co-supervisor, Dr. Cátia Teixeira. 
Further evaluation of HEFLECINs against liver-stage P. berghei parasites and 
Leishmania was carried out by Dr. Miguel Prudêncio’s team at Instituto de Medicina 
Molecular, Faculdade de Medicina, Universidade de Lisboa and Dr. M. S. Gomes’s team 
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in IBMC (Instituto de Biologia Molecular e Celular) in Universidade do Porto, 
respectively.  
 
4.1. Chloroquinoline-based HEFLECINs 
 
According to previous results found for HEDICINs, N-alkylcinnamoylated/chloroquine 
analogues were synthesized to evaluate the influence of the alkyl chain instead of the 
dipeptide chain in the antimalarial properties of the chloroquinoline derivatives here 
reported. 
 
4.1.1. Synthesis and characterization of HEFLECINs  
 
Synthesis of HEFLECINs 13-15, 20-21, and 24-25 
Chloroquinoline-based HEFLECINs 13-15 were synthesized in two steps, starting with 
an SNAr reaction between the appropriate alkanediamine and 4,7-dichloroquinoline, 
which was followed by condensation of the resulting 4-(N-aminoalkyl)amino-7-
chloroquinoline with the relevant cinnamic acid (Scheme 11). In order to form the amide 
bond, the respective carboxylic acid was activated using TBTU and DIEA as coupling 
reagents, and the amine 16-18 was added to reaction. The main challenge found in the 
synthetic procedure was that most cinnamoyl/chloroquinoline derivatives were only 
partially soluble in DCM turning difficult the extraction of the desired product from 
reaction mixture. The same solubility issue appeared when using other polar organic 
solvent as ethyl acetate, known to extract electron donor solutes.3 Nonetheless, all 
reactions afforded the cinnamoyl derivatives from low to good yields (8-67%). 
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Scheme 11. Synthetic pathway of HEFLECINs (13-15). 
 
As in HEDICINs and HECINs, the p-NO2 derivative of series 13 presented significantly 
lower yield than the other compounds of the series. However, experimental observations 
suggested that there was no difference behavior between the reactions. For instance, for 
each cinnamic acid, once its activation started, a solid began to appear and stopped 
forming at around half the activation time suggesting that this activation step was 
straightforward. Moreover, this solid disappeared when the corresponding amine was 
added to the reaction to obtain the desired amide bond. Calculation of the atomic Fukui 
indices (f+), derived from Natural Bond Order population analysis of the neutral 
compound and its respective anion,4 was done to quantify the electrophilicity of the 
carbonyl moiety for the activated unsubstituted cinnamic acid 19a and p-nitrocinnamic 
acid 19b, which correspond to the best (%yield = 52) and the worst (%yield = 8) yields 
for compounds 13, respectively. The Fukui indices obtained (f+19a = 0.08; f+19b = 0.04) 
suggested that the greater the magnitude of f+, the greater the change in electron 
density near the atoms of interest, and thus the higher reactivity of a molecule at that 
atomic site towards nucleophilic attack. The latter explains the higher yield obtained for 
the generation of the unsubstituted compound as compared to the p-nitro substituted 
derivative. 
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Furthermore, compounds 20-21 were synthesized, following similar procedures as the 
above described (Scheme 12), to assess the influence of the ester bond and chlorine 
substituent in position seven of the quinoline ring on the antimalarial activity. Briefly, the 
convenient amine 22 and alcohol 23 derivatives were synthesized. The amine 22 was 
further coupled to cinnamic acids using TBTU and DIEA, whereas the cinnamoylated 
product 21 was obtained through reaction of alcohol 23 with the adequate cinnamoyl 
chloride, in the presence of Et3N. Accordingly, compounds 20-21 were obtained in low 
yields (11-21%). 
 
	  
Scheme 12. Synthetic pathway to obtain cinnamoylated derivatives 20-21. 
 
Moreover, in order to assess the influence of the quinoline moiety on the antimalarial 
activity, two additional N-cinnamoylated compounds were synthesized, the pyridine 
derivative 24 and the morpholine derivative 25. Compound 24 was synthesized following 
the procedure previously used to achieve the CQ analogues 13-15. Initially, it was 
obtained the corresponding amine 26 that was later coupled to p-methoxy cinnamic acid 
(Scheme 13). To yield the morpholine derivative 24, first an N-alkylation with N-
bromobutylphthalimide was carried, followed by the removal of the phthalimide protecting 
group; subsequently, p-isopropyl cinnamic acid was coupled to the resulting amine 27 
using TBTU and DIEA (Scheme 13). Both compounds 24 and 25 were obtained in fairly 
good yields (30-61%). 
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Scheme 13. Synthetic route to yield cinnamoylated derivatives 24-25. 
 
Characterization of HEFLECINs 13-15 and 20-21 and 24-25 
All compounds 13a-l, 14a-l, 15a-c, 20, 21, 24 and 25 were characterized by 1H-NMR, 
13C-NMR, ESI-IT MS, and HPLC, and the data obtained agreed with the desired 
compounds. As an example, the NMR spectra of compound 13i is shown (Fig. 35-36). 
Accordingly, figure 35 displays the characteristic signals of compound 13i, for instance, 
the shielded region below 4 ppm shows the 4 protons corresponding to the methylene 
groups at 3.36 ppm overlapped with the protons of water from the use of DMSO-d6 as a 
solvent to run the NMR spectra, and the 4 protons of the most shielded methylene 
groups in 13i at 1.64 ppm. The α-vinyl proton is observed at 6.64 ppm with J= 15.6 Hz, a 
coupling characteristic of a trans-vinyl proton. The deshielded aromatic protons are also 
visible. For example, in the downfield region, the 1H-NMR spectrum shows the 
characteristic signal of the proton at position 3 of the quinoline ring at 6.47 ppm, the 
protons of the position 8 in the quinoline ring at 7.77 ppm with a small coupling constant 
J= 2 Hz, and the triplet of one of the proton bound to a nitrogen atom at 8.17 ppm. The 
13C-NMR (Fig. 36) displays the number of signals in agreement with the structure of the 
desired compounds: 16 signals in the downfield region and four signals in the upfield 
region, the most deshielded signal corresponding to the carbonyl functionality. For more 
detailed analysis of the NMR data, please refer to the experimental section of this 
chapter. In the mass spectrum, two signals were expected since bromine atom has two 
isotopes approximately equally abundant. Interestingly, instead of displaying two peaks 
associated to two different molecules, containing different isotope 79Br and 81Br, 
respectively, the m/z peak showed only one peak corresponding to the compound 
containing the isotope of 81Br (Fig. 37).  
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Figure 35. 1H-NMR (400 MHz, DMSO-d6) of compound 13i. 
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Figure 36. 13C-NMR (100 MHz, DMSO-d6) of compound 13i. 
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Figure 37. ESI-MS of the compound 13i. 
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4.1.2. In vitro assays of HEFLECINs 
Once all compounds were obtained they were evaluated as inhibitors of blood stage 
Plasmodia. Compounds were tested in vitro against a CQ-resistant strain (Pf W2) and 
some of them were also tested against a CQ-sensitive strain (Pf 3D7). As shown in table 
12, most tested chloroquinoline derivatives resulted more active against the blood stage 
Pf 3D7 parasites than the parent drug, CQ. More importantly, all compounds displayed 
activity higher than CQ against CQ-resistant Pf W2 parasites. Compound 13c (IC50 (Pf 
3D7) = 15.6 nM and IC50 (Pf W2) = 11.0 nM) and 13h (IC50 (Pf 3D7) = 26.2 nM and IC50 
(Pf W2) = 11.6 nM) were the most active of the series against Pf 3D7 and Pf W2, 
respectively, displaying activity comparable to ART, the key component of artemisinin 
combination therapies (ACT) which is currently recommended by the WHO as first-line 
treatment against CQ-resistant malaria.  
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Table 12. In vitro data of HEFLECINs against Pf W2 and Pf 3D7. clog P of the series of compounds 13 are 
also shown. 
 
Compound HET n X R2 Pf W2 IC50 (nM)[b] 
Pf 3D7 
IC50 (nM)[b] 
clogP[e] 
13a 
Cq 
R1= Cl 3 N 
H 46.6 ± 5.5 62.9 ± 3.5 4.51 
13b p-Me 16.9 ± 1.2 24.2 ± 0.2 4.90 
13c p-iPr[a] 11.0 ± 6.2 15.6 ± 5.4 5.72 
13d p-OMe[a] 20.0 ± 2.6 30.6 ± 9.5 4.45 
13e p-NH2 58.8 ± 1.5 78.1 ± 2.2 3.77 
13f m-F 34.1 ± 4.2 50.9 ± 1.0 4.68 
13g p-F 19.7 ± 0.4 39.9 ± 3.5 4.69 
13h p-Cl[a] 11.6 ± 0.4 26.2 ± 2.0 5.12 
13i p-Br 18.2 ± 2.8 28.8 ± 6.3 5.26 
13j o-NO2 38.3 ± 4.2 56.9 ± 5.1 4.37 
13k m-NO2 26.2 ± 2.1 42.1 ± 7.1 4.41 
13l p-NO2 23.5 ± 1.3 48.9 ± 3.2 4.43 
13m p-NMe2 25.8 ± 2.1 ND 
ND 
13n m,p-diOMe 110.8 ± 13.0 ND 
14a 
Cq 
R1= Cl 2 N 
H 74.8 ± 2.0 141 ± 9.3 
14b p-Me 47.4 ± 1.2 55.9 ± 5.1 
14c p-iPr 38.0 ± 11.2 50.2 ± 50.3 
14d p-OMe 55.1 ± 2.3 49.5 ± 5.8 
14e p-NH2 79.8 ± 2.0 135 ± 5.4 
14f m-F 73.3 ± 6.8 138 ± 1.2 
14g p-F 46.7 ± 3.3 47.7 ± 1.3 
14h p-Cl 41.6 ± 2.9 46.5 ± 4.5 
14i p-Br 38.2 ± 6.9 50.0 ± 3.5 
14j o-NO2 52.1 ± 4.0 64.2 ± 6.7 
14k m-NO2 50.3 ± 1.3 52.7 ± 5.3 
14l p-NO2 23.7 ± 2.1 52.5 ±10.8 
15a 
Cq 
R1= Cl 4 N 
p-iPr 31.5 ± 3.8 
ND[d] 
15b p-OMe 50.3 ± 2.6 
15c p-Cl 25.1 ± 0.2 
20 Cq R1= Cl 3 O p-OMe 122 ± 6  
21 Cq R1= H 3 N p-
iPr 115 ± 3 
24 Py 3 N p-OMe >10000 
25 Mu 3 N p-iPr >10000 
ART     9.5 23.5 2.86 (2.90)[f] 
CQ     138[c] 52.5 4.49 (4.63)[f] 
[a] Tested in vivo; [b] blood-stage antiplasmodial activity against Pf strain W2 and strain 3D7; [c] Value taken 
from Ref5; [d] Not determined; [e] clogP was calculated using ALOGPS 2.1 (http://www.vcclab.org/lab/ 
alogps/). [f] Experimental values for artemisinin and CQ are given in parentheses; 
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Results demonstrate that the cinnamoyl moiety seems to have a key role in reversing 
parasite resistance to CQ. In vitro data in table 12 show that tested quinoline-based 
HEFLECINs are generally more active against Pf W2 (IC50 = 11.0-79.8 nM) than against 
Pf 3D7 (IC50 = 15.6-141 nM). Similar trends were observed against both strains. For 
instance, compounds 13 (IC50 (Pf 3D7) = 15.6-62.9 nM and IC50 (Pf W2) = 11.0-111 nM) 
are mostly more active than compounds 14 (IC50 (Pf 3D7) = 46.5-141 nM and IC50 (Pf 
W2) = 23.7-79.8 nM). Detailed inspection of the data shows the following: 
• Compounds 13, 14, and 15 are highly active against Pf W2 (IC50 = 11.0-79.8 nM) 
except for compound 13n. Comparison between the homologues, which differ 
only on the length of the polymethylene spacer, shows that a butyl spacer is 
preferred over the pentyl and propyl spacers. For instance, compound 13c (IC50 = 
11.0 nM) is more active than compounds 14c (IC50 = 38.0 nM) and 15a (IC50 = 
31.5 nM). 
• Removal of the chlorine in position 7 of the quinoline ring leads to a 10-fold 
decrease in the activity, as demonstrated by compound 21 (IC50 = 115 nM) that 
was ten times less active than compound 13c (IC50 = 11.0 nM). 
• Substitution of the amide bond by an ester functionality negatively influences the 
activity of the compounds. For example, compound 20 (IC50 = 122 nM) was 6 
times less active than compound 13d (IC50 = 20.0 nM). 
• Replacement of the quinoline ring by pyridine or by a non-aromatic heterocyclic 
ring, such as morpholine, leads to complete loss of activity as shown by 
compounds 24 and 25, which were both inactive (IC50 > 10000 nM).  
• In vitro data of compounds 13 and 14 suggest that the electro-donating or 
electro-withdrawing character of the substituent on the cinnamoyl ring seems to 
have not significant effect on the activity of the compounds. Still, there seems to 
be a preference for substituents in the para position over the meta one as 
demonstrated by the p-F derivative 13g (IC50 = 19.7 nM) vs the m-F substituted 
compound 13f (IC50 = 34.1 nM), and the p-NO2 derivative 13l (IC50 = 23.5 nM) 
over the m-NO2 substituted compound 13k (IC50 = 26.2 nM). In addition, as 
shown in table 12 and fig. 38, there seems to exist some correlation between 
antiplasmodial activity and the lipophilicity of the compounds, as estimated by 
calculating logP values. 
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Figure 38. Plot of IC50 vs clogP values. 
 
 
 
• Results also show some correlation of the antiplasmodial activity of the 
compounds with the Charton’s steric parameter values6 of p-alkyl substituent on 
the aryl ring of compounds 13-14, with values of 0.0, 0.52 and 0.76 for the 
unsubstituted, p-Me, and p-iPr substituents, respectively. For instance, 
compound 13a (IC50 = 46.6 nM) is about 2 times less active than compound 13b 
(IC50 = 16.9 nM), and three times less active than compound 13c (IC50 = 11.0 
nM). However, this trend is not clearly observed in the halogen substituted 
cinnamoyl derivatives. 
 
4.1.3. Treatment of P. berghei-infected mice 
For the most promising compounds, namely, the two most active compounds 13c 
and 13h, which had activity comparable to ART, and compound 13d, the most active 
compound which complied with the Lipinski,7 Veber,8 and leadlikeness filters,9 were 
further studied in vivo using the P. berghei mouse model. Briefly, mice were infected 
intraperitoneally (ip) with P. berghei and treated twice a day with intraperitoneal (ip) 
injections of 100 mg/kg, 30 mg/kg and 10 mg/kg. CQ was used as a positive control 
at concentrations of 30 mg/kg, 10 mg/kg and 3mg/kg, and was ip administered twice 
daily. In order to compare compounds efficacy, survival rate over time was analyzed 
(Fig. 39). According to fig. 39, compound 13d was active in vivo at the highest 
concentration tested (100 mg/kg) while compounds 13c and 13h were highly toxic at 
this concentration. At 30 mg/kg and 10 mg/kg, compound 13h extended survival 
compared to untreated control, contrary to compound 13c. Finally, compound 13d 
did not appear to have deadly toxic effect at any tested concentration. In vivo studies 
in rodent malaria model confirm that compounds 13d and 13h have in vivo 
antimalarial activity. The lack of activity of compound 13c might be attributed to its 
high lipophilicity (logP > 5),7 still compound 13d and 13h are only slightly less 
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lipophilic (logP ≈ 5). In addition, compounds’ in vivo activities were significantly lower 
compared to the in vitro result, this could be explained by: i) the compounds’ limited 
bioavailability, ii) biological difference between P. berghei and Pf, and/or iii) extensive 
binding to plasma proteins. Further studies need to be carried out to assess the 
bioavailability properties of the compounds to proceed with any needed structural 
modifications in order to improve the correlation between the in vitro and in vivo 
displayed activities.  
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Figure 39. Survival curves for P.berghei-infected mice treated with compounds 13c, 13d and 13h, and CQ. 
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4.1.4. Mechanism of action of N-cinnamoylated derivatives 
 
Inhibition of falcipain activity and of β-hematin formation 
Docking calculations showed that CQ-derived HEFLECINs could fit well into the active 
pocket of falcipain-2, making electrostatic and Van der Waals interactions with the 
residues in the cavity of the protease. However, further MD demonstrated that the ligand 
moves away from the binding pocket. Possibly, the non-covalent interactions that the 
ligand establishes with the residues of the active site are not strong enough to keep it 
within the cavity. These last results suggest that the α,β-unsaturated portion of the ligand 
will not be able to alkylate the catalytic Cys. However, since the docked conformations of 
compounds 13-14 place the vinyl within ~3.5 Å from the thiolate, we still envisaged that, 
if favoured by its kinetics, the reaction could occur and the ligand could form a covalent 
interaction with Cys before being expulse of the active cavity of falcipain. In this context, 
compounds 13-14 were evaluated as inhibitors of falcipain-2 by Rosenthal’s team.10 In 
addition, in vitro assays against β-H formation (Table 13) were carried following the 
procedure described in the experimental section of chapter 2.  
Although none of the compounds exhibited activity against FP2, most of them showed to 
be active in vitro against β-H formation. Accordingly, results suggest that inhibition of the 
β-H formation seems to be one of the mechanisms contributing to the antiplasmodial 
activities of the compounds since variation of inhibition of β-H formation follows the same 
trend of activities against CQ-resistant strain Pf W2, as shown by compounds 13c vs 14c 
vs 15a. Also, the chlorine in position 7 of the chloroquinoline aromatic ring is once again 
shown to be essential for the activity of CQ and its analogues against the β-H 
formation.11, 12 However, since the most active compounds inhibiting the parasite 
development, namely, the p-iPr and p-Cl derivatives 13c (IC50 = 11.0 nM) and 13h (IC50 
= 11.6 nM), were not the most active inhibitors of β-H formation, results suggest the 
existence of an additional mechanism through which HEFLECINs exert their activities. 
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Table 13. In vitro assays against β-hematin formation. 
 
Compound R1 n X R2 β-H[a] 
13a 
Cl 
 
3 N 
H - 
13b p-Me - 
13c p-iPr[c] + 
13d p-OMe[c] + 
13e p-NH2 - 
13f m-F + 
13g p-F + 
13h p-Cl[d] + 
13i p-Br ++ 
13j o-NO2 + 
13k m-NO2 - 
13l p-NO2 ++ 
13m p-NMe2 + 
13n m,p-diOMe - 
14a 
2 N 
H - 
14b p-Me - 
14c p-iPr - 
14d p-OMe - 
14e p-NH2 - 
14f m-F - 
14g p-F - 
14h p-Cl + 
14i p-Br - 
14j o-NO2 + 
14k m-NO2 + 
14l p-NO2 + 
15a 
4 N 
p-iPr + 
15b p-OMe - 
15c p-Cl - 
20 3 O p-OMe + 
21 H 3 N p-iPr - 
CQ     ++ 
 [a] β-H inhibition was determined and ranked as shown in chapter 2; test compounds were ranked as 
follows: <50%, not active (-); between 50 and 75%, moderately active (+); ≥75%, highly active (++). 
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Inhibition of New Permeability Pathways in Pf-infected erythrocytes 
One possible additional mechanism underlying the activity of HEFLECINs against blood-
stage Pf could be inhibition of intraerythrocytic parasite’s nourishment: the growth of Pf 
within RBC relies on the uptake of certain nutrients from the extracellular medium; during 
the intraerythrocytic development of the parasite, the RBC show increased permeability 
to a wide range of structurally unrelated low molecular weight solutes, through the so-
called “New Permeability Pathways” (NPP), whose nature is still elusive and may 
comprehend one or several host-encoded channels, or a single parasite-encoded 
channel also known as plasmodial surface anion channel (PSAC).13, 14 Some inhibitors of 
these NPP include furosemide (XXXII), 5-nitro-2-(3-phenylpropylamino) benzoic acid 
(NPPB, XXXIII)15 and dantrolene (XXXIV).13 The latter nitro-substituted compound 
(XXXIV) was found not to have any measurable effect on other anion channels 
previously identified, consequently, addressing the concern of designing inhibitors with 
specificity towards this relatively new antimalarial target.13  
 
 
 
 
Remarkably, the nitro substituted HEFLECINs are highly active as compared with most 
of the other substituted derivatives. Additionally, Kanaani and co-workers found that 
cinnamic acid derivatives inhibit NPP.16 Interestingly, they found that the antiplasmodial 
activity correlated with the hydrophobic character of the molecules evaluated. In addition, 
Kirk’s team found, through the study of a series of arylaminobenzoates,17 analogues of 
the anion channel blocker 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB), that the 
antimalarial activity of the derivatives increase with the length and lipophilicity of the 
hydrophobic tail. These findings are comparable to the results obtained for HEFLECINs, 
which might suggest that NPP could be the additional mechanism of action through 
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which the cinnamoyl derivatives here presented exert their activity. In order to test this 
hypothesis, preliminary NPP-inhibition assays were carried out by sorbitol-induced 
hemolysis assays, as following described.  
The erythrocyte membrane is normally impermeant to sorbitol, but NPP appearance in 
the infected RBC membrane allows the passage of sorbitol and, when mature 
parasitized erythrocytes are suspended in an isosmotic sorbitol solution, there is a net 
uptake of sorbitol and water into the erythrocyte, resulting in cell swelling and 
hemolysis.18 The rate of hemolysis can be correlated with the influx of sorbitol, hence, 
can be used as a good indicator of NPP inhibitory activity. In this context, the rate of 
hemolysis of p-isopropyl cinnamic derivatives 13c and 1c was evaluated since the p-
isopropyl derivatives were the compounds which generally presented the highest activity 
among the series (Fig. 40). These in vitro assays were performed by Egée’s team at 
Université Pierre et Marie Curie, France. Compound 13c was shown to display (at 1 µM) 
significant NPP-inhibition activity as it markedly delayed sorbitol-induced hemolysis in Pf 
infected RBC, whereas 1c did not. These results correlate with in vitro antiplasmodial 
data since HEFLECIN 13c (IC50 = 11 nM) was more active than HEDICIN 1c (IC50 = 830 
nM) against Pf W2. However, these are only preliminary results and additional 
experiments are already scheduled to test all HEFLECINs using the patch-clamp 
technique, which is today the most precise way to decipher subtle changes in channel 
activity.19  
 
	  
 
Figure 40. Half-haemolysis time of p-isopropyl cinnamic derivatives 13c and 1c. 
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Although the results here presented reinforce the idea that HEFLECINs might exert their 
antimalarial action through inhibition of NPP, other MOA cannot be ruled out. For 
instance, inhibition of plasmodial cytosolic proteases20, 21 like aminopeptidases PfA-M1 
and PfA-M1722 or CQ-chemosensitization.23 It has been shown that resistance to 
chloroquine is due to mutations in a putative transmembrane chloroquine transporter, 
PfCRT, which seems to allow the drug to rapidly efflux from the parasite digestive 
vacuole, preventing sufficient inhibition of heme polymerization to block parasite 
development.24 Chloroquine chemosensitizers are thought to interact with PfCRT in such 
a way that drug efflux is impeded.23 HEFLECINs described here match relevant 
structural factors of chloroquine-chemosensiziting agents recently reported by Kelly25 
and Lavrado26 such as a hydrogen bond acceptor (nitrogen) or aminobutyl chains 
between the heterocyclic core of the compound and its N-substituted terminal amine. 
Therefore, we cannot rule out that HEFLECINs might (also) through this mechanism, and 
future investigations should be undertaken to pursue this hypothesis. 
 
4.1.5. Antiplasmodial assays against liver-stage P. berghei parasites 
Motivated by the fact that preliminary studies suggest HEFLECINs to be capable of 
inhibiting NPP (see previous section), and since similar anion channel enhanced activity 
has been described for P. berghei-infected liver cells,27 we decided to further evaluate 
the in vitro activity of HEFLECINs against liver stage malaria. In vitro assays were 
carried out following procedure previously reported.28 Remarkably, all CQ-derived 
HEFLECINs were active against liver stage parasites (Fig. 41 and Table 14), displaying 
activity in the low micromolar range (IC50 = 1.1-6.5 µM). These are unprecedented results 
since CQ has been reported to be inactive against liver stage malaria29 and, to the best 
of our knowledge, HEFLECINs were the first CQ analogues with dual-stage antimalarial 
activity. As shown in table 14, compounds present IC50 5 to 15 times lower than CQ and 
3-7 times lower than those of the reference drug for liver stage malaria, PQ. Some 
preliminary SAR could be devised from the liver stage inhibition results: 
• As observed for blood stage activity, the butyl spacer is preferred over the propyl 
and pentyl spacers, for instance, activity displayed by 13c-d,h vs 14c-d,h and 
15a-c. 
• Contrary to results against blood stage malaria, substitution on the cinnamoyl 
moiety leads to a decrease in the activity, as the most active compound was the 
unsubstituted derivative 13a (IC50 = 1.1 µM). 
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• The presence of electro-withdrawing groups in the para position of the cinnamoyl 
ring leads to a slight increase on the activity, as demonstrated by 13b-d (IC50 = 
2.4-2.9 µM) and 13g-i (IC50 = 1.1-1.4 µM). 
• Similar to blood stage results, removal of the chlorine in position 7 of the 
quinoline ring or substitution of the amide bond by an ester functionality lead to a 
decrease in the activity (Fig. 41).  
• Substitution of the chloroquinoline core by a non-aromatic ring or pyridine is also 
detrimental for liver-stage activity, as shown by compound 13c (IC50 = 2.5 µM) vs 
25 (IC50 > 10 µM) and 13d (IC50 = 2.9 µM) vs 24 (IC50 = >10 µM). 
 
The mechanism of HEFLECINs against liver stage Plasmodia remains to be elucidated, 
and work is currently in course that aims at investigating whether the compounds are 
also able to inhibit anion channel activity in P. berghei-infected hepatocytes. Based on 
the antiplasmodial results against both liver and blood stage parasite, compound 13d 
and 13h were evaluated in vivo against the liver stage form of malaria. In vivo assays 
were carried out by Prudêncio’s team at Universidade de Lisboa. However, none of the 
compounds displayed in vivo activity against this stage. The latter might be explained by 
the fact that the liver is responsible for most drug metabolism, since the liver has the 
most drug metabolising enzymes relative to other organs.30, 31 Thus HEFLECINs might 
be metabolized into inactive compounds. Nonetheless, compounds here presented 
represent new leads towards the discovery of multistage antimalarials.  
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Figure 41. Anti-infective activity vs toxicity to hepatoma cells plot. PQ and CQ were included for comparison. 
The black, red, and blue circles represent results for the tested compounds at 10, 5, and 1 µM, respectively. 
Infection loads of Huh7 cells, from a human hepatoma cell line, were determined by bioluminescence 
measurements of cell lysates 48 h after infection with luciferase-expressing P. berghei parasites by 
Prudêncio’s team. 
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Table 14.  In vitro assays of N-cinnamoylated derivatives 13-14, 20-21, and 24-25 against P. berghei liver 
stage malaria. 
 
Compound HET n X R2 Liver Stage IC50 (µM)[a] 
13a 
Cq 
R1= Cl 3 N 
H 1.1 ± 0.1 
13b p-Me 2.4 ± 0.5 
13c p-iPr[c] 2.5 ± 0.2 
13d p-OMe[c] 2.9  ± 0.4 
13e p-NH2 ND 
13f m-F 1.1 ± 0.2 
13g p-F 1.4 ± 0.2 
13h p-Cl[d] 1.4 ± 0.3 
13i p-Br 2.3 ± 0.6 
13j o-NO2 1.1 ± 0.2 
13k m-NO2 
ND 13l p-NO2 
13m p-NMe2 
13n m,p-diOMe 4.1 ± 0.2 
14a 
Cq 
R1= Cl 2 N 
H 
ND 14b p-Me 
14c p-iPr 
14d p-OMe 4.0 ± 0.6 
14e p-NH2 
ND 
14f m-F 
14g p-F 
14h p-Cl 
14i p-Br 
14j o-NO2 
14k m-NO2 
14l p-NO2 
15a 
Cq 
R1= Cl 4 N 
p-iPr 
15b p-OMe 2.3 ± 0.6 
15c p-Cl 1.6 ± 0.1 
20 Cq R1= Cl 3 O p-OMe 6.5 ± 0.9 
21 Cq R1= H 3 N p-
iPr ND 
24 Py 3 N p-OMe >10 
25 Mu 3 N p-iPr >10 
ART     ND 
CQ     15.9 
PQ     7.5 
[a] IC50 of the most active compounds against liver stage. 
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4.2. PQ-based HEFLECINs 
Given the rather promising findings made with N-cinnamoylated analogues of CQ, 
especially in what concerns the display of activity against liver forms of Plasmodia, 
further studies were carried to evaluate whether N-cinnamoylation would also enhance 
the activity of PQ against liver stage malaria. Any advance towards development of liver-
stage malaria drugs is of particular importance, not only because liver parasites silently 
open the doorway for establishment of the malarial infection, but also due to the fact that 
drugs acting against liver forms of Plasmodia are scarce, and PQ is the only drug in 
clinical use worldwide. In this view, a series of PQ-cinnamic acid conjugates (28) was 
synthesized and characterized following a similar procedure to that previously used for 
compound 13-15. 
 
4.2.1. Synthesis and characterization of PQ-based HEFLECINs 
 
Synthesis of PQ-based HEFLECINs 
The synthetic procedure to obtain PQ-based HEFLECINs was straightforward. Initially, 
cinnamic acids were activated using TBTU as coupling reagent and DIEA. After this 
activation step, a solution of PQ in DMF was added and the reaction allowed to proceed 
(Scheme 14) to finally yield the desired conjugate. 
 
 
	  
Scheme 14. Synthetic pathway of PQ-based HEFLECINs (28). 
 
Characterization of PQ-based HEFLECINs 
All PQ-based HEFLECINs obtained were characterized by 1H-NMR and 13C-NMR, ESI-
IT MS, and HPLC. Obtained data were in agreement with structure of PQ-based 
HEFLECINs. Figures 42-43 display an example of the NMR results for PQ-based 
HEFLECIN 28f. As shown, the 1H-NMR of compound 28f displays the expected signals 
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of the methyl and methylene groups in the upfield region: i) a doublet at 1.30 ppm of the 
protons of the methyl group attached to the alkyl spacer, ii) a singlet at 3.86 ppm 
corresponding to the protons of the methoxy group, and iii) the signal of the 3 methylene 
groups of the alkyl chain at 1.73 and 3.40 ppm respectively. The 1H-NMR spectrum also 
displayed in the downfield region the characteristic signals of the aromatic protons 
present in quinoline ring such as the doublets with small coupling constants at 6.34 ppm 
and 6.30 ppm, which belong to protons at position 5 and 7 of the heterocycle, 
respectively. Regarding the cinnamoyl functionality, the 1H-NMR spectrum (Fig. 42) 
shows the α,β-unsaturated vinyl protons at 6.18 ppm and 7.53 ppm. In the 1H-NMR, it is 
also displayed the deshielded protons attached to a nitrogen atom at 5.86 and 7.31 ppm. 
Furthermore, the 13C-NMR (Fig. 43) shows the signals related to PRIMACIN 28f, for 
instance, it displays the deshielded signal of the carbonyl group at 165.7 and 6 signals in 
the shielded region. Moreover, in the ESI-IT MS (Fig. 44) is observed i) one strong peak 
at 408.33 which is associated with the desired compound, ii) a peak at 837 that might 
suggest that the compound forms a dimer, and iii) a peak at 1243.13 which suggest the 
formation of a trimer. 
 
	  
Figure 42. 1H-NMR (400 MHz, CDCl3) of compound 28f. 
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Figure 43. 13C-NMR (100 MHz, CDCl3) of compound 28f. 
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Figure 44. ES-IT MS of compound 28f. 	  
4.2.2. Antiplasmodial assays of PQ-based HEFLECINs 
Once the desired PQ-based HEFLECINs were obtained, they were evaluated against 
liver stage malaria following procedures previously reported.32 Accordingly, all cinnamoyl 
derivatives 28 were found to inhibit the parasite activity in the micromolar range (IC50 = 
1.29 - 3.33 µM) with IC50 values lower than those presented by PQ (IC50 = 7.5 µM), the 
reference drug for liver stage malaria (Table 15). Although results present a relative short 
activity range, it seems that the electro-donating or electro-withdrawing properties of the 
substituent in the para position of the cinnamoyl ring do not have an effect on the activity 
against liver stage parasites. In addition, though it seems that the meta substitution is 
preferred over the para substitution for both the fluoro- and nitro-substituted derivatives 
such detailed conclusion cannot be made since compounds presented a range of activity 
significantly short. Furthermore, as observed in fig. 45, compounds resulted non-toxic to 
Huh7 human hepatoma cells in vitro. 
 PQ-based HEFLECINs were also evaluated against blood stage parasite to assess 
other quinoline moiety against this stage. Except for compound 28c (IC50 = 4.84 µM) that 
was modestly active, none of PQ-based HEFLECINs resulted active (IC50 = ≥ 10 µM). 
This result is in agreement with the fact that PQ-based structures are not efficient blood-
Schizontocidals. The latter could be explained by the findings that suggest that the 8-
amino-6-methoxyquinoline core is not an efficient inhibitor of hemozoin formation 
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because it forms a weak binding with heme that does not interfere with hemozoin 
formation.33, 34 Consequently, results from PQ-based HEFLECINs’ blood-stage activity 
reinforce our previous findings regarding the essential role of the chloroquine core for the 
activity of HEFLECINs 28 against intraerythrocytic parasites. Moreover, based on the 
fact that PQ-based HEFLECINs presented a short range of activity and cytotoxicity and 
the p-methoxy chloroquine-based HEFLECIN 13d did not present deathly toxicity when 
assessed in vivo against blood stage parasite at any of the tested concentrations, PQ 
derivative 28d was further evaluated in vivo against liver stage. However, compound 28d 
did not display in vivo activity against liver stage parasite. 
 
	  
	  
Figure 45. P. berghei liver stages activities of PQ-based HEFLECINs 28. Data shown are for the screening 
of anti-infective activity (infection scale, bars) and toxicity to human hepatoma Huh-7 cells (cell confluency 
scale, dotted lines with round markers). 
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Table 15. Antiplamosdial activity of compounds against liver stage malaria. 
 
Compound R 
IC50 (µM)  
against  
liver-stage 
 P. berghei 
IC50 (µM)  
against  
blood-stage  
Pf[a] 
Reference drug[b] - 7.50 (PQ) 5.64 ± 0.04 nM (ART) 
28a H  2.01 ± 0.27 ≥ 10 28b p-Me 2.13 ± 0.58 
28c p-iPr 1.54 ± 0.35 4.84 ± 0.98 
28d p-OMe 2.35 ± 0.19 
≥ 10	  
28e m-F 1.63 ± 0.16 
28f p-F 2.33 ± 0.47 
28g p-Cl 2.39 ± 0.19 
28h p-Br 1.38 ± 0.33 
28i o-NO2 2.36 ± 0.58 
28j m-NO2 2.12 ± 0.49 
28k p-NO2 (0.78) 2.24 ± 0.27 
[a] CQ-resistance Pf W2; [b] reference drug for liver stage (PQ: 
Primaquine (III)) and blood stage malaria (ART).  Highlighted in blue the 
most active compound against liver stage malaria. 
 
4.3. Acridine-based HEFLECINs 
Other heteroaromatic cores such as acridine have demonstrated to display activity 
against malaria.35 For instance, acridine analogue of CQ (XXXV) presented nanomolar 
activity against Pf CQ-sensitive strain 3D7 (EC50 = 720 nM; Molecule ChEMBL ID: 
CHEMBL532286). Accordingly, we decided to evaluate whether a similar effect to that 
displayed by the N-cinnamoylation of the PQ and CQ will be observed by the N-
cinnamoylation of the AQ core. In this context, the chloroquine core was substituted by 
an acridine nucleus to evaluate the antiplasmodial activity of the resulted compounds. 
Compound 29a-g were synthesized following previous synthetic procedure used for 
chloroquinoline-based HEFLECINs (Scheme 15).  
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4.3.1. Synthesis and characterization of acridine-based HEFLECINs 
 
Synthesis of acridine-based HEFLECINs (29) 
Acridine-based HEFLECINs were synthesized following procedure depicted in Scheme 
15. Significant challenges were encountered when trying to synthesize compound 29 
due to the low purity of the intermediate compound 30 that was used in the coupling 
reaction. Although different attempts were carried out in order to purify compound 30, 
this was not achieved. Consequently, the oily mixture containing compound 30 as major 
component was used in the following coupling reaction with cinnamic acids. Accordingly, 
N-alkylcinnamoylated acridine derivatives were obtained in low yields but the procedure 
allowed fast generation of the compounds 29 for in vitro screening. 
 
 
	  
Scheme 15. Synthetic pathway of acridine derivatives 29. 
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Interestingly, in spite of the fact that similar coupling conditions were used for the 
synthesis of HEFLECINs 13, 28 and 29, significant yield differences were observed in 
between series. Yields globally decreased in the following order: PQ-based HEFLECINs 
28 > CQ-based HEFLECINs 13 > Acridine-based HEFLECINs 29. Knowing that the 
nucleophiles constitute the main difference between the reactions, the corresponding 
structures were analyzed to better understand why yield decreases in the previously 
stated order. Since the three relevant nucleophiles PQ, 16, and 30 consisted in a primary 
amine linked to a butyl chain placing the amino group at the same distance from the 
heteroaromatic core, the nucleophilic power of the primary amine should not be 
influencing the reactivity of the respective compounds. In fact, the main difference 
between those three nucleophiles is their heteroaromatic cores. Accordingly, pKa value 
of the heteroaromatic nitrogen was estimated for each of the three structures, using 
MarvinSketch (Fig. 46). Remarkably, results show that the lowest the pKa of the 
heterocyclic nitrogen in the nucleophile, the highest the yield of its condensation with 
cinnamic acids. Therefore, one possible explanation is that as the pKa of the 
heteroaromatic nitrogen increases, so does the organization of molecules in solution, 
through formation of intermolecular hydrogen bonds. The latter may turn the amino 
group less available to perform the nucleophilic attack to the activated cinnamic acid. 
However, this is just a hypothesis and further studies should be done to confirm such 
premise. 
 
  
	  
 
Figure 46. Nucleophiles and estimated pKa values for their nitrogen-based groups.
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Characterization of acridine-based HEFLECINs 
All acridine-based derivatives were characterized through NMR, ESI-IT MS, and HPLC. 
Data resulted in agreement with the structure of the target compounds. Compounds 
presented 1H-NMR spectra similar to those of compounds 13, with major differences 
located at the deshielded region. As an example, fig. 47-48 display the downfield region 
of the NMR spectra of compound 29c, where such distinctive signals are observed. For 
instance, fig. 47 shows the deshielded protons of the acridine ring at 8.05 ppm, 7.60 
ppm, 7.29 ppm, and 7.00 ppm, the characteristic signals of the α,β-unsaturated carbons 
at 6.58 ppm and 7.60 ppm, and the signals of the cinnamoyl ring protons at 7.17 ppm 
and 7.40 ppm. Furthermore, fig. 48 displays the 14 signals associated to the deshielded 
carbons of compound 29c in the downfield region, including the signal of the carbonyl 
group at 178.0 ppm. In addition, the ESI-IT MS (Fig. 49) shows the base peak at m/z 
438.53 which matches the expected value for the quasi-molecular ion of the desired 
compound 29c.  
 
	  
Figure 47. 1H-NMR (400 MHz, CDCl3) of compound 29c. 
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Figure 48. 13C-NMR (100 MHz, CDCl3) of compound 29c. 
	  
Figure 49. ES-IT MS of compound 29c. 
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4.3.2. In vitro assays of acridine-based HEFLECINs  
 
All acridine derivatives 29 were evaluated against blood stage parasites and β-H 
formation in vitro (Table 16), and three of the compounds were further assessed against 
liver stage parasites. Accordingly, compounds 29 presented blood-stage activity activity 
in the mid-nanomolar range, with compounds 29c-d and 29f-g exhibiting activity in the 
same order of magnitude than reference CQ. The most active compound of the series 
was the p-isopropyl cinnamoyl derivative 29c was significantly more active than the 
unsubstituted cinnamoyl derivative 29a, demonstrating the importance of substituent on 
the cinnamoyl moiety. A similar effect had already been observed for CQ-based 
HEFLECINs, where the p-iPr cinnamoyl and the unsubstituted derivatives were amongst 
the best and worst, respectively, against blood-stage Plasmodia. In addition, the para-
fluoro derivative 29f shows activity (IC50 = 145 nM) almost 3-fold higher than the meta-
fluoro derivative 29e (IC50 = 345 nM), suggesting a preference for para over meta 
substitution in the cinnamoyl moiety.  
The mechanism of antimalarial action of acridine-based compounds remains to be 
elucidated.35 Still, some authors have reported that acridine derivatives were able to 
inhibit  β-H formation.36 Hence, compounds 29 were also tested in vitro for their ability to 
inhibit β-H formation in vitro, but none resulted active, indicating that an alternative MOA 
underlies their activity against blood-stage malaria parasites. 
Compounds 29c, 29d and 29e were taken further to in vitro liver-stage activity assays. 
Compound selection was made according to: i) highest blood-stage activity (29c), ii) 
highest drug-likeness, compound 29d being the most active compound which best 
complied with the Veber filter,8 Lipinski’s rules,7 and lead-likeness9 properties, iii) the 
likelihood to present good stability, solubility, and bioavailability, properties expectedly 
enhanced in derivatives bearing a fluorinated cinnamoyl ring (29f).37 Accordingly, the 
three selected compounds displayed higher liver-stage activity than the reference drug, 
PQ, and were non-toxic to Huh7 human hepatoma cells at 10 µM (Fig. 50). Compound 
29d presented the best activity/citotoxicity profile, so its IC50 value was determined (3.2 
µM), and found to be approximately 2 times lower than that of PQ (IC50 = 7.5 µM).  
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Table 16. In vitro efficiency of acridine derivatives 29 against CQ-resistant Pf W2 and IC50 of compound 29d 
against liver stage parasite. 
 
Compound R β-H[a] Pf W2 IC50 (nM)[b] 
Liver 
Stage 
IC50 (µM)[c] 
29a H - 892 ± 152 
ND 29b p-Me - 225 ± 3 
29c p-iPr - 126 ± 2 
29d p-OMe - 138 ± 2 3.2 
29e m-F - 345 ± 32 
ND 29f p-F - 145 ± 6 
29g m-NO2 - 142 ± 2 
ART   9.5 ND 
CQ  ++ 138[d] 15.9 
PQ   ND 7.5 
[a] Inhibition of β-H formation calculated and ranked as shown in previous 
chapters; [b] blood-stage antiplasmodial activity  against Pf strain W2; [c] 
IC50 of the most active compounds against liver stage; [d] Value taken from 
Ref;5 
 
 
	  
	  
Figure 50. In vitro results of acridine-based HEFLECINs 29 against liver stage malaria. 
 
DMSO         PQ                     29c                       29d                        29f 
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4.4. Quinoline-based HEFLECINs as antileishmanial agents 
Leishmaniasis is a neglected disease that affects mainly tropical countries.38 There are 
three different clinical forms of leishmaniasis: visceral, cutaneous, and mucocutaneous.39 
Visceral leishmaniasis (VL) is caused by Leishmania dovani and Leishamania infantum 
and if untreated, it can lead to death.40 Phlebotomine insects, also known as sand fly, are 
the insects responsible for transmitting the disease. Leishmania parasites life cycle 
alternates between the promastigotes and amastigotes form of Leishmania.41 During a 
blood meal a sand fly injects promastigotes (Fig. 51) which subsequently are 
phagocytized and released. These promastigotes transform into amastigotes inside 
macrophages and continue to multiply in cells. When ingested by another sand fly, 
amastigotes eventually transform into promastigotes within the sand fly midgut and as 
such, the Leishmania life cycle continues. 
 
 
	  
Figure 51. Life cycle of Leishmania retrieved from NIAID website.41 
 
The conventional chemotherapy to treat against leishmaniasis such as antimonials and 
liposomal amphotericin B are either too toxic or expensive for routine use. In addition, 
miltefosine (XXXVI), an anticancer agent, which has become a first-choice therapy by 
oral route for leishmaniasis, has a median long terminal half-life that can promote 
developing resistance.42 Also, there are side effects and drawback related to treatment 
with miltefosine. Another drug with acceptable efficacy as an oral VL therapy in clinical 
trials is sitamaquine (XXXVII).42, 43 However, there are still unanswered question
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regarding sitamaquine’s potential toxicity. Therefore, there is a need for safer, cheaper, 
and more effective antileishmanial drugs. In view of the above and encouraged by i) PQ 
and other 8-aminoquinoline analogues activity against other protozoan species such as 
Leishmania,44 and ii) the fact that N-cinnamoylation of heterocyclic aromatic antimalarial 
cores enhances the antiplasmodial activity of the corresponding compounds against both 
blood and liver stage malaria; the most potent HEFLECINs and PQ-based HEFLECINs 
were further evaluated in vitro against Leishmania.  
 
  
 
 
Compounds 13 and 28 were assessed in vitro against the promastigote forms of 
Leishmania infantum (Table 17-18). Those compounds which resulted highly active 
against L. infantum promastigotes were further evaluated against the intramacrophagic 
amastigote forms of L. infantum. In vitro assays against L. infantum promastigotes and 
amastigotes and cytotoxicity assays on mouse bone marrow-derived macrophages were 
carried out following procedures previously reported.45 Synthesis of the corresponding 
compounds was carried following before presented procedures (Scheme 11 and 14).  
Most of the N-cinnamoylated CQ derivatives presented higher activities than miltefosine 
against promastigote. However, there seems to not be any clear correlation between the 
electro-withdrawing properties of the substituents in the cynnamoyl ring and the 
antileishmanial activity. In addition, the compounds lipophilicity did not correlate with the 
corresponding activities against L. infantum, contrary to antiplasmodial results. In the 
case of PQ-based HEFLECINs, cinnamoyl derivatives with a p-Me, p-iPr, p-OMe or m-
NO2 substituent, (28b, 28c, 28d, 28j) respectively, present moderately higher activity 
(IC50 = 16.0-24.7 µM) than PQ (IC50 = 33.5 µM). However, the remaining compounds had 
not significant effect on the activity of the compounds as shown in table 17. 
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On the contrary, choroquinoline derivatives 13 presented about the same range of 
activity against promastigotes forms as CQ. Conjugation of cinnamic acid (CA) with 
compound 16 through an amide bond demonstrated to enhance activity against the 
promastigotes and amastigotes since compound 13a was more active than the cinnamic 
acid alone, compound 16 alone, or the 1:1 mixture of the cinnamic acid and compound 
16. Moreover, the CQ analogues 13 which presented the lowest IC50 against 
promastigotes were also evaluated in vitro against amastigotes. All of the selected 
compounds were more active against amastigotes (IC50 = 1.2-9.3 µM) than CQ (IC50 = 
23.0 µM), whose in vitro properties have been reported against VL,46, 47 and presented 
activity comparable to miltefosine (IC50 = 1.7µM). Contrary to antiplasmodial results 
against blood stage of CQ analogues 13, the most active compound against L. infantum 
amastigotes was the unsubstituted compound 13a.  
Regarding the cytotoxicity assays all compounds resulted more cytotoxic than CQ which 
could explain their higher activity against intramacrophagic amastigotes as compared to 
CQ. Nonetheless, except for compound 13h, all N-cinnamoylated analogues presented 
the same range of cytotoxicity against macrophages than mitelfosine. Furthermore, as 
shown in table 18, compound 13a represents a hit identification according to the World 
Health Organization’s criteria48 against Leishmania intramacrophagic amastigotes 
(IC50 < 1-2 µg/mL) and a selectivity index (SI) > 20). However, these results are only 
preliminary and further work is needed in order to elucidate the MOA of the N-
cinnamoylated compounds 13 evaluated against L. infantum. 
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Table 17. In vitro data of PQ-based HEFLECINs against L. infantum promastigotes (PM) 
 
Compound R IC50 (µM)PM[a] 
28a H 39.0 ± 4.5 
28b p-Me 18.3 ± 1.3 
28c p-iPr 16.0 ± 3.0 
28d p-OMe 22.3 ± 1.8 
28e m-F 52.9 ± 17.4 
28f p-F 35.7 ± 11.2 
29g p-Cl 35.1 ± 6.3 
28h p-Br 30.1 ± 9.0 
28i o-NO2 35.4 ± 5.2 
28j m-NO2 24.7 ± 2.9 
28k p-NO2 >160 
PQ  33.5 ± 8.7 
Miltefosine  19.6 ± 4.3 
[a] IC50 (µM) on L. infantum promastigotes at 72h (mean ± SD) 
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Table 18. In vitro data of CQ-based HEFLECINs against L. infantum promastigotes (PM) and amastigotes 
(AM) and cytotoxicity results on mouse bone marrow-derived macrophages (MP). 
 
Compound R IC50 (µM) PM[a] 
IC50 (µM) 
AM[b] 
IC50 
(µg/mL) 
AM[c] 
CC50 (µM) 
MP[d] 
CC50 
(µg/mL) 
MP[e] 
SI[f] 
13a H 3.1 ± 1.8 1.2 ± 0.8 0.5 ± 0.3 25.4 ± 6.7 9.6 ± 2.5 21.2 
16 - 18.8 ± 2.9 43.9 ± 5.8 11.0 ± 1.4 74.5 ± 1.8 18.6 ± 0.4 1.7 
Cinnamic 
Acid (CA) - > 80 47.1 ± 16.1 7.0 ± 2.4 > 80 > 11.9 > 1.7 
16 + CA  18 ± 5.0 65.5 ± 34.5 - 34.1 ± 16.9 - - 
13b p-Me 21.8 ± 15.4 ND
[g] 
13c p-iPr 2.6 ± 0.4 4.0 ± 0.9 1.7 ± 0.4 13.5 ± 6.2 5.7 ± 2.6 3.4 
13d p-OMe 3.9 ± 2.0 9.3 ± 1.9 3.8 ± 0.8 61.9 ± 26.5 
25.4 ± 
10.9 6.7 
13f m-F 3.3 ± 1.4 4.2 ± 2.9 1.7 ± 1.2 17.6 ± 0.6 7.0 ± 0.2 4.2 
13g p-F 5.5 ± 2.1 5.7 ± 2.7 2.3 ± 1.1 22.2 ± 5.9 8.8 ± 2.3 3.9 
13h p-Cl 3.1 ± 0.9 6.6 ± 2.3 2.7 ± 1.0 7.7 ± 2.1 3.2 ± 0.9 1.2 
13i p-Br 10.8 ± 1.6 
ND[g] 
13j o-NO2 
7.3 ± 0.4 
CQ  1.3 ± 0.2 23.0 ± 12.1 11.9 ± 6.9 71.3 ± 2.7 36.8 ± 1.4 3.1 
PQ  33.5 ± 8.7 ND 
Miltefosine  19.6 ± 4.3 4.1 ± 3.3 1.7 ± 1.3 25.5 ± 4.5 10.4 ± 1.8 6.2 
[a] IC50 (µM) on L. infantum promastigotes at 72h (mean ± SD); [b] IC50 (µM) on L. infantum intramacrophagic 
amastigotes at 72h (mean ± SD); [c] IC50 (µg/mL) on L. infantum intramacrophagic amastigotes at 72h (mean 
± SD); [d] CC50 (µM) on mouse bone marrow-derived macrophages (MP) at 72h (mean ± SD); [e] CC50 
(µg/mL) on mouse bone marrow-derived macrophages at 72h (mean ± SD); [f] SI – selectivity index 
calculated as the ratio between CC50 and IC50.; [g] Not Determined. 
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4.5. Experimental section 
 
4.5.1. Chemistry 
 
4.5.1.1. Chemicals and Instrumentation. All solvents and common chemicals were 
from Sigma-Aldrich (Spain) and the coupling agent TBTU was from Bachem 
(Switzerland). NMR spectra were acquired on a Bruker Avance III 400 spectrometer from 
solutions in either deuterated chloroform or deuterated dimethylsulfoxide (DMSO-d6) 
containing tetramethylsilane as internal reference. Mass spectrometry (MS) analyses 
were run on a Thermo Finnigan LCQ Deca XP Max LC/MSn instrument operating with 
electrospray ionization and ion-trap (ESI-IT) quadrupole detection. The target 
compounds were confirmed to have at least 85% purity, based on peak areas obtained 
through HPLC analyses that were run using the following conditions: 10-70% for 
chloroquinoline-based HEFLECINs and 30−100% for PQ-based HEFLECINs of B in A (A 
= H2O with 0.05% of trifluoroacetic acid; B = acetonitrile) in 22 min with a flow rate of 1 
mL/min on a Merck-Hitachi Lachrom Elite instrument equipped with a diode array 
detector (DAD) and thermostated (Peltier effect) autosampler, using a Purospher STAR 
RP-18e column (150 mm × 4.0 mm; particle size, 5 µm). 
 
4.5.1.2. Synthesis of 4-(N-aminobutyl)amino-7-chloroquinoline (16)  
1,4-Diaminobutane (10 eq) and 4,7-
dichloroquinoline (1 eq) were stirred at 100oC for 
3h. After cooling to RT, the mixture was diluted with 
CH2Cl2 (25 mL), and the solution was washed with 
5 % aq Na2CO3. The organic layer was separated 
and dried over anhydrous Na2SO4, filtered, and 
concentrated to yield the title compound. Further purification was not required. Desired 
compound resulted a white solid (198 mg, 64%); mp 62-65oC; δH (400 MHz, DMSO-d6) 
8.37 (d, J= 5.6 Hz, 1H, Ha), 8.27 (d, J= 8.8 Hz, 1H, He), 7.77 (d, J= 2.4 Hz, 1H, Hh), 
7.46-7.30 (m, 2H, Hf, -NH), 6.45 (d, J= 5.6 Hz, 1H, Hb), 3.27-3.17 (m, 4H, Hj, -NH2), 
2.64-2.55 (m, 2H, Hm), 1.77-1.43 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 151.8, 150.0, 
133.2, 127.4, 124.1, 123.9 (Ca, Cc, Ce-i), 117.4 (Cd), 98.5 (Cb), 42.3 (Cj), 41.1 (Cm), 
30.4, 25.2 (Ck-l); ESI-IT MS: m/z (M+H+) 249.10 (C13H16ClN3) requires 250.27. 
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4.5.1.3. Synthesis of chloroquinoline-based HEFLECINs 13. 
A solution of substituted cinnamic acid (1.1 eq), TBTU (1.1 eq) and DIEA; 2.2 eq in DMF 
(5 mL) was stirred at 0oC for 10 min. Then, a solution of compound 16 (1.1 eq) in DMF 
was added, and the reaction proceeded at RT for an additional 24 h. The mixture was 
diluted with CH2Cl2 (25 mL), and the solution was washed with 5 % aq Na2CO3. The 
organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated. 
The crude product was purified by column chromatography (EtOAc/MeOH, 4:1 v/v) to 
give the desired compound 13.  
 
4-(N-cinnamoylaminobutyl)amino-7-chloroquinoline (13a). 
White solid (39.5 mg, 52%); mp 194-
198oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.2 
Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 1H, 
He), 8.16 (t, J= 5.6 Hz, 1H, -NH), 7.77 
(d, J= 2 Hz, 1H, Hh), 7.56-7.54 (m, 2H, 
Hr), 7.44-7.32 (m, 6H, Hf, Hp, Hs-t, -NH), 6.63 (d, J= 15.6 Hz, 1H, Ho), 6.48 (d, J= 5.6 
Hz, 1H, Hb), 3.33-3.23 (m, 4H, Hj-m), 1.73-1.55 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 
164.8 (Cn), 151.8, 150.0, 149.0, 138.4, 134.9, 133.3, 129.3, 128.8, 127.4, 124.0, 123.9, 
122.2, 117.4 (Ca, Cc-i, Co-t), 98.6 (Cb), 42.0, 38.3 (Cj, Cm), 26.7, 25.2 (Ck-l); ESI-IT 
MS: m/z 380.47 (M+H+); (C22H22ClN3O requires 379.15); HPLC-DAD: rt = 13.25 min (% 
Area = 100). 
 
4-[N-(p-methyl)cinnamoylaminobutyl]amino-7-chloroquinoline (13b). 
White solid (24.8 mg, 32%); mp 
200-203oC; RF (DCM/MeOH 8:2) 
0.44;  δH (400 MHz, DMSO-d6) 8.38 
(d, J= 5.6 Hz, 1H, Ha), 8.29 (d, J= 
9.2 Hz, 1H, He), 8.10 (t,  J= 5.2 Hz, 
1H, -NH), 7.77 (d, J= 1.6 Hz, 1H, 
Hh), 7.52-7.28 (m, 5H, Hf, Hp, Hr, -NH), 7.20 (d, J= 7.6 Hz, 2H, Hs), 6.56 (d, J= 15.6 Hz, 
1H, Ho), 6.47 (d, J= 5.6 Hz, 1H, Hb), 3.36-3.16 (m, 4H, Hj, Hm), 2.31 (s, 3H, Hu), 1.74-
1.54 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 165.0 (Cn), 151.8, 
150.0, 149.0, 139.0, 133.3, 132.1, 129.4, 128.8, 127.4, 124.0, 123.9, 121.2, 117.4 (Ca, 
Cc-i, Co-t), 98.6 (Cb), 42.0, 38.3 (Cj,Cm), 26.8, 25.2, 20.1 (Ck-l, Cu); ESI-IT MS (M+H+) 
394.40 (C23H24ClN3O requires 393.16); HPLC-DAD: rt= 14.14 (% Area = 100). 
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4-[N-(p-isopropyl)cinnamoylaminobutyl]amino-7-chloroquinoline (13c). 
White solid (24 mg, 28%); mp 179-
184oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.6 
Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 1H, 
He), 8.12 (t, J= 5.6 Hz, 1H, -NH), 
7.77 (d, J= 2.4 Hz, 1H, Hh), 7.47-
7.22 (m, 7H, Hf, Hp, Hr-s, -NH), 6.57 (d, J= 15.6 Hz, 1H, Ho), 6.48 (d, J= 5.6 Hz, 1H, 
Hb), 3.30-3.22 (m, 4H, Hj, Hm), 2.94-2.84 (m, 1H, Hu), 1.77-1.51 (m, 4H, Hk-l), 1.19 (d, 
J= 5.8 Hz, 6H, Hv); δC (100 MHz, DMSO-d6) 165.0 (Cn), 151.8, 150.0, 149.9, 149.0, 
138.3, 133.3, 132.5, 127.5, 127.4, 126.8, 124.0, 123.9, 121.2, 117.4 (Ca, Cc-i, Co-t), 
98.6 (Cb), 42.0, 38.3 (Cj, Cm), 33.2, 26.8, 25.2, 23.6 (Ck-l, Cu-v); ESI-IT MS: m/z (M+H+) 
422.40 (C25H28ClN3O requires 421.19); HPLC-DAD: rt = 16.01 min; (% Area = 99.16). 
 
4-[N-(p-methoxy)cinnamoylaminobutyl]amino-7-chloroquinoline (13d). 
White solid (24.7 mg, 30%); mp 176-
178oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.2 
Hz, 1H, Ha), 8.28 (d, J= 8.8 Hz, 1H, 
He), 8.04 (t, J= 5.6 Hz, 1H, -NH), 7.77 
(d, J= 2.4 Hz, 1H, Hh), 7.50-7.32 (m, 
5H, Hf, Hp, Hr, -NH), 6.96 (d, J= 8.8 Hz, 2H, Hs), 6.52-6.42 (m, 2H, Hb, Ho), 3.77 (s, 3H, 
Hu), 3.30-3.21 (m, 4H, Hj, Hm), 1.72-1.54 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 165.1 
(Cn), 160.2, 151.8, 150.0, 149.0, 138.1, 133.2, 128.9, 127.4, 124.0, 123.9, 119.7, 117.4, 
114.3 (Ca, Cc-i, Co-t), 98.6 (Cb), 55.1 (Cu), 42.0, 38.2 (Cj, Cm), 26.8, 25.2 (Ck-l); ESI-IT 
MS: m/z (M+H+) 410.52 (C23H24ClN3O2) requires 409.16; HPLC-DAD: rt = 13.25 min; (% 
Area = 100). 
 
4-[N-(p-(N-tert-butoxycarbonyl)amino)cinnamoylaminobutyl]amino-7-
chloroquinoline (13e’).  
White solid (67.1mg, 57%); 
mp 178-182 oC; RF 
(EtOAc/MeOH 8:2) 0.25; δH 
(400 MHz, DMSOd6) 9.53 
(s, 1H, -NH), 8.38 (d, J= 
5.6 Hz, 1H, Ha), 8.28 (d, 
J= 8.8 Hz, 1H, He), 8.05 (t, J= 5.6 Hz, 1H, -NH), 7.77 (d, J= 2 Hz, 1H, Hh), 7.50 -7.42(m, 
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5H), 7.35-7.30 (m, 2H) (Hf, Hp, -NH, Hr-s), 6.50-6.46 (m, 2H, Ho, Hb), 3.32-3.20 (m, 4H, 
Hj, Hm), 1.74-1.52 (m, 4H, Hk-l), 1.45 (s, 9H, Hw); δC (100 MHz, DMSOd6) 165.1 (Cn), 
152.5, 151.8, 150.0, 149.0, 140.6, 138.1, 133.2, 128.6, 128.0, 127.4, 124.0, 123.9, 
120.0, 118.0 (Ca, Cc-i, Co-u), 98.6 (Cb), 79.2 (Cv), 42.0, 38.2 (Cj, Cm), 28.0, 26.7, 25.2 
(Ck-l, Cw); ESI-IT MS: m/z (M+H+) 495.33 (C27H31ClN4O3) requires 494.21; HPLC-DAD rt 
= 15.09 (% Area = 99). 
 
4-[N-(p-amino)cinnamoylaminobutyl]amino-7-chloroquinoline (13e). 
White solid (8 mg, 18%); mp 134-
139oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.37 (d, J= 5.2 
Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 1H, 
He), 7.88 (t, J= 5.6 Hz, 1H, -NH), 7.77 
(d, J= 2.4 Hz, 1H, Hh), 7.43 (dd, J= 8.6 
Hz, J= 2.4 Hz, 1H, Hf), 7,33 (t, J= 5.2 Hz, 1H, -NH), 7.26-7.18 (m, 3H, Hp, Hr), 6.54 (d, 
J= 8.4 Hz, 2H, Hs), 6.47 (d, J= 5.2 Hz, 1H, Hb), 6.27 (d, J= 15.6 Hz, 1H, Ho), 5.54 (b, 
2H, -NH2), 3.32-3.16 (m, 4H, Hj, Hm), 1.63-1.55 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 
165.7 (Cn), 151.8, 150.3, 149.0, 139.2, 133.2, 128.9, 127.4, 124.0, 123.9, 122.1, 117.4, 
115.9, 113.6 (Ca, Cc-i, Co-t), 98.6 (Cb), 42.0, 38.1 (Cj, Cm), 26.9, 25.2 (Ck-l); ESI-IT 
MS: m/z (M+H+) 395.47 (C22H23ClN4O requires 394.16); HPLC-DAD: rt = 9.21min (% 
Area = 86.38). 
 
4-[N-(m-fluoro)cinnamoylaminobutyl]amino-7-chloroquinoline (13f). 
White solid (37.3 mg, 52%); mp 195-
200oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.2 
Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 1H, 
He), 8.18 (t, J= 5.6 Hz, 1H, -NH), 7.77 
(d, J= 2.4 Hz, 1H, Hh), 7.49-7.32 (m, 
5H, Hf, Hp, Hr, Ht, Hv), 7.33 (t, J= 5.6 Hz, 1H, -NH), 7.20 (t, J= 7.2 Hz, 1H, Hs), 6.67 (d, 
J= 16 Hz, 1H, Ho), 6.47 (d, J= 5.6 Hz, 1H, Hb), 3.32-3.20 (m, 4H, Hj, Hm), 1.66-1.58 (m, 
4H, Hk-l); δC (100 MHz, DMSO-d6) 164.5 (Cn), 163.6, 161.2, 151.8, 150.0, 149.0, 137.5, 
137.1, 133.3, 130.8, 127.4, 123.8, 123.5, 117.4, 116.6, 113.9 (Ca, Cc-i, Co-v), 98.6 (Cb), 
42.0, 38.3 (Cj, Cm), 26.7, 25.2 (Ck-l); ESI-IT MS: m/z (M+H+) 398.40 (C22H21ClFN3O 
requires 397.14); HPLC-DAD: rt = 13.53 min (% Area = 99.23). 
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4-[N-(p-fluoro)cinnamoylaminobutyl]amino-7-chloroquinoline (13g). 
White solid (24.1 mg, 34%); mp 
195-200oC; RF (DCM/MeOH 8:2) 
0.44; δH (400 MHz, DMSO-d6) 8.38 
(d, J= 5.2 Hz, 1H, Ha), 8.28 (d, J= 
9.2 Hz, 1H, He), 8.14 (t, J= 5.6 Hz, 
1H, -NH), 7.77 (d, J= 1.6 Hz, 1H, 
Hh), 7.60 (dd, J= 8.8 Hz, J= 5.6 Hz, 
2H, Hr), 7.46-7.39 (m, 2H, Hf, Hp), 7.33 (t, J= 5.2 Hz, 1H, -NH), 7.24 (t, J= 8.8 Hz, 2H, 
Hs), 6.57 (d, J= 15.6 Hz, 1H, Ho), 6.47 (d, J= 5.6 Hz, 1H, Hb), 3.32-3.20 (m, 4H, Hj, Hm), 
1.68-1.60 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 164.7 (Cn), 151.8, 150.0, 149.0, 137.2, 
133.3, 131.5, 129.5, 127.4, 124.0, 123.9, 122.1, 117.4, 115.9 (Ca, Cc-i, Co-t), 98.6 (Cb), 
42.0, 38.3 (Cj, Cm), 26.8, 25.2 (Ck-l); ESI-IT MS: m/z (M+H+) 398.40 (C22H21ClFN3O 
requires 397.14); HPLC-DAD: rt = 13.46 min (% Area = 100) 
 
4-[N-(p-chloro)cinnamoylaminobutyl]amino-7-chloroquinoline (13h). 
 White solid (13 mg, 16%); mp 194-
196oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.2 
Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 1H, 
He), 8.17 (t, J= 5.6 Hz, 1H, -NH), 7.77 
(d, J= 2 Hz, 1H, Hh), 7.57 (d, J= 8.4 
Hz, 2H), 7.48-7.37 (m, 4H) (Hf, Hp, 
Hr-s), 7.33 (t, J= 5.6 Hz, 1H, -NH), 6.66 (d, J= 16 Hz, 1H, Ho), 6.47 (d, J= 5.6 Hz, 1H, 
Hb), 3.32-3.20 (m, 4H, Hj, Hm), 1.68-1.60 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 164.6 
(Cn), 151.8, 150.0, 149.0, 137.2, 133.8, 133.3, 129.1, 128.9, 127.4, 124.0, 123.9, 123.0, 
117.4, 115.9 (Ca, Cc-i, Co-t), 98.6 (Cb), 42.0, 38.3 (Cj, Cm), 26.7, 25.2 (Ck-l); m/z (ESI-
IT MS) 414.47 (M+H+); M+ C22H21Cl2N3O requires 413.11; HPLC-DAD: rt = 14.51 min (% 
Area = 99.71).  
 
 
 
 
 
 
 
 
176 | Chapter 4  	  
4-[N-(p-bromo)cinnamoylaminobutyl]amino-7-chloroquinoline (13i). 
White solid (13 mg, 16%); mp 194-
196oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.2 
Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 1H, 
He), 8.17 (t, J= 5.2 Hz, 1H, -NH), 7.77 
(d, J= 1.6 Hz, 1H, Hh), 7.60 (d, J= 8.4 
Hz, 2H), 7.50 (d, J= 8.4 Hz, 2H) (Hr-s), 7.44-7.30 (m, 3H, Hf, Hp, -NH), 6.64 (d, J= 15.6 
Hz, 1H, Ho), 6.47 (d, J= 5.6 Hz, 1H, Hb), 3.32-3.20 (m, 4H, Hj, Hm), 1.68-1.60 (m, 4H, 
Hk-l); δC (100 MHz, DMSO-d6) 164.6 (Cn), 151.8, 150.0, 149.0, 137.1, 134.2, 133.3, 
131.8, 129.3, 127.4, 124.0, 123.9, 123,1, 122.4, 117.4 (Ca, C-i, Co-t), 98.6 (Cb), 42.0, 
38.3 (Cj, Cm), 26.7, 25.2 (Ck-l); ESI-IT MS: m/z (M+H+) 460.33 (C22H21ClBrN3O requires 
457.06); HPLC-DAD: rt = 14.81 min (% Area = 98.62). 
 
4-[N-(o-nitro)cinnamoylaminobutyl]amino-7-chloroquinoline (13j). 
Yellow solid (56.7 mg, 67%); mp 114-
116oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.38 (d, J= 5.6 
Hz, 1H, Ha), 8.32-8.27 (m, 2H, He, -
NH), 8.04 (d, J= 8 Hz, 1H, Hu), 7.78-
7.60 (m, 5H, Hh, Hp, Hr-t), 7.42 (d, J= 
9 Hz, J= 2 Hz, 1H, Hf), 7.34 (t, J= 5.2 Hz, 1H, -NH), 6.62 (d, J= 15.6 Hz, 1H, Ho), 6.47 
(d, J= 5.6 Hz, 1H, Hb), 3.33-3.21 (m, 4H, Hj, Hm), 1.68-1.60 (m, 4H, Hk-l); δC (100 MHz, 
DMSO-d6) 172.0 (Cn), 164.0, 151.8, 150.0, 149.0, 148.2, 133.7, 133.3, 130.1, 130.0, 
128.5, 127.4, 126.9, 124.4, 124.0, 123.9, 117.4 (Ca, Cc-i, Co-v), 98.6 (Cb), 42.0, 38.4 
(Cj, Cm), 26.7, 25.2 (Ck-l); ESI-IT MS: m/z (M+H+) 425.40 (C22H21ClN4O3 requires 
424.13); HPLC-DAD: rt = 13.20 min (% Area = 100). 
 
4-[N-(m-nitro)cinnamoylaminobutyl]amino-7-chloroquinoline (13k). 
Yellow solid (31 mg, 36%); mp 195-
200 oC; RF (DCM/MeOH 8:2) 0.44; 
δH (400 MHz, DMSO-d6) 8.39-8.35 
(m, 2H, Ha, Hv), 8.30-8.18 (m, 3H, 
He, Ht, -NH), 8.00 (d, J= 8 Hz, 1H, 
Hr), 7.77 (d, J= 2.4 Hz, 1H, Hh), 
7.70 (t, J= 8 Hz, 1H, Hs), 7.54 (d, J= 16 Hz, 1H, Hp), 7.44 (dd, J= 9.2 Hz, J= 2.4 Hz, 1H, 
Hf), 7.34 (t, J= 5.2 Hz, 1H, -NH), 6.82 (d, J= 15.6 Hz, 1H, Ho), 6.47 (d, J= 5.2 Hz, 1H, 
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Hb), 3.33-3.21 (m, 4H, Hj, Hm), 1.68-1.60 (m, 4H, Hk-l); δC (100 MHz, DMSO-d6) 164.3 
(Cn), 151.8, 150.0, 148.2, 136.8, 136.1, 133.8, 133.3, 130.4, 127.4, 125.1, 124.0, 123.9, 
123.6, 121.4, 117.4 (Ca, Cc-i, Co-v), 98.6 (Cb), 42.0, 38.4 (Cj, Cm), 26.7, 25.2 (Ck-l); 
ESI-IT MS: m/z (M+H+) 425.47 (C22H21ClN4O3 requires 424.13); HPLC-DAD: rt = 13.41 
min (% Area = 95.93). 
 
4-[N-(p-nitro)cinnamoylaminobutyl]amino-7-chloroquinoline (13l). 
Yellow solid (13 mg, 8%); mp 178-182 
oC; RF (DCM/MeOH 8:2) 0.44; δH (400 
MHz, DMSO-d6) 8.38 (d, J= 5.2 Hz, 
1H, Ha), 8.30-8.18 (m, 4H, He, Hs, -
NH), 7.82-7.74 (m, 3H, Hh, Hr), 7.52 
(d, J= 16 Hz, 1H, Hp), 7.44 (dd, J= 9 
Hz, J= 2 Hz, 1H, Hf), 7.35 (t, J= 5.2 Hz, 1H, -NH), 6.81 (d, J= 15.6 Hz, 1H, Ho), 6.47 (d, 
J= 5.2 Hz, 1H, Hb), 3.34-2.22 (m, 4H, Hj, Hm), 1.71-1.63 (m, 4H, Hk-l); δC (100 MHz, 
DMSO-d6) 164.1 (Cn), 151.7, 150.0, 148.9, 147.4, 141.5, 136.1, 133.3, 128.5, 127.3, 
126.5, 124.0, 123.9, 117.4 (Ca, Cc-i, Co-t), 98.6 (Cb), 42.0, 38.4 (Cj, Cm), 26.7, 25.2 
(Ck-l); ESI-IT MS: m/z (M+H+) 425.35 (C22H21ClN4O3 requires 424.13); HPLC-DAD: rt = 
13.94 min (% Area = 85.94). 
 
4-[N-(p-dimethylamino)cinnamoylaminobutyl]amino-7-chloroquinoline (13m)  
White solid (14 mg, 8%); mp=176-
180oC; RF (DCM/MeOH 8:2) 0.44; δH 
(400 MHz, DMSO-d6) 8.39 (d, J= 5.6 
Hz, 1H, Ha), 8.32 (d, J= 8.8 Hz, 1H, 
He), 7.95 (t, J= 5.6 Hz, 1H, -NH), 7.79 
(d, J= 2 Hz, 1H, Hh), 7.62 (t, J= 5.2 
Hz, 1H, -NH), 7.47 (dd, J= 8.8 Hz, J= 2.4 Hz, 1H, Hf), 7.36 (d, J= 8.8 Hz, 2H, Hr), 7.29 
(d, J= 16 Hz, 1H, Hp), 6.70 (d, J= 8.8 Hz, 2H, Hs), 6.53 (d, J= 5.6 Hz, 1H, Hb), 6.35 (d, 
J= 16 Hz, 1H, Ho), 3.36-3.30 (m, 2H), 3.25-3.19 (m, 2H) (Hj, Hm), 2.94 (s, 6H, -NMe2), 
1.72-1.64 (m, 2H), 1.60-1.54 (m, 2H) (Hk-Hl); δC (100 MHz, DMSO-d6) 165.6 (Cn), 150.9, 
150.7, 150.6, 147.6, 138.8, 133.9, 128.7, 126.3, 124.3, 122.3, 117.1, 116.7, 111.9 (Ca, 
Cc-i, Co-t), 98.6 (Cb), 42.1, 38.1 (Cj, Cm) 26.9, 25.1 (Ck-l); ESI-IT MS: m/z (M+H+) 
423.47 (C24H27ClN4O requires 422.19); HPLC-DAD: rt = 11.7 min, (% Area = 93.0). 
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4-[N-(m,p-dimethoxy)cinnamoylaminopropyl]amino-7-chloroquinoline (13n) 
White solid (29 mg, 17%); mp=168-172 
oC; RF (DCM/MeOH 8:2) 0.44; δH (400 
MHz, DMSO-d6) 8.44-8.35 (d, J= 5.6 
Hz, 1H, Ha), 8.36 (d, J= 9.2 Hz, 1H, 
He), 8.06 (t, J= 5.6 Hz, 1H, -NH), 7.84-
7.81 (m, 2H, Hh, -NH); 7.50 (dd, J= 9.4 
Hz, J= 2.4 Hz, 1H, Hf), 7.34 (d, J= 16 Hz, 1H, Hp), 7.13-7.08 (m, 2H), 6.96 (d, J= 8.4 Hz, 
1H) (Hr-s, Hv), 6.60-6.46 (d, J= 5.6 Hz, 1H, Hb), 6.51 (d, J= 16 Hz, 1H, Ho), 3.78 (s, 3H), 
3.77 (s, 3H) (Hw-x), 3.37-3.31 (m, 2H), 3.26-3.21 (m, 2H) (Hj, Hm), 1.77-1.66 (m, 2H), 
1.63-1.52 (m, 2H) (Hk-Hl); δC (100 MHz, DMSO-d6) 165.2 (Cn), 151.2, 150.0, 149.8, 
148.8, 146.6, 138.4,134.3, 127.6, 125.5, 124.5, 124.4, 121.2, 119.9, 116.9, 111.7, 109.9 
(Ca, Cc-i, Co-v), 98.6 (Cb), 55.4, 55.3 (Cw-x), 42.2, 38.2 (Cj, Cm), 26.7, 25.1 (Ck-l); ESI-
IT MS: m/z (M+H+) 440.40 (C24H26ClN3O3 requires 439.17); HPLC-DAD: rt = 12.5 min (% 
Area = 100). 
 
4.5.1.4. Synthesis of compounds 14-15. 
Compounds 14 and 15 were synthesized by methods similar to those previously 
described for compounds 13. Briefly, 4,7-dichloroquinoline (1 eq, 1.2 mmol) was reacted 
with the appropriate diaminoalkane (10 eq, 12 mmol) at 100 ºC for 3 h; the mixture was 
brought to room temperature and then diluted with DCM, and the resulting solution was 
washed with 5% aqueous Na2CO3. The organic layer was isolated and dried over 
anhydrous Na2SO4, filtered and evaporated to dryness to afford the desired 4-(N-
aminoalkyl)amino-7-chloroquinoline (17-18). Each compound was then coupled to the 
respective cinnamic acid in DMF, using TBTU and DIEA: a solution of cinnamic acid (1.1 
eq, 0.2 mmol), TBTU (1.1 eq, 0.22 mmol), and 2.2eq of DIEA (68 µL) in DMF was stirred 
at 0 ºC for 10 min; a solution of the appropriate compound 17-18 (1.1 eq, 0.2 mmol) in 
DMF was then added, and the reaction allowed to proceed at room temperature for 24 h. 
The mixture was diluted with DCM and the resulting solution was washed with 5% 
aqueous Na2CO3. The organic layer was separated, dried over anhydrous Na2SO4, 
filtered and evaporated to dryness, and the crude product was purified by liquid 
chromatography on silica using EtOAc/MeOH, 8:2 (v/v) to give the desired compounds 
14, 15. In the particular case of 14e, 4-(N-aminopropyl)amino-7-chloroquinoline was first 
coupled to p-(N-tert-butoxycarbonyl)aminocinnamic acid as above, to yield the N-tert-
butoxycarbonyl (Boc) protected precursor (14e’), followed by removal of Boc through 
acidolysis with neat trifluoroacetic acid (TFA). Spectral/analytical data on compounds 14-
15 follows. 
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4-(N-cinnamoylaminopropyl)amino-7-chloroquinoline (14a) 
White solid (32 mg, 42%); mp 174-192 
oC; RF (EtOAc/MeOH 8:2) 0.25; δH (400 
MHz, DMSO-d6) 8.39 (d, J= 5.6 Hz, 1H, 
Ha), 8.29-8.25 (m, 2H, He, -NH), 7.79 (d, 
J= 2.4 Hz, 1H, Hh), 7.57-7.35 (m, 8H, Hf, 
Ho, Hq-s, -NH), 6.67 (d, J= 15.6 Hz, 1H, 
Hn), 6.49 (d, J= 5.6 Hz, 1H, Hb), 3.34-3.30 (m, 4H, Hj, Hl), 193-1.84 (m, 2H, Hk); δC (100 
MHz, DMSO-d6) 172.0, (Cm), 165.1, 151.9, 150.0, 149.0, 138.5, 134.8, 133.3, 129.3, 
128.8, 127.4, 127.4, 124.0, 122.1, 117.4 (Ca, Cc-i, Cn-s), 98.6 (Cb), 40.0, 36.6 (Cj, Cl), 
27.8 (Ck); ESI-IT MS: m/z (M+H+) 366.47 (C21H20ClN3O requires 365.13); HPLC-DAD: rt 
= 13.0 min (% Area = 100). 
 
4-[N-(p-methyl)cinnamoylaminopropyl]amino-7-chloroquinoline (14b) 
White solid (53 mg, 68%); mp 204-209 
oC; RF (EtOAc/MeOH 8:2) 0.25; δH 
(400 MHz, DMSO-d6) 8.39 (d, J= 5.6 
Hz, 1H, Ha), 8.27 (d, J= 9.2 Hz, 1H, 
He), 8.22 (t, J= 5.6 Hz, 1H, -NH), 7.79 
(d, J= 2.4 Hz, 1H, Hh), 7.46-7.34 (m, 
5H, -NH, Hf, Ho, Hq), 7.20 (d, J= 8 Hz, 2H, Hr), 6.60 (d, J= 16 Hz, 1H, Hn), 6.48 (d, J= 
5.6 Hz, 1H, Hb), 3.34-3.30 (m, 4H, Hj, Hl), 2.30 (s, 3H, Ht), 1.90-1.84 (m, 2H, Hk); δC 
(100 MHz, DMSO-d6) 165.2 (Cm), 151.8, 149.9, 149.0, 139.1, 138.5, 133.3, 132.1, 
129.4, 127.4, 127.4, 124.0, 121.0, 117.4 (Ca, Cc-i, Cn-s), 98.6 (Cb), 39.4, 36.6 (Cj, Cl), 
27.8, 20.8 (Ck, Ct); ESI-IT MS: m/z (M+H+) 380.4 (C22H22ClN3O requires 379.15); HPLC-
DAD: rt = 14.0 min (% Area =100). 
 
4-[N-(p-isopropyl)cinnamoylaminopropyl]amino-7-chloroquinoline (14c) 
White solid (28.7 mg, 33%); mp 
173-178oC; RF (EtOAc/MeOH 8:2) 
0.25; δH (400 MHz, DMSO-d6) 
8.39 (d, J= 5.2 Hz, 1H, Ha), 8.27 
(d, J= 9.2 Hz, =1H, He), 8.22 (t, J= 
5.6 Hz, 1H, -NH), 7.79 (d, J= 2.4 
Hz, 1H, Hh), 7.49-7.23 (m, 5H, -NH, Hf, Ho, Hq), 7.27 (d, J= 8 Hz, 2H, Hr), 6.59 (d, J= 
15.6 Hz, 1H, Hn), 6.49 (d, J= 5.6 Hz, 1H, Hb), 3.35-3.29 (m, 4H, Hj, Hl), 2.92-2.85 (m, 
1H, Ht), 1.90-1.81 (m, 2H, Hk), 1.19 (d, J= 6.8 Hz, 6H, Hu); δC (100 MHz, DMSO-d6) 
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165.2 (Cm), 151.8, 150.0, 149.9, 149.0, 138.5, 133.3, 132.5, 127.5, 127.5, 126.8, 124.0, 
121.1, 117.4 (Ca, Cc-i, Cn-s), 98.6 (Cb), 40.0, 36.6 (Cj, Cl), 33.2, 27.8, 23.6 (Ck, Ct-u); 
ESI-IT: m/z (M+H+) 408.47 (C24H26ClN3O requires 407.18); HPLC-DAD: rt = 16.0 min (% 
Area =90.9). 
 
4-[N-(p-methoxy)cinnamoylaminopropyl]amino-7-chloroquinoline (14d)  
White solid (15 mg, 7%); mp 178-
180oC; RF (EtOAc/MeOH 8:2) 0.25; 
δH (400 MHz, DMSO-d6) 8.39 (d, J= 
5.6 Hz, 1H, Ha), 8.28 (d, J= 9.2 Hz, 
=1H, He), 8.18 (t, J= 5.6 Hz, 1H, -
NH), 7.79 (d, J= 2.4 Hz, 1H, Hh), 
7.54-7.36 (m, 5H, -NH, Hf, Ho, Hq), 6.97 (d, J= 8.8 Hz, 2H, Hr), 6.51-6.47 (m, 2H, Hb, 
Hn), 3.78 (s, 3H, Ht), 3.36-3.28 (m, 4H, Hj, Hl), 1.90-1.80 (m, 2H, Hk); δC (100 MHz, 
DMSO-d6) 172.0 (Cm), 165.4, 160.2, 151.6, 150.1, 148.7, 138.2, 133.4, 129.0, 127.4, 
127.2, 124.0, 119.6, 117.4, 114.2 (Ca, Cc-i, Cn-s), 98.6 (Cb), 55.2 (Ct), 40.0, 36.5 (Cj, 
Cl), 27.8 (Ck); ESI-IT MS: m/z (M+H+) 396.53 (C22H22ClN3O2 requires 395.14); HPLC-
DAD: rt = 13.1 min (% Area = 98.0). 
 
4-[N-(p-(N-tert-butoxycarbonyl)amino)cinnamoylaminopropyl]amino-7-
chloroquinoline (14e’)  
White solid (124.5 mg, 41%); 
mp 218-220 oC; RF 
(EtOAc/MeOH 8:2) 0.1; δH (400 
MHz, DMSO-d6) 9.54 (s, 1H, -
NHBoc), 8.39 (d, J= 5.6 
Hz, 1H, Ha), 8.27 (d, J= 8.8 Hz, 
1H, He), 8.15 (t, J= 5.6 Hz, 1H, -NH), 7.78 (d, J= 2.4 Hz, 1H, Hh), 7.51-7.44 (m, 5H, Hf, 
Hq-r), 7.37-7.32 (m, 2H, Ho, -NH), 6.52-6.48 (m, 2H, Hb, Hn), 3.36-3.28 (m, 4H, Hj, Hl), 
1.88-1.82 (m, 2H, Hk), 1.48 (s, 9H, Hw); δC (100 MHz, DMSO-d6) 165.3 (Cm), 152.5, 
151.8, 149.9, 149.0, 140.7, 138.3, 133.3, 128.5, 128.1, 127.4, 124.0, 123.9, 119.9, 
118.0, 98.6 (Ca-I, Cn-s, Cu), 79.3 (Cv), 40.0, 36.5 (Cj, Cl), 28.0, 27.8 (Ck, Cw); ESI-IT: 
m/z (M+H+) 481.33 (C26H29ClN4O3 requires 480.19); HPLC-DAD: rt = 15.0 min (% Area = 
100). 
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4-[N-(p-amino)cinnamoylaminopropyl]amino-7-chloroquinoline (14e). 
White solid (28.8 mg, 73%); mp 103-
105 oC; RF (EtOAc/MeOH 8:2) 0.1; δH 
(400 MHz, DMSO-d6) 8.39 (d, J= 5.2 
Hz, 1H, Ha), 8.27 (d, J= 9.2 Hz, 1H, 
He), 8.0 (t, J= 5.6 Hz, 1H, -NH), 7.79 
(d, J= 2 Hz, 1H, Hh), 7.44 (dd, J= 8.8 
Hz, J=2Hz, 1H, Hf), 7.36-7.22 (m, 4H, Ho, Hq, -NH), 6.56 (d, J= 8.4Hz, 2H, Hr), 6.48 (d, 
J= 5.6 Hz, 1H, Hb), 6.29 (d, J= 15.6 Hz, 1H, Ho), 5.55 (b, 2H, -NH2), 3.31-3.27 (m, 4H, 
Hj, Hl), 1.87-1.81 (m, 2H, Hk); δC (100 MHz, DMSO-d6) 166.0 (Cm), 151.8, 150.4, 150.0, 
149.0, 139.4, 133.3, 129.0, 127.4, 124.0, 122.1, 117.4, 115.7, 113.6 (Ca, Cc-I, Cn-s), 
98.6 (Cb), 40.0, 36.5 (Cj, Cm), 27.9 (Ck); ESI-IT MS: m/z (M+H+) 381.40 (C21H21ClN4O 
requires 380.14); HPLC-DAD: rt = 8.65 min (% Area = 96.0). 
 
4-[N-(m-fluoro)cinnamoylaminopropyl]amino-7-chloroquinoline (14f)  
White solid (36 mg, 45%); mp 185-190 
oC; RF (EtOAc/MeOH 8:2) 0.25; δH 
(400 MHz, DMSO-d6) 8.39 (d, J= 5.2 
Hz, 1H, Ha), 8.30-8.24 (m, 2H, He, -
NH), 7.79 (d, J= 2Hz, 1H, Hh), 7.47-
7.35 (m, 6H, Hf, Ho, Hq, Hs, Hu, -NH), 
7.20 (t, J= 8.8 Hz, 1H, Hr), 6.67 (d, J= 16 Hz, 1H, Hn), 6.48 (d, J= 5.6 Hz, 1H, Hb), 3.36-
3.30 (m, 4H, Hj, Hl), 1.90-1.84 (m, 2H, Hk); δC (100 MHz, DMSO-d6) 172.7 (Cm), 164.8, 
163.6, 161.2, 151.8, 150.0, 149.0, 137.4, 137.2, 133.3, 130.7, 127.4, 124.0, 123.6, 
117.4, 115.9, 113.8 (Ca, Cc-i, Cn-u), 98.6 (Cb), 40.0, 36.7 (Cj, Cl), 27.7 (Ck); ESI-IT MS: 
m/z (M+H+) 384.40 (C21H19ClFN3O requires 383.12); HPLC-DAD: rt = 13.4 min (% Area 
= 100). 
 
4-[N-(p-fluoro)cinnamoylaminopropyl]amino-7-chloroquinoline (14g) 
White solid (27 mg, 34%); mp 187-193 
oC; RF (EtOAc/MeOH 8:2) 0.25; δH (400 
MHz, DMSO-d6) 8.39 (d, J= 5.2 Hz, 1H, 
Ha), 8.30-8.26 (m, 2H, He, -NH), 7.78 
(d, J= 2.4 Hz, 1H, Hh), 7.61 (dd, J= 8.6 
Hz, J= 5.6 Hz, 2H, Hq), 7.46-7.35 (m, 
2H, Hf, Ho), 7.36 (t, J= 5.2 Hz, 1H, -NH), 7.24 (t, J= 8.8 Hz, 2H, Hr), 6.59 (d, J= 16 Hz, 
1H, Hn), 6.48 (d, J= 4.8 Hz, 1H, Hb), 3.34-3.30 (m, 4H, Hj, Hl), 1.91-1.83 (m, 2H, Hk); δC 
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(100 MHz, DMSO-d6) 172.1 (Cm), 165.0, 163.8, 161.3, 151.8, 150.0, 149.0, 137.4, 
133.3, 129.6, 127.4, 124.0, 122.0, 117.4, 115.9 (Ca, Cc-i, Cn-s), 98.6 (Cb), 40.0, 36.6 
(Cj, Cl), 27.8 (Ck); ESI-IT MS: m/z (M+H+) 384.47 (C21H19ClFN3O requires 383.12); 
HPLC-DAD: rt = 13.3 min (% Area = 100). 
 
4-[N-(p-chloro)cinnamoylaminopropyl]amino-7-chloroquinoline (14h) 
White solid (39 mg, 46%); mp 191-
195 oC; RF (EtOAc/MeOH 8:2) 0.25; 
δH (400 MHz, DMSO-d6) 8.39 (d, J= 
5.6 Hz, 1H, Ha), 8.28 (m, 2H, He, -
NH), 7.78 (d, J= 2.4 Hz, 1H, Hh), 
7.58 (d, J= 8.4 Hz, 2H), 7.49-7,37 
(m, 5H) (Hf, Ho, -NH, Hq-r), 6.63 (d, J= 15.6 Hz, 1H, Hn), 6.49 (d, J= 5.6 Hz, 1H, Hb), 
3.34-3.30 (m, 4H, Hj, Hl), 1.90-1.83 (m, 2H, Hk); δC (100 MHz, DMSO-d6) 164.9 (Cm), 
151.7, 150.1, 148.8, 137.2, 133.8, 133.4, 129.1, 128.9, 127.3, 124.1, 124.0, 122.9, 117.4 
(Ca, Cc-i, Cn-s), 98.6 (Cb), 40.0, 36.6 (Cj, Cl), 27.8 (Ck); ESI-IT MS: m/z (M+H+) 400.40 
(C21H19Cl2N3O requires 399.09); HPLC-DAD: rt = 13.4 min (% Area = 96.2). 
 
4-[N-(p-bromo)cinnamoylaminopropyl]amino-7-chloroquinoline (14i) 
White solid (22 mg, 39%); mp 214-
219oC; RF (EtOAc/MeOH 8:2) 0.25; δH 
(400 MHz, DMSO-d6) 8.39 (d, J= 5.2 
Hz, 1H, Ha), 8.32-8.26 (m, 2H, He, -
NH), 7.78 (d, J= 2 Hz, 1H, Hh), 7.60 
(d, J= 8.4 Hz, 2H), 7.51 (d, J= 8.8 Hz, 
2H) (Hq-r), 7.46-7.34 (m, 3H, -NH, Hf, Ho), 6.65 (d, J= 16 Hz, 1H, Hn), 6.48 (d, J= 5.6 
Hz, 1H, Hb), 3.34-3.30 (m, 4H, Hj, Hl), 1.89-1.82 (m, 2H, Hk); δC (100 MHz, DMSO-d6) 
164.9 (Cm), 151.8, 150.0, 149.0, 137.3, 134.1, 133.3, 131.8, 129.4, 127.4, 124.0, 123.0, 
122.5, 117.4 (Ca, Cc-i, Cn-s), 98.6 (Cb), 40.0, 36.6 (Cj, Cl), 27.7 (Ck); ESI-IT MS: m/z  
(M+H+) 446.20  (C21H19ClBrN3O requires 443.04); HPLC-DAD: rt = 14.7 (% Area = 100). 
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(4-[N-(o-nitro)cinnamoylaminopropyl]amino-7-chloroquinoline (14j).  
White solid (61.7 mg, 72%); mp 190-
195oC; RF (EtOAc/MeOH 8:2) 0.25; δH 
(400 MHz, DMSO-d6) 8.41-8.39 (m, 
2H, Ha, -NH), 8.29 (d, J= 9.2 Hz, 1H, 
He), 8.03 (d, J= 8 Hz, 1H, Ht), 7.79-
7.58 (m, 5H, Hh, Ho, Hq-s), 7.44 (dd, 
J= 9 Hz, J=2Hz, 1H, Hf), 7.33 (t, J= 5.2 Hz, 1H, -NH), 6.63 (d, J= 15.6 Hz, 1H, Hn), 6.49 
(d, J= 5.2 Hz, 1H, Hb), 3.35-3.31 (m, 4H, Hj, Hl), 1.94-1.85 (m, 2H, Hk); δC (100 MHz, 
DMSO-d6) 164.2 (Cm), 151.8, 149.9, 149.0, 148.2, 133.7, 133.5, 133.3, 130.1, 130.0, 
128.6, 127.4, 126.8, 124.5, 124.0, 117.4 (Ca, Cc-i, Cn-u), 98.6 6 (Cb), 40.0, 36.7 (Cj, Cl), 
27.7 (Ck); ESI-IT MS: m/z (M+H+) 411.47 (C21H19ClN4O3 requires 410.11); HPLC-DAD: rt 
= 13.0 min (% Area = 100). 
 
4-[N-(m-nitro)cinnamoylaminopropyl]amino-7-chloroquinoline (14k) 
Yellow solid (22 mg, 25%); mp 209-
214oC; RF (EtOAc/MeOH 8:2) 0.25; 
δH (400 MHz, DMSO-d6) 8.40-8.38 
(m, 2H, Ha, Hu), 8.35-8.26 (m, 2H, 
He, -NH), 8.20 (dd, J= 8 Hz, J= 1.6 
Hz, 1H, Hs), 8.01 (d, J= 7.6 Hz, 1H, 
Hq), 7.77 (d, J= 2 Hz, 1H, Hh), 7.70 (t, J= 8 Hz, 1H, Hr), 7.55 (d, J= 15.6 Hz, 1H, Ho), 
7.44 (dd, J= 8.8 Hz, J= 2.4Hz, 1H, Hf), 7.34 (t, J= 5.2 Hz, 1H, -NH), 6.82 (d, J= 15.6 Hz, 
1H, Hn), 6.49 (d, J= 5.6 Hz, 1H, Hb), 3.36-3.32 (m, 4H, Hj, Hl), 1.93-1.85 (m, 2H, Hk); δC 
(100 MHz, DMSO-d6) 164.5 (Hm), 151.8, 149.9, 149.0, 148.2, 136.7, 136.2, 133.8, 
133.3, 130.4, 127.4, 125.0, 123.8, 123.6, 121.4, 117.4 (Ca, Cc-i, Cn-u), 98.6 (Cb), 36.7 
(Cl), 27.7 (Ck); ESI-IT MS: m/z (M+H+) 411.40 (C21H19ClN4O3 requires 410.11); HPLC-
DAD: rt = 13.2 min (% Area = 93.2). 
 
4-[N-(p-nitro)cinnamoylaminopropyl]amino-7-chloroquinoline (14l) 
Yellow solid (42 mg, 49%); mp 200-
205oC; RF (EtOAc/MeOH 8:2) 0.25; δH 
(400 MHz, DMSO-d6) 8.39 (m, 2H, Ha, -
NH), 8.26 (m, 3H, He, Hr), 7.81 (m, 3H, 
Hh, Hq), 7.53 (d, J= 15.6 Hz, 1H, Ho), 
7.45 (d, J= 9 Hz, J= 2.4 Hz, 1H, Hf), 
7.35 (t, J= 5.6 Hz, 1H, -NH), 6.81 (d, J= 16 Hz, 1H, Hn), 6.49 (d, J= 5.6 Hz, 1H, Hb), 
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3.36-3.32 (m, 4H, Hj, Hl), 1.92-1.84 (m, 2H, Hk); δC (100 MHz, DMSO-d6) 164.4 (Cm), 
151.7, 150.0, 149.0, 147.4, 141.5, 136.2, 133.4, 128.5, 127.3, 126.4, 124.0, 124.0, 117.4 
(Ca, Cc-i, Cn-s), 98.6 (Cb), 36.8 (Cl), 27.8 (Ck); ESI-IT MS: m/z (M+H+) 411.40 
(C21H19ClN4O3 requires 410.11); HPLC-DAD: rt = 13.2 min (% Area = 94.0). 
 
4-[N-(p-isopropyl)cinnamoylaminopentyl]amino-7-chloroquinoline (15a) 
White solid (190 mg, 50%); 
mp=152-155oC;RF (DCM/MeOH 
8:2) 0.58; δH (400 MHz, DMSO-
d6) 8.38 (d, J= 5.6 Hz, 1H, Ha), 
8.28 (d, J= 9.5 Hz, 1H, He), 
8.07 (t, J= 5.6 Hz, 1H, -NH), 
7.77 (d, J= 2 Hz, 1H, Hh), 7.47-7.39 (m, 4H, Hf, Hq, Hs), 7.30-7.26 (m, 3H, Ht, -NH), 
6.56 (d, J= 16 Hz, 1H, Hp), 6.46 (d, J= 5.6 Hz, 1H, Hb), 3.27-3.17 (m, 4H, Hj, Hn), 2.92-
2.86 (m, 1H, Hv), 1.73-1.65 (m, 2H), 1.56-1.36 (m, 4H) (Hk-m), 1.19 (d, J=6.8Hz, 6H, 
Hw); δC (100 MHz, DMSO-d6) 164.9 (Co), 151.8, 150.0, 149.8, 148.9, 138.2, 133.3, 
132.5, 127.4, 127.3, 126.8, 124.0, 123.9, 121.3, 117.3 (Ca, Cc-i, Cp-u), 98.5 (Cb), 42.3, 
38.5 (Cj, Cn), 33.2, 28.9, 27.4, 24.0, 23.6 (Ck-l, Cv-w); ESI-IT MS: m/z (M+H+) 436.47 
(C26H30ClN3O requires 435.21); HPLC-DAD: rt = 16.3 min (% Area = 98.0). 
 
4-[N-(p-methoxy)cinnamoylaminopentyl]amino-7-chloroquinoline (15b) 
White solid (100 mg, 27%); 
mp=142.144oC; RF (DCM/MeOH 8:2) 
0.58; δH (400 MHz, DMSO-d6) 8.38 
(d, J= 5.6 Hz, 1H, Ha), 8.28 (d, J=9.2 
Hz, 1H, He), 8.01 (t, J= 5.6 Hz, 1H, -
NH), 7.77 (d, J= 2 Hz, 1H, Hh), 7.50-7.25 (m, 4H, Hf, Hq, Hs), 7.29 (t, J= 5.2 Hz, 1H, -
NH), 6.96 (d, J= 8.8 Hz, 2H, Ht), 6.48-6.45 (m, 2H, Hb, Hp), 3.78 (s, 3H, Hv), 3.27-3.17 
(m, 4H, Hj, Hn), 1.76-1.62 (m, 2H), 1.56-1.39 (m, 4H) (Hk-m); δC (100 MHz, DMSO-d6) 
165.1 (Co), 160.1, 151.7, 150.0, 148.9, 138.0, 133.3, 128.9, 127.4, 127.3, 124.0, 123.9, 
119.8, 117.3, 114.3 (Ca, Cc-i, Cp-u), 98.5 (Cb), 55.1 (Cv), 42.3, 38.4 (Cj, Cn), 28.9, 27.4, 
24.0 (Ck-m); ESI-IT MS: m/z (M+H+) 424.40 (C24H26ClN3O2 requires 423.17); HPLC-
DAD: rt = 13.7 min (% Area = 100). 
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(4-[N-(p-chloro)cinnamoylaminopentyl]amino-7-chloroquinoline (15c)  
Yellowish solid (65 mg, 17%); 
mp=164-168oC;RF (DCM/MeOH 
8:2) 0.58; δH (400 MHz, DMSO-
d6) 8.38 (d, J= 5.2 Hz, 1H, Ha), 
8.29 (d, J= 8.8 Hz, 1H, He), 8.16 
(t, J= 5.6 Hz, 1H, -NH), 7.77 (d, 
J= 2 Hz, 1H, Hh), 7.56 (d, J= 8.8 Hz, 2H), 7.46-7.38 (m, 4H) (Hs-t, Hf, Hq), 7.32 (t, J= 4.8 
Hz, 1H, -NH), 6.64 (d, J= 16 Hz, 1H, Hp), 6.44 (d, J= 5.2 Hz, 1H, Hb), 3.26-3.18 (m, 4H, 
Hj, Hn), 1.71-1.65 (m, 2H), 1.56-1.38 (m, 4H, Hk-m); δC (100 MHz, DMSO-d6) 164.6 
(Co), 151.7, 150.1, 148.8, 136.9, 133.8, 133.7, 133.3, 129.0, 128.8, 127.2, 124.1, 123.9, 
123.1, 117.3 (Ca, Cc-i, Cp-u), 98.5 (Cb); 42.3, 38.5 (Cj, Cn), 28.9, 27.4, 24.0 (Ck-m); 
ESI-IT MS: m/z (M+H+) 428.53 (C23H23Cl2N3O requires 427.12); HPLC-DAD: rt = 14.9, 
(% Area = 100). 
 
4-[(7-chloroquinolin-4-yl)amino]butan-1-ol (16)  
1 eq of 4,7-dichloroquinoline (0.5g, 2.5mmol) was 
mixed with 4 eq of 4-aminobutan-1-ol (0.9g, 
10mmol) in a round bottom flask, and reaction was 
allowed to proceed at 100oC for 4 h. Then, DCM (25 
mL) was added, followed by addition of 30% 
aqueous Na2CO3 (25 mL), with concomitant 
precipitation of a light pink solid; the solid was submitted to column chromatography on 
silica, using DCM:MeOH (8:2 v/v) as eluent, and pure 18 was obtained as a white solid 
(0.49 g, 78%); mp=171-174oC; RF=0.26 (DCM/MeOH 8:2); δH (400 MHz, DMSO-d6); 8.38 
(d, J= 5.2 Hz, 1H, Ha), 8.27 (d, J= 9.2 Hz, 1H, He), 7.77 (d, J= 2.4 Hz, 1H, Hh), 7.42 (dd, 
J= 9.2 Hz, 2.4 Hz, 1H, Hf), 7.32 (t, J= 5.2 Hz, 1H, -NH), 6.44 (d, J= 5.6 Hz, 1H, Hb), 4.51 
(b, 1H, -OH), 3.47-3.44 (m, 2H, Hm), 3.28-3.24 (m, 2H, Hj), 1.78-1.66 (m, 2H), 1.57-1.50 
(m, 2H) (Hk-l); δC (100 MHz, DMSO-d6) 151.8, 150.0, 149.0, 133.2, 127.4, 124.0, 123.9 
(Ca, Cc-i), 117.4, 98.5 (Cb), 60.4 (Cm), 42.2 (Cj), 30.0, 24.4 (Ck-l); ESI-IT MS: m/z 
(M+H+) 251.33 (C13H15ClN2O requires 250.09). 
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4-[N-(p-methoxy)cinnamoyloxypropyl]amino-7-chloroquinoline (20) 
1 eq of p-methoxycinnamoyl 
chloride (0.08 g, 0.4 mmol) was 
reacted with 4 eq of 22 in 
refluxing DCM (2 mL), in the 
presence of 2 eq of 
triethylamine (112 µL); the 
solution turned yellow after 10 
min and the reaction ran for 24 h. The organic layer was washed with 5% aqueous 
Na2CO3 (3 × 2 mL), dried with anhydrous Na2SO4, filtered, and led to dryness on a rotary 
evaporator. The residue was submitted to column chromatography on silica, using 
DCM:Me2CO (1:1 v/v) as eluent, to yield 20 as a white solid (34 mg, 21%); mp=129-
134oC; RF (DCM/Me2CO 1:1) 0.26; δH (400 MHz, CDCl3) 8.49 (d, J= 5.2 Hz, 1H, Ha), 
7.93 (d, J= 2 Hz, 1H, Hh), 7.71 (d, J= 9.2 Hz, 1H, He), 7.63 (d, J= 16 Hz, 1H, Hp), 7.43 
(d, J= 8.4 Hz, 2H, Hr), 7.31 (dd, J= 8.8 Hz, J= 2 Hz, 1H, Hf), 6.88 (d, J= 8.4 Hz, 2H, Hs), 
6.39 (d, J= 5.2 Hz, 1H, Hb), 6.28 (d, J= 16 Hz, 1H, Ho), 5.38 (b, 1H, -NH), 4.28-4.26 (m, 
2H, Hm), 3.82 (s, 3H, Hu), 3.37-3.36 (m, 2H, Hj), 1.90-1.84 (m, 4H, Hk-l); δC (100 MHz, 
CDCl3) 167.3 (Cn), 161.4, 151.7, 149.8, 148.8, 144.7, 134.9, 129.7, 128.4, 126.9, 125.3, 
121.1, 117.1, 115.1, 114.3 (Ca, Cc-Ci, Co-t), 99.0 (Cb), 63.7 (Cm), 55.3 (Cu), 42.9 (Cj), 
26.5, 25.3 (Ck-l); ESI-IT MS: m/z (M+H+) 411.33 (C23H23ClN2O3 requires 410.14); HPLC-
DAD: rt = 15.4 min (% Area = 97). 
 
4-[N-(p-isopropyl)cinnamoylaminopropyl]aminoquinoline (21) 
Following the experimental procedure 
previously described for compounds 
16 and 17-18, and starting from 4-
chloroquinoline (0.25 g, 1.5 mmol) 
instead of 4,7-dichloroquinoline, 
compound 21 was obtained as a 
beige solid (55 mg, 11%); mp=73-
78oC; RF (DCM/MeOH 8:2) 0.30; δH (400 MHz, CDCl3) 8.41 (d, J= 5.6 Hz, 1H, Ha), 8.02 
(d, J= 8.4 Hz, 1H, He), 7.95 (d, J= 8.4 Hz, 1H, Hh), 7.67-7.57 (m, 2H), 7.42-7.39 (m, 3H) 
(Hf-g, Hp, Hr), 7.18 (d, J= 8 Hz, 2H, Hs), 6.52 (t, J= 5.6 Hz, 1H, -NH), 6.46 (d, J= 16 Hz, 
1H, Ho), 6.34 (d, J= 5.6 Hz, 1H, Hb), 6.15 (b, 1H, -NH), 3.49-3.42 (m, 2H), 3.40-3.30 (m, 
2H) (Hj, Hm), 2.95-2.83 (m, 1H, Hu), 1.78-1.70 (m, 4H, Hk-l), 1.22 (d, J= 6.8 Hz, 6H, Hv); 
δC (100 MHz, CDCl3) 166.7 (Cn), 150.9, 149.2, 146.6, 141.0, 132.4, 129.7, 128.0, 127.9, 
126.9, 125.0, 120.5, 119.7, 118.5 (Ca, Cc-i, Co-t), 98.4 (Cb), 43.1, 39.1 (Cj, Cm), 34.0 
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(Cu), 27.8, 25.5, 23.8 (Ck-l, Cv); ESI-IT MS: m/z (M+H+) 388.27 (C25H29N3O requires 
387.23); HPLC-DAD: rt = 15.2 min (% Area = 99). 
 
4.5.1.5. Synthesis of pyridine and morpholine derivatives 
 
N1-(pyridin-4-yl)butane-1,4-diamine (26) 
1 eq of 4-chloropyridine (0.5 g, 3.3 mmol) was reacted with 10 eq of butane-1,4-diamine 
(2.9 g, 33 mmol) in a round bottom flask put under reflux for 2 hours; after cooling the 
reaction mixture to room temperature, 25 mL of distilled water were added, and the 
desired product was extracted with DCM (3 × 25 mL); the organic layer was dried over 
anhydrous Na2SO4, filtered, and led to dryness on a rotary evaporator; this afforded 26 
as a yellow oil (0.22 g, 40%); ESI-IT MS: m/z (M+H+) 166.33 (C9H15N3 requires 165.13). 
Compound 26 was used without further purification in the synthesis of 24 
 
4-[N-(p-methoxy)cinnamoylbutyl]aminopyridine (24) 
In a round bottom flask put at 0 oC, 1.1 eq 
of p-methoxycinnamic acid (0.29 g, 1.5 
mmol) was dissolved in DMF (2.5 mL) 
and activated by addition of 1.1 eq of 
TBTU (0.47 g, 1.5 mmol) and 2 eq of 
DIEA (454 µL); after 10 min, a solution of 
1 eq of 26 (0.22 g, 1.3 mmol) in DMF (2.5 mL) was added to the previous mixture and 
the reaction allowed to proceed for 24 h. Water (25 mL) was added to the reaction 
mixture and the desired product was extracted with DCM (3 × 25 mL); the organic extract 
was then washed with 5% aqueous Na2CO3 (3 × 25mL), dried over anhydrous Na2SO4, 
filtered, and taken to dryness on a rotary evaporator. The residue was submitted to 
column chromatography on silica, using DCM/MeOH 8:2 (v/v) as eluent, to afford 24 as a 
white solid (0.13 g, 30%); mp= 132-136 oC; RF (DCM/MeOH 8:2) 0.13; δH (400 MHz, 
CDCl3) 8.04 (b, 2H, Ha), 7.54 (d, J= 16 Hz, 1H, Hj), 7.33 (d, J= 8.8 Hz, 2H, Hl), 7.29-7.26 
(m, 1H, -NH), 6.77 (d, J= 8.8 Hz, 2H, Hm), 6.38-6.34 (m, 3H, Hb, Hi), 5.14 (t, J= 4.8 Hz, 
1H, -NH), 3.73 (s, 3H, Ho), 3.36-3.34 (m, 2H), 3.07-3.05 (m, 2H) (Hd, Hg), 1.61-1.59 (m, 
4H, He-f); δC (100 MHz, CDCl3) 166.8 (Ch), 160.6, 153.7, 149.0, 140.0, 129.1, 127.4, 
118.5, 114.1, 107.4 (Ca-c, Ci-n), 55.2 (Co), 42.1, 39.1 (Cd, Cg), 27.2, 26.0 (Ce-f); ESI-IT 
MS: m/z (M+H+) 326.33 (C19H23N3O2 requires 325.18); HPLC-DAD: rt = 11.6 min, (% 
Area = 100). 
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N-(N-phthaloyl)aminobutylmorpholine (27’) 
2 eq of morpholine (0.5g, 5.7 mmol) were reacted with 
1 eq of 1-(N-phthaloyl)amino-4-bromobutane (0.8 g, 
2.9 mmol) in refluxing DCM for 24 h, after which the 
reaction mixture was washed three times with 5% 
aqueous Na2CO3, dried over anhydrous Na2SO4, 
filtered, and led to dryness in a rotary evaporator; the residue was submitted to column 
chromatography on silica, using as eluent DCM:MeOH (8:2 v/v), to afford 27’ as a white 
solid (0.53 g, 64%); mp=61-63oC; RF (DCM/MeOH 8:2) 0.67; δH (400 MHz, CDCl3) 7.84-
7.76 (m, 2H), 7.74-7.66 (m, 2H) (Hi-j), 3.67-3.64 (m, 6H, Ha, Hf), 2.46-2.32 (m, 6H, Hb-
c), 1.70-1.66 (m, 2H), 1.56-1.47 (m, 2H) (Hd-e); δC (100 MHz, CDCl3) 168.4 (Cg), 133.8, 
132.1, 123.1 (Ch-j), 66.9 (Ha), 58.3 (Cf), 53.6 (Cb), 37.8, 26.4, 23.8 (Hc-e); ESI-IT MS: 
m/z (M+H+) 289.40 (C16H20N2O3 requires 288.15). 
 
N-aminobutylmorpholine (27). 1 eq of 27’ (100 mg, 0.30 mmol) was reacted with 50% 
ethanolic hydrazine (0.40 mL) for 2 h at room temperature, for removal of the phthaloyl 
N-protecting group; water was then added to the reaction mixture and the desired 
product was extracted with DCM (3 × 25 mL), the organic layer was dried over 
anhydrous sodium sulfate, filtered, and led to dryness on the rotary evaporator to afford 
27 as a yellowish oil (25 mg, 45%); ESI-IT MS: m/z (M+H+) 159.27 (C8H18N2O requires 
158.14). Compound 27 was used without further purification in the synthesis of 25. 
 
N-(p-isopropyl)cinnamoylaminobutylmorpholine (25) 
1 eq of N-aminobutylmorpholine (0.025 g, 
0.16 mmol) was immediately used in the 
coupling with p-isopropylcinnamic acid 
(0.032 g, 0.17 mmol) carried out as above 
described for 24 but using PyBOP (0.088 
g, 0.17 mmol) instead of TBTU as coupling 
reagent, and DCM as a solvent; this yielded 25 as a white solid (32 mg, 61%); mp=92-
94oC; RF (DCM/MeOH 8:2) 0.52; δH (400 MHz, CDCl3) 7.59 (d, J= 15.6 Hz, 1H, Hi), 7.40 
(d, J= 8.4 Hz, 2H, Hk), 7.20 (d, J= 8.4 Hz, 2H, Hl), 6.36-6.33 (m, 2H, Hh, -NH), 3.73-3.71 
(m, 4H, Ha), 3.40-3.36 (m, 2H, Hf), 2.95-2.85 (m, 1H, Hn), 2.44-2.42 (m, 4H, Hb), 2.38-
2.34 (m, 2H, Hc), 1,60 (m, 4H, Hd-e), 1.23 (d, J= 6.8 Hz, 6H, Ho); δC (100 MHz, CDCl3); 
160.1 (Cg), 150.7, 140.7, 132.5, 127.7, 126.9, 119.8 (Ch-m), 66.9 (Ca), 58.3 (Cf), 53.6 
(Cb), 39.5 (Cc), 34.0, 27.4, 24.0, 23.8 (Cd-e, Cn-o); ESI-IT MS: m/z (M+H+) 331.40 
(C20H30N2O2 requires 330.23); HPLC-DAD: rt = 13.2 min (% Area = 100). 
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4.5.1.6. Synthesis of PQ-based HEFLECINs (28). 
In a round bottom flask, the relevant cinnamic acid (1.1 eq., 0.6 mmol) was solubilized in 
DMF (2.5 mL) and the solution put in an ice bath; then, TBTU (1.1 eq., 0.6 mmol) and 
DIEA (2 eq., 1.0 mmol) were added and the mixture stirred at 0 ºC for 10 minutes. A 
solution of primaquine biphosphate in DMF (2.5mL) was then added to the mixture, 
which was left under stirring for one day at room temperature. Following 50 mL of DCM 
were added to the reaction mixture and the organic layer was washed with 5% aqueous 
Na2CO3. Finally, the organic layer was dried over anhydrous Na2SO4, filtered, and 
evaporated under reduced pressure. The residue was submitted to column liquid 
chromatography on silica, using dichloromethane:acetone (6:1 v/v) as eluent. All target 
compounds were isolated in high purity degrees and presented correct analytical and 
spectral data, as given below. 
 
N-cinnamoylprimaquine (28a).  
Yellow oil (0.13 g, 58%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 
MHz, DMSO-d6) 8.53 (dd, J= 4 Hz, 
J= 1.6 Hz, 1H, Hh), 7.91 (dd, J= 8.4 
Hz, J= 1.6 Hz, 1H, Hf), 7.58 (d, J= 
15.6 Hz, 1H, Hr), 7.44-7.42 (m, 2H, 
Ht), 7.35-7.28 (m, 4H, Hg, Hu-v), 
6.35-6.27 (m, 3H, Hb, Hd, Hq), 6.01-5.95 (m, 2H, -NH-QN, -NH-C=O), 3.85 (s, 3H, Hj), 
3.67-3.59 (m, 1H, Hk), 3.44-3.34 (m, 2H, Ho), 1.76-1.66 (m, 4H, Hm-n), 1.28 (d, J= 
6.3Hz, 3H, Hl); δC (100 MHz, DMSO-d6) 165.9 (Cp), 159.4, 144.8, 144.3, 140.7, 135.3, 
134.9, 134.8, 129.9, 129.5, 128.7, 127.7, 121.9, 120.8 (Ca, Cc, Ce-i, Cq-v), 96.9, 91.7 
(Cb, Cd), 55.1 (Cj), 47.8, 39.7 (Ck, Co), 34.1, 26.1, 20.1 (Cl-n); ESI-IT MS: m/z (M+H+) 
390.33 (C24H27N3O2 requires 389.21); HPLC-DAD: rt = 16.8 min (% Area =99.5%). 
 
N-(4-methylphenyl)cinnamoylprimaquine (28b).  
Yellow oil (0.08 g, 36%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 
MHz, DMSO-d6) 8.53 (dd, J= 4 Hz, 
J= 1.6 Hz, 1H, Hh), 7.92 (dd, J= 8.4, 
J= 1.6 Hz, 1H, Hf), 7.55 (d, J= 15.6 
Hz, 1H, Hq), 7.35-7.28 (m, 3H, Ht, 
Hg), 7.15 (d, J= 8 Hz, 2H, Hu), 6.34 
(d, J= 2.8 Hz, 1H), 6.30 (d, J= 2.4 Hz, 1H) (Hb, Hd), 6.23 (d, J= 15.6 Hz, 1H, Hq), 6.00 
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(d, J= 8.4 Hz, 1H, -NH-QN), 5.80 (t, J= 5.2 Hz, 1H, -NH-C=O), 3.86 (s, 3H, Hj), 3.67-3.63 
(m, 1H, Hk), 3.45-3.34 (m, 2H, Ho), 2.35 (s, 3H, Hw), 1.78-1.69 (m, 4H, Hm-n), 1.30 (d, 
J= 6.4 Hz, 3H, Hl); δC (100 MHz, DMSO-d6) 166.1 (Cp), 159.4, 144.9, 144.3, 140.7, 
135.3, 134.9, 132.1, 129.9, 129.4, 127.7, 121.9, 119.7 (Ca, Cc, Ce-i, Cq-v), 96.9, 91.8 
(Cb, Cd), 55.2 (Cj), 47.9, 39.7 (Ck, Co), 34.1, 26.1, 21.4, 20.1 (Cl-n, Cw); ESI-IT MS: m/z 
(M+H+) 404.27 (C25H29N3O2 requires 403.23); HPLC-DAD: rt = 17.6 min (% Area = 
99.9%). 
 
N-(4-isopropylphenyl)cinnamoylprimaquine (28c).  
Yellow oil (0.18 g, 78%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 MHz, 
DMSO-d6) 8.53 (dd, J=4.4 Hz, J= 1.6 
Hz, 1H, Hh), 7.92 (dd, J= 8 Hz, J= 1.6 
Hz, 1H, Hf), 7.56 (d, J= 15.6 Hz, 1H, 
Hr), 7.37 (d, J= 8 Hz, 2H, Ht), 7.30 
(dd, J= 8 Hz, J= 4 Hz, 1H, Hg), 7.19 
(d, J= 8 Hz, 2H, Hu), 6.36-6.23 (m, 3H, Hb, Hd, Hq), 6.00 (d, J= 8.4 Hz, 1H, -NH-QN), 
5.83 (t, J= 5.2 Hz, 1H, -NH-C=O), 3.86 (s, 3H, Hj), 3.68-3.32 (m, 1H, Hk), 3.45-3.33 (m, 
2H, Ho), 2.94-2.86 (m, 1H, Hw), 1.76-1.70 (m, 4H, Hm-n), 1.30 (d, J= 6.4 Hz, 3H, Hl), 
1.24 (d, J= 6.8 Hz, 6H, Hx); δC (100 MHz, DMSO-d6) 166.1 (Cp), 159.4, 150.7, 144.9, 
144.3, 140.7, 135.3, 134.8, 132.5, 129.9, 127.8, 126.8, 121.9, 119.8 (Ca, Cc, Ce-i, Cq-v), 
96.9, 91.8 (Cb, Cd), 55.2 (Cj), 47.8, 39.7 (Ck, Co), 34.1,  34.0, 26.3, 23.7, 20.6 (Cl-n, 
Cw-x); m/z (ESI-IT MS) (M+H+) 432.33 (C22H21ClN4O3 requires 431.26); HPLC-DAD: rt = 
19.00 min (% Area = 99.90). 
 
N-(4-methoxyphenyl)cinnamoylprimaquine (28d).  
Yellow oil (0.19 g, 79%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 
MHz, DMSO-d6) 8.53 (dd, J= 4.2 Hz, 
J= 2 Hz, 1H, Hh), 7.92 (dd, J= 8.4 
Hz, J= 2 Hz, 1H, Hf), 7.53 (d, J= 15.6 
Hz, 1H, Hr), 7.38 (d, J= 8.8 Hz, 2H, 
Ht), 7.29 (dd, J= 8 Hz, J= 2 Hz, 1H, 
Hg), 6.86 (d, J= 8.8 Hz, 2H, Hu), 6.33 (d, J= 2.4 Hz, 1H), 6.29 (d, J= 2.4 Hz, 1H) (Hb, 
Hd), 6.15 (d, J= 15.2 Hz, 1H, Hq), 6.00 (d, J= 8.4 Hz, 1H, -NH-QN), 5.78 (t, J= 5.6 Hz, 
1H, -NH-C=O), 3.86 (s, 3H, Hj), 3.81 (s, 3H, Hw), 3.68-3.60 (m, 1H, Hk), 3.46-3.34 (m, 
2H, Ho), 1.79-1.67 (m, 4H, Hm-n), 1.30 (d, J= 6.4 Hz, 3H, Hl); δC (100 MHz, DMSO-d6) 
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166.2 (Cp), 160.7, 159.4, 144.9, 144.3, 140.3, 135.3, 134.8, 129.9, 129.3, 127.6, 121.9, 
118.4, 114.1 (Ca, Cc, Ce-i, Cq-v), 96.9, 91.8 (Cb, Cd), 55.3, 55.2 (Cj, Cw), 47.8, 39.6 
(Ck, Co), 34.1, 26.3, 20.6 (Cl-n); ESI-IT MS: m/z (M+H+) 420.30 (C25H29N3O3 requires 
419.22); HPLC-DAD: rt = 16.7 min (% Area = 99.9%). 
 
N-(3-fluorophenyl)cinnamoylprimaquine (28e).  
Yellow oil (0.13 g, 60%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 MHz, 
DMSO-d6) 8.53 (dd, J= 4.4 Hz, J= 1.6 
Hz, 1H, Hh), 7.93 (dd, J= 8.4 Hz, J= 1.6 
Hz, 1H, Hf), 7.51 (d, J= 15.6 Hz, 1H, 
Hr), 7.34-7.26 (m, 2H, Hx, Hg), 7.18 (d, 
J= 7.6 Hz, 1H, Ht), 7.11-6.99 (m, 2H, 
Hu-v), 6.34 (d, J= 2.4 Hz, 1H), 6.30 (d, 
J= 2.4 Hz, 1H) (Hb, Hd), 6.15 (d, J= 15.6 Hz, 1H, Hq), 6.00 (d, J= 8.4 Hz, 1H, -NH-QN), 
5.91 (t, J= 4.8 Hz, 1H, -NH-C=O), 3.85 (s, 3H, Hj), 3.70-3.60 (m, 1H, Hk), 3.45-3.35 (m, 
2H, Ho), 1.80-1.68 (m, 4H, Hm-n), 1.29 (d, J= 6.4 Hz, 3H, Hl); δC (100 MHz, DMSO-d6) 
165.4 (Cp), 164.2, 161.7, 159.4, 144.8, 144.4, 139.4, 137.2, 135.3, 134.9, 130.2, 129.9, 
123.9, 122.0, 116.3, 113.7 (Ca, Cc, Ce-i, Cq-x), 97.0, 91.9 (Cb, Cd), 55.2 (Cj), 47.8, 39.8 
(Ck, Co), 34.1, 26.1, 20.7 (Cl-n); ESI-IT MS: m/z (M+H+) 408.33 (C24H26FN3O2 requires 
407.20); HPLC-DAD: rt = 17.2 min (% Area = 100%). 
 
N-(4-fluorophenyl)cinnamoylprimaquine (28f). 
 Yellow oil (0.17 g, 77%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 
MHz, DMSO-d6) 8.53 (dd, J= 4.2 Hz, 
J= 2Hz, 1H, Hh), 7.92 (dd, J= 8 Hz, 
J= 1.6 Hz, 1H, Hf), 7.53 (d, J= 15.6 
Hz, 1H, Hr), 7.40 (dd, J= 8.6 Hz, J= 
5.4 Hz, 2H, Ht), 7.31 (dd, J= 8 Hz, J= 
4 Hz, 1H, Hg), 7.02 (t, J= 8.8 Hz, 2H, Hu), 6.34 (d, J= 2.8 Hz, 2H), 6.30 (d, J= 2.4 Hz, 
2H) (Hb, Hd), 6.18 (d, J= 15.6 Hz, 1H, Hq), 6.00 (d, J= 8.4 Hz, 1H, -NH-QN), 5.86 (t, J= 
5.2 Hz, 1H, -NH-C=O), 3.86 (s, 3H, Hj), 3.68-3.61 (m, 1H, Hk), 3.45-3.32 (m, 2H, Ho), 
1.79-1.67 (m, 4H, Hm-n), 1.29 (d, J= 6.4 Hz, 3H, Hl); δC (100 MHz, DMSO-d6) 165.7 
(Cp), 159.4, 144.9, 144.4, 139.5, 135.3, 134.8, 129.9, 129.5, 129.4, 121.9, 120.5, 115.8, 
115.7 (Ca, Cc, Ce-i, Cq-v), 97.0, 91.8 (Cb, Cd), 55.2 (Cj), 47.8, 39.7 (Ck, Co), 34.1, 26.2, 
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20.6 (Cl-n); ESI-IT MS: m/z (M+H+) 408.33 (C24H26FN3O2 requires 407.20); HPLC-DAD: 
rt = 17.1 min (% Area = 100%). 
 
N-(4-chlorophenyl)cinnamoylprimaquine (28g).  
Yellow oil (0.15 g, 59%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 
MHz, DMSO-d6) 8.53 (dd, J= 4.2 
Hz, J= 1.6 Hz, 1H, Hh), 7.92 (dd, J= 
8.4 Hz, J= 1.6 Hz, 1H, Hf), 7.50 (d, 
J= 15.6 Hz, 1H, Hr), 7.35-7.29 (m, 
5H, Hg, Ht-u), 6.34 (d, J= 2.8 Hz, 
1H, Hd), 6.30 (d, J= 2.4 Hz, 1H, Hb), 6.22 (d, J= 15.6 Hz, 1H, Hq), 5.99 (d, J= 8.4  Hz, 
1H, -NH-QN), 5.88 (t, J= 5.2 Hz, 1H, -NH-C=O), 3.86 (s, 3H, Hj), 3.67-3.63 (m,1H, Hk), 
3.45-3.35 (m, 2H, Ho), 1.79-1.67 (m, 4H, Hm-n), 1.29 (d, J= 6.4 Hz, 3H, Hl); δC (100 
MHz, DMSO-d6) 165.6 (Cp), 159.4, 144.9, 144.4, 139.4, 135.3, 135.3, 134.8, 133.4, 
129.9, 128.9, 128.9, 121.9, 121.3 (Ca, Cc, Ce-i, Cq-v), 97.0, 91.9 (Cb, Cd), 55.2 (Cj), 
47.8, 39.7 (Ck, Co), 34.1, 26.2, 20.7 (Cl-n); ESI-IT MS: m/z (M+H+) 424.33 
(C24H26ClN3O2 requires 423.17); HPLC-DAD: rt = 18.0 min (% Area = 100%). 
 
N-(4-bromophenyl)cinnamoylprimaquine (28h). 
Yellow solid (0.19 g, 73%); mp 110-
112oC, RF (DCM/Me2CO 
6:1) 0.49; δH (400 MHz, DMSO-d6) 
8.53 (dd, J= 4.4, J= 1.6 Hz, 1H, Hh), 
7.92 (dd, J= 8.2 Hz, J= 1.2 Hz, 1H, 
Hf), 7.54-7.43 (m, 3H), 7.34-7.27 (m, 
3H, Hg, Hr, Ht-u), 6.34 (d, J= 2.8 Hz, 
1H), 6.30 (d, J= 2.4 Hz, 1H) (Hb, Hd), 6.22 (d, J= 15.6 Hz, 1H, Hq), 6.00 (d, J= 8.8 Hz, 
1H, -NH-QN), 5.86 (t, J= 4.8 Hz, 1H, -NH-C=O), 3.86 (s, 3H, Hj), 3.67-3.63 (m, 1H, Hk), 
3.45-3.35 (m, 2H, Ho), 1.79-1.67 (m, 4H, Hm-n), 1.30 (d, J= 6.4 Hz, 3H, Hl); δC (100 
MHz, DMSO-d6) 165.5 (Cp), 159.4, 144.9, 144.4, 139.4, 135.3, 134.8, 133.8, 131.9, 
129.9, 129.1, 123.6, 121.9, 121.4 (Ca, Cc, Ce-i, Cq-v), 97.0, 91.9 (Cb, Cd), 55.2 (Cj), 
47.8, 39.7 (Ck, Co), 34.1, 26.2, 20.7 (Cl-n); ESI-IT MS: m/z (M+H+) 468.37 
(C24H26BrN3O2 requires 467.12); HPLC-DAD: rt = 18.2 min (% Area = 100%). 
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N-(2-nitrophenyl)cinnamoylprimaquine (28i).  
Orange oil (0.18 g, 75%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 MHz, 
DMSO-d6) 8.51 (dd, J= 4.4 Hz, J= 1.6 
Hz, 1H, Hh), 7.97 (dd, J= 8 Hz, J= 1.2 
Hz, 1H, Hf), 7.92-7.88 (m, 2H, Hr, 
Hw), 7.59-7.44 (m, 3H, Ht-v), 7.28 (dd, 
J= 8.4 Hz, J= 4.4 Hz, 1H, Hg), 6.31 (d, 
J= 2.4 Hz, 1H), 6.29 (J= 2.4 Hz, 1H) (Hb, Hd), 6.20 (d, J= 15.2 Hz, 1H, Hq), 6.07 (t, J= 
5.6 Hz, 1H, -NH-C=O), 5.98 (d, J= 8.4 Hz, 1H, -NH-QN), 3.85 (s, 3H, Hj), 3.65-3.61 
(m,1H, Hk), 3.45-3.35 (m, 2H, Ho), 1.78-1.66 (m, 4H, Hm-n), 1.29 (d, J= 6.4 Hz, 3H, Hl); 
δC (100 MHz, DMSO-d6) 164.9 (Cp), 159.4, 148.2, 144.8, 144.3, 135.7, 135.3, 134.8, 
133.2, 131.1, 129.9, 129.6, 129.1, 126.2, 124.7, 121.9 (Ca, Cc, Ce-i, Cq-x), 96.9, 91.8 
(Cb, Cd), 55.2 (Cj), 47.8, 39.8 (Ck, Co), 34.1, 26.1, 20.6 (Cl-n); ESI-IT MS: m/z (M+H+) 
435.40 (C24H26N4O4 requires 434.20); HPLC-DAD: rt = 16.7 min (% Area = 100%). 
 
N-(3-nitrophenyl)cinnamoylprimaquine (28j).  
Orange oil (0.16 g, 65%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 MHz, 
DMSO-d6) 8.53 (dd, J= 4.4 Hz, J= 1.6 
Hz, 1H, Hh), 8.26 (t, J= 1.8 Hz, 1H, 
Hx), 8.15 (ddd, J= 8.4 Hz, J= 2.4 Hz, 
J= 1.2 Hz, 1H, Hv), 7.92 (dd, J= 8 Hz, 
J= 1.6 Hz, 1H, Hf), 7.68 (d, J= 7.6 Hz, 
1H, Ht), 7.58 (d, J= 15.6 Hz, 1H, Hr), 
7.50 (t, J= 8 Hz, 1H, Hu), 7.30 (dd, J= 8.4 Hz, J= 4.4 Hz, 1H, Hg), 6.36-6.29 (m, 3H, Hb, 
Hd, Hq), 6.10-5.99 (m, 2H, -NH-QN, -NH-C=O), 3.84 (s, 3H, Hj), 3.67-3.63 (m, 1H, Hk), 
3.47-3.37 (m, 2H, Ho), 1.79-1.67 (m, 4H, Hm-n), 1.29 (d, J= 6.4Hz, 3H, Hl); δC (100 
MHz, DMSO-d6) 164.9 (Cp), 159.4, 148.5, 144.8, 144.4, 138.0, 136.7, 135.3, 134.9, 
134.0, 129.9, 129.8, 123.8, 123.8, 121.9, 121.5 (Ca, Cc, Ce-i, Cq-x), 97.0, 91.9 (Cb, Cd), 
55.2 (Cj), 47.8, 39.8 (Ck, Co), 34.1, 26.0, 20.6 (Cl-n); ESI-IT MS: m/z (M+H+) 435.27 
(C24H26N4O4 requires 434.20); HPLC-DAD: rt = 17.1 min (% Area = 99.8%).  
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N-(4-nitrophenyl)cinnamoylprimaquine (28k).  
Orange oil (0.17 g, 69%); RF 
(DCM/Me2CO 6:1) 0.49; δH (400 
MHz, DMSO-d6) 8.52 (dd, J= 4.4 
Hz, J= 1.6 Hz, 1H, Hh), 8.16 (d, J= 
8.8 Hz, 2H, Hu), 7.92 (dd, J= 8.4 
Hz, J= 1.6 Hz, 1H, Hf), 7.60-7.49 
(m, 3H, Hr, Ht), 7.30 (dd, J= 8 Hz, 
J= 2 Hz, 1H, Hg), 6.37-6.27 (m, 3H, Hb, Hd, Hq), 6.01 (t, J= 5.6 Hz, 1H, -NH-C=O), 5.98 
(d, J= 8.4 Hz, 1H, -NH-QN), 3.85 (s, 3H, Hj), 3.67-3.63 (m, 1H, Hk), 3.45-3.35 (m, 2H, 
Ho), 1.80-1.68 (m, 4H, Hm-n), 1.29 (d, J= 6.4 Hz, 3H, Hl); δC (100 MHz, DMSO-d6) 164.8 
(Cp), 159.4, 148.0, 144.8, 144.4, 141.2, 138.0, 135.3, 134.9, 129.9, 128.2, 125.0, 124.0, 
122.0 (Ca, Cc, Ce-i, Cq-v), 97.1, 91.9 (Cb, Cd), 55.2 (Cj), 47.9, 39.9 (Ck, Co), 34.2, 26.0, 
20.6 (Cl-n); ESI-IT MS: m/z (M+H+) 435.26 (C24H26N4O4 requires 434.20); HPLC-DAD: rt 
= 17.1 min (% Area = 100%). 
 
4.5.1.7. Synthesis of acridine derivatives 
 
9-(N-aminobutyl)aminoacridine (30) 
10 eq of butane-1,4-diamine (414 mg, 4.7 mmol) and 1 eq of 9-chloroacridine (100 mg, 
0.47 mmol) were added in a round bottom flask and put in an oil bath. The temperature 
was raised to 100oC and let it react for two hours. The reaction mixture was allowed to 
reach room temperature, and 25 mL of water were added; the desired product 30 was 
extracted three times with DCM. The organic layer was dried with anhydrous Na2SO4, 
filtered, and evaporated to yield an orange oil. The resulted oil was analyzed by ESI-IT 
MS and used without further purification in the synthesis of compound 29. ESI-IT MS: 
m/z (M+H+) 266.33 (C17H19N3 requires 265.16). 
 
4.5.1.7.1. Synthesis of compounds 9-(N-cinnamoylaminobutyl)acridines (29) 
The relevant cinnamic acid (1.1 eq), TBTU (1.1 eq), DIEA (2 eq.) and DMF (1 mL) were 
mixed in a round bottom flask and put under stirring for 20 minutes. Then, a solution of 
30 (1 eq) in DMF (1 mL) was added and the reaction allowed to proceed for one day, 
after which DCM (25 mL) was added to the reaction mixture. The mixture was washed 
with 5% aqueous Na2CO3 (3×25mL), dried over anhydrous Na2SO4 and evaporated to 
yield a crude product that was purified by liquid column chromatography on silica using 
DCM:MeOH (8:2 v/v) as eluent. 
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9-(N-cinnamoylaminobutyl)aminoacridine (29a) 
Yellow oil (8 mg, 6%); RF (DCM/MeOH 
8:2) 0.4; δH (400 MHz, CDCl3) 8.01 (d, 
J= 8.4Hz, 2H, He), 7.64-7.53 (m, 4H, 
Hb, -NH, Hn), 7.50-7.47 (m, 2H, Hp), 
7.37-7.26 (m, 6H) (-NH, Hc, Hq-r), 7.00 
(t, J= 7.6 Hz, 2H, Hd), 6.64 (d, J= 16 Hz, 
1H, Hm), 3.91-3.83 (m, 2H), 3.48-3.45 
(m, 2H) (Hh, Hk), 2.05-1.97 (m, 2H), 1.76-1.70 (m, 2H) (Hi-j); δC (100 MHz, CDCl3) 166.7 
(Cl), 156.1, 140.4, 139.7, 135.0, 133.4, 129.5, 128.7, 127.8, 124.7, 122.7, 121.2, 119.4, 
112.0 (Ca-g, Cm-r), 48.4, 38.9 (Ch, Ck), 27.3, 26.6 (Ci-j); ESI-IT MS: m/z (M+H+) 396.40 
(C26H25N3O requires 395.20); HPLC-DAD: rt = 14.12 min; (% Area = 85). 
 
9-[N-(p-methylcinnamoyl)aminobutyl]aminoacridine (29b) 
Yellow oil (7 mg, 5%); RF (DCM/MeOH 8:2) 0.4; δH (400 MHz, CDCl3) 8.03 (d, J= 8.4 Hz, 
2H, He), 7.61-7.47 (m, 4H, Hb, Hn, -
NH), 7.37 (d, J= 8 Hz, 2H, Hp), 7.34-
7.27 (m, 2H, Hc), 7.12 (d, J= 8 Hz, 2H, 
Hq), 7.01 (t, J= 8 Hz, 2H, Hd), 6.58 (d, 
J= 16 Hz, 1H, Hm), 3.89-3.83 (m, 2H), 
3.48-3.45 (m, 2H) (Hh, Hk), 2.33 (s, 3H, 
Hs), 2.06-1.96 (m, 2H), 1.78-1.71 (m, 2H) (Hi Hj); δC (100 MHz, CDCl3) 166.8 (Cl), 156.0, 
140.4, 140.0, 139.7, 133.2, 132.3, 129.5, 127.7, 124.7, 122.6, 120.1, 119.7, 112.1 (Ca-g, 
Cm-r), 48.4, 38.9 (Ch, Ck), 27.4 (Cs), 26.7, 21.4 (Ci-j); ESI-IT MS: m/z (M+H+) 410.6 
(C27H27N3O requires 409.22); HPLC-DAD: rt = 15.15 min; (% Area = 93). 
 
9-[N-(p-isopropylcinnamoyl)aminobutyl]aminoacridine (29c) 
Orange solid (37 mg, 18%); mp = 49-
52 oC; RF (DCM/MeOH 8:2) 0.4; δH 
(400 MHz, CDCl3) 8.04 (d, J= 8.4 Hz, 
2H, He), 7.63-7.59 (m, 3H, Hn, Hb), 
7.53 (t, J= 5.2 Hz, 1H, -NH), 7.40 (d, 
J= 8.4 Hz, 2H, Hp), 7.32-7.27 (m, 2H, 
Hc), 7.17 (d, J= 8 Hz, 2H, Hq), 7.0 (t, 
J= 7.6 Hz, 2H, Hd), 6.58 (d, J= 16 Hz, 1H, Hm), 3.88-3.83 (m, 2H), 3.48-3.42 (m, 2H) 
(Hh, Hk), 2.91-2.85 (m, 1H, Hs), 2.05-1.96 (m, 2H), 1.81-1.69 (m, 2H) (Hi-j), 1.22 (d, J= 
7.2 Hz, 6H, Ht); δC (100 MHz, CDCl3) 178.0 (Cl), 166.8, 155.9, 150.7, 140.5, 133.1, 
196 | Chapter 4  	  
132.6, 127.8, 126.9, 124.7, 122.6, 120.2, 119.9, 112.2 (Ca-g, Cm-r), 48.4, 38.9 (Ch, Ck), 
34.0 (Cs), 27.4, 26.7 (Ci-j), 23.8 (Ct); ESI-IT MS: m/z (M+H+) 438.53 (C29H31N3O requires 
437.25); HPLC-DAD: rt = 17.03 min; (% Area = 98). 
 
9-[N-(p-methoxycinnamoyl)aminobutyl]aminoacridine (29d) 
Yellow oil (5 mg, 2%); RF (DCM/MeOH 
8:2) 0.4; δH (400 MHz, CDCl3) 8.07 (d, 
J= 8.4 Hz, 2H, He), 7.92 (d, J= 8.4 Hz, 
2H, Hb), 7.62-7.50 (m, 4H, -NH, Hn, 
Hc), 7.42 (d, J= 8.8 Hz, 2H, Hp), 7.30-
7.24 (m, 2H, Hd), 6.87 (d, J= 8.8 Hz, 
2H, Hq), 6.31 (d, J= 16 Hz, 2H, Hm, -
NH), 3.85 (m, 2H), 3.86-3.81 (s, 3H), 3.49-3.41 (m, 2H) (Hh, Hk, Hs), 1.93.1.83 (m, 2H), 
1.78-1.68 (m, 2H) (Hi-j); δC (100 MHz, CDCl3) 166.8 (Cl), 160.9, 140.6, 130.8, 129.3, 
127.7, 127.5, 125.9, 124.8, 123.8, 123.3, 123.0, 118.3, 114.2 (Ca-g, Cm-r), 55.3 (Cs), 
49.9, 39.1 (Ch, Ck), 28.5, 27.1 (Ci-j); ESI-IT MS: m/z (M+H+) 426.47 (C27H27N3O2 
requires 425.21); HPLC-DAD: rt = 14.17 min (% Area = 92). 
 
9-[N-(m-fluorocinnamoyl)aminobutyl]aminoacridine (29e) 
Orange oil (7.4 mg, 3%); RF (DCM/MeOH 
8:2) 0.4; δH (400 MHz, CDCl3) 8.10 (d, J= 8 
Hz, 2H, He), 7.98-7.90 (m, 3H, Hb, Hp), 
7.64-7.44 (m, 4H, Hc, Hn, -NH), 7.35-7.22 
(m, 3H, Hd, Ht), 7.16 (d, J= 9.6 Hz, 1H, Hr), 
7.04-6.97 (m, 1H, Hq), 6.65 (b, 1H, -NH), 
6.49 (d, J= 16 Hz, 1H, Hm), 3.91-3.85 (m, 2H), 3.49-3.45 (m, 2H) (Hh, Hk), 1.98-1.88 (m, 
2H), 1.80-1.71 (m, 2H) (Hi-j); δC (100 MHz, CDCl3) 165.9 (Cl), 164.2, 161.7, 139.6, 
137.1, 131.1, 130.5, 130.3, 129.8, 125.9, 123.5, 123.0, 122.2, 116.3, 115.4, 113.8 (Ca-g, 
Cm-t), 49.8, 39.1 (Ch, Ck), 28.4, 26.9 (Ci-j); ESI-IT MS: m/z (M+H+) 414.40 (C26H24FN3O 
requires 413.19); HPLC-DAD: rt = 14.6 min (% area = 88). 
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9-[N-(p-fluorocinnamoyl)aminobutyl]aminoacridine (29f) 
Orange oil (6.8 mg, 3%); RF (DCM/MeOH 
8:2) 0.4; δH (400 MHz, CDCl3); 8.08 (d, 
J= 8.8 Hz, 2H, He), 7.92 (d, J= 8.4 Hz, 
2H, Hb), 7.62-7.42 (m, 5H, Hc, Hn, Hp, -
NH), 7.31-7.23 (m, 2H, Hd), 7.03 (t, J= 
8.4 Hz, 2H, Hq), 6.35 (d, J= 15.6 Hz, 1H, 
Hm), 6.29 (b, 1H, -NH), 3.90-3.83 (m, 2H), 3.48-3.41 (m, 2H) (Hh, Hk), 1.95-1.85 (m, 
2H), 1.78-1.70 (m, 2H) (Hi-j); δC (100 MHz, CDCl3) 166.1 (Cl), 139.8, 130.8, 130.6, 
129.8, 129.6, 129.5, 126.0, 123.8, 123.3, 123.0, 120.4, 116.0, 115.8 (Cm-r), 49.9, 39.1 
(Ch, Ck), 28.5, 27.0 (Ci-j); ESI-IT MS: m/z (M+H+) 414.53 (C26H24FN3O requires 413.19); 
HPLC-DAD: rt = 14.4 min (% Area = 90). 
 
9-[N-(m-nitrocinnamoyl)aminobutyl]aminoacridine (29g) 
Orange solid (3 mg, 1%); mp=65-70oC; RF 
(DCM/MeOH 8:2) 0.4; δH (400 MHz, 
CDCl3) 8.40 (s, 1H, Ht), 8.28-8.24 (m, 1H, 
Hr), 8.17 (dd, J= 8.4 Hz, 1.6Hz, 1H, Hp), 
8.05 (d, J= 8.8 Hz, 2H, He), 7.81-7.75 (m, 
1H, Hq), 7.69-7.49 (m, 4H, Hb, Hn, -NH), 
7.32 (t, J= 7.6 Hz, 2H, Hc), 7.06 (t, J= 7.6 Hz, 2H, Hd), 6.80 (d, J= 16 Hz, 1H, Hm), 6.79 
(b, 1H, -NH), 3.93-3.88 (m, 2H), 3.55-3.49 (m, 2H) (Hh, Hk), 2.11-2.02 (m, 2H), 1.88-1.78 
(m, 2H) (Hi-j); δC (100 MHz, CDCl3) 165.5 (Cl), 155.5, 148.6, 137.7, 136.9, 134.0, 132.7, 
130.7, 129.9, 126.2, 124.4, 123.8, 122.6, 121.7, 120.8, 112.8 (Ca-g, Cm-t), 48.5, 39.1 
(Ch, Ck), 27.7, 26.5 (Ci-j); ESI-IT MS: m/z (M+H+) 441.47 (C26H24N4O3 requires 440.18); 
HPLC-DAD: rt = 14.4 min; (% Area = 92). 
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4.5.2. In silico studies 
 
Fukui indices 
The local fukui indices were calculated to obtain information regarding the electrophilicity 
of the carbonyl group of compound 19a-19b using the following equation: 
 fA+=  PA(N+1)  -­‐  PA(N)    
where fA+ represents the electrophilicity of atom A in a molecule and P the population of 
atom A (with N electrons) in a neutral (N) or anionic molecule (N+1). N and N+1 species 
were obtained from Natural Bond Order population analysis49 for the optimized structures 
of the compounds in the gaseous phase. The calculations took into account the hybrid 
density functional B3LYP50, 51 approach and the 6-31+G(d) basis set as included in the 
Gaussian 03 suite.52 
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5.0. Preamble 
Malaria chemotherapy control strategy relies on the use of safe and highly effective 
drugs to impair the parasite development.1 Chemotherapy combined with other 
strategies such as a preventive vaccination could be a sustainable way to fight against 
malaria. A malaria vaccine should protect not only semi-immune adults but also pregnant 
women and children.2 The latter two groups are the most susceptible to die from the 
disease. In one hand, in infants, the predominance of parasitemia significantly increases 
at 20 weeks of age.3 Children usually start to be more susceptible to fever and severe 
malaria when they become 6 months old although the risk of presenting clinical malaria 
is also dependent on the transmission level.4 On the other hand, pregnant women are 
especially susceptible to malaria, because Pf-infected erythrocytes adhere to the 
placenta.5   
Nowadays, there is not a licensed vaccine that prevents against malaria.6 Most vaccine 
candidates target a single stage of the malaria life cycle and the most efficacious 
vaccines have demonstrated to be those which target the pre-erythrocytic stage of the 
malaria parasite. One example of a pre-erythrocytic vaccine constitute RTS,S, 
formulated as a recombinant protein in an adjuvant, which has shown partial efficacy in 
human trials.7 Still a malaria pre-erythrocytic vaccine should be 100% effective since the 
escape of one liver stage form will lead to a thousand of merozoites.6, 8 However, the 
inadequate understanding of the mechanism of action of RTS,S has hindered its 
subsequent efficacy improvement. In addition, the development of a more efficacious 
vaccine has mainly been impaired by the parasite complexity, the failure to completely 
understand naturally acquired immunity (NAI) to malaria parasites, and the poor 
understanding of the antigenic targets to induce protective immunity.3, 7, 9 
In this context, a three and a half month study was carried out to contribute to the 
understanding of the immune response to Pf in RTS,S-vaccinated children and the effect 
of the intensity of exposure on IgG levels, thus providing input in the development of 
future attempts to improve vaccine efficacy against malaria. The antibody (Ab) 
responses were measured by Luminex assays, which permit the detection of IgG 
responses against multiple antigenic targets. The corresponding experimental procedure 
was carried out at the Barcelona Centre for International Health Research (CRESIB) 
under the direction of Dr. Carlota Dobaño and the laboratory supervision of Joseph J. 
Campo, who also performed the statistical analysis of the data obtained. 
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5.1. Protective immunity to Malaria 
NAI has been observed to be i) effective in adults continuously and heavily exposed to 
the parasite, ii) species-specific, since protection against one parasite species does not 
confer protection against others, but not necessarily strain-specific since strain-
transcendent immunity can be acquired after few infections, and iii) acquired at a rate 
dependent upon the degree of exposure.3 Acquired immunity may be active, a result of 
the immune response of the host due to previous exposure to the parasite, or passive, 
by the transfer of prenatal or postnatal protective immune factors (e.g. antibodies) to the 
child.3 Acquired, or adaptive, immunity against Plasmodium can be generally classified in 
i) anti-disease immunity: decrease the risk of death associated to a given parasite 
density, ii) anti-parasite immunity: influences the density of parasites circulating in the 
body, and iii) premunition: the absence of symptomatic malaria but low burden of 
parasitemia. For instance, most semi-immune adults reside across sub-Saharan Africa 
without experiencing the disease, but with a parasite density in their blood that could 
prove fatal in a person who has never been exposed to the parasite. This last immunity 
takes longer to develop and it might be of shorter duration.3 However, other studies in 
transmigrants have shown adults to acquire clinical immunity rather quickly.10 This 
incomplete immunity is a consequence of Pf’s ability to avoid protective immune effects 
while coexisting with the human host. The slow development of this type of immunity is 
mostly due to the parasite’s ability to evade the host’s immune response by antigenic 
polymorphism.3 Thus, to be superior to this slowly gained exposure-dependent NAI, a 
vaccine is needed to insure long lasting protection.  
Pre-erythrocytic immunity has been achieved by the infection of volunteers with 
irradiated sporozoites. These attenuated sporozoites are capable of liver cell invasion 
but can not complete hepatocyte development or progression to the blood stage.11, 12 
Although immunization by irradiated sporozoites has been proved to be safe and last for 
at least 42 weeks, it requires a minimum of 1000 bites of irradiated mosquitoes in order 
to induce sterile immunity in human,13 a type of immunity that exists after the malaria 
parasite has disappeared from the host. Moreover, the efficacy of this methodology was 
lower compared to the one achieved in rodent models.14 Pre-erythrocytic immunity can 
also be generated by inoculating intact sporozoites while treating with CQ, a drug known 
to impair erythrocytic parasite development but that has no effect on the pre-erythrocytic 
stage of the malaria life cycle, as explained in previous chapters of this dissertation.15 
This model was recently tested in volunteers who have not been previously exposed to 
malaria.16 The study proved to induce immunity in humans by presenting the host 
immune system with a broader range of pre-erythrocytic as well as erythrocytic 
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antigens.16 Strategies for human immunization with whole Pf parasites (attenuated or 
with CQ veil) are presently being actively pursued by many research groups.17 
Antigens generated by recombinant or synthetic peptide chemistry have been other 
methodology used to develop a malaria vaccine. However, these efforts have been 
hindered by the difficulty to identify the target antigens and a specific immune response 
which protects against malaria.18 For instance, the brevity of Ab response and the 
heterogeneity of exposure to malaria are two factors which can hinder individual immune 
responses against malaria related to protection18	   and, consequently, make difficult the 
discovery of antigens which could be used towards the development of vaccines. High 
Ab levels are usually associated with high transmission and Abs tend to be higher in 
those individuals who present parasitemia than those who do not. These types of 
responses are generally observed in children contrary to adults whose Ab responses are 
higher and take more time to wane even in the absence of infection.  
Longitudinal studies where Ab responses drop rapidly over time suggest that Ab 
response to specific antigens might be short-lived.19 For instance, studies done by 
Kinyanjui and co-workers demonstrated the brevity of IgG responses to merozoite 
antigens such as EBA-175 (Erythrocyte binding antigen 175), MSP-1 (Merozoite surface 
protein), and AMA-1 (Apical Membrane Antigen 1) in children from Kenya who were 
recovering from malaria over a period of 12 weeks.19 Accordingly, the majority of the Ab 
responses reached a high peak and then dropped rapidly to low levels in less than eight 
weeks. However, Kinyanjui et al were unable to explain whether this short-lived response 
was characteristic to the antigen and they observed that re-infection seemed to not 
significantly improve the Ab responses. Therefore, it becomes necessary to take into 
account the longevity of the Ab response and transmission heterogeneity for the design 
of serological studies and selection of antigens to develop a vaccine that induces specific 
Ab responses against malaria. In addition, in a study by Greenhouse et al, Ab responses 
were measured against AMA-1, MSP1- and 3 and the results showed that stronger 
immune responses to these antigens were not associated with blood stage protection 
when taking into account prior exposure. Therefore, when analyzing mechanisms of 
protective immune response, the study design should integrate information regarding 
prior exposure, and ideally assess multiple immune responses.20  
Up today, numerous antigens have been identified as potential candidates for the 
development of a malaria vaccine. For instance, a malaria vaccine based on the AMA-1 
antigen has shown to be well-tolerated and induce high and sustained Ab levels in 
children exposed to malaria.21 Other antigens which have shown to be potential 
candidates for a malaria vaccine include CelTOS (Cell-traversal protein for ookinetes 
and sporozoites),22 EBA-175,23 LSA-1 (Liver stage antigen-1),24 and VAR2CSA DBL 
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(Duffy binding-like)25 and SSP2 (Second sporozoite surface protein).26 However, today 
the most studied and developed candidate is the CSP (Circumsporozoite surface 
protein).  
 
5.2. RTS,S malaria vaccine candidate 
 
RTS,S, the most clinically advanced malarial vaccine candidate in the world, contains a 
portion of the CSP.27 The role of CSP in the development of immunity against 
sporozoites has been described.28 CSP is the most prominent protein in the surface of 
sporozoites and is involved in the liver stage invasion of the Pf parasite. CSP promotes 
binding to liver cells, and it is vital for the sporozoite development in the mosquito.29 
Epitopes of CSP are found to react with Abs that inhibit hepatocytic cell invasion and 
also promote an immune response that eliminates the sporozoites from inside liver cells. 
The CSP antigen contains a major B cell epitope composed of repeat amino acid 
sequences Asn-Ala-Asn-Pro (NANP) and Asn-Val-Asp-Pro (NVDP), and CD4+ and CD8+ 
T cell epitopes at the C-terminal end (Fig. 52).30  
 
	  
Figure 52. CSP including its major B cell epitope, CD4+ and CD8+ T cell epitopes at the C-terminal end. 
 
In the RTS,S vaccine, the central repeat and C-terminal portion of the Pf CSP “R” and 
major “T” cell epitopes were combined with the hepatitis B virus surface antigen “S”. 
Subsequently, these fused proteins were auto-assembled as a virus-like particle which 
also includes non-combined “S.”31 RTS,S does not seem to induce strain-specific 
immune responses.32 In addition, CSP itself is poorly immunogenic and therefore, an 
adjuvant needs to be incorporated in the vaccine formulation in order to promote the 
immune response.  
In early clinical trials of RTS,S in adults, the adjuvant which displayed the best results 
was AS0233 which consists of an oil-in-water emulsion combined with two 
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immunostimulants, monophosphoryl Lipid A (MPL), and Quillaja saponaria fraction 21 
known as QS21, with mercury based reagents (thymerosal) used as preservatives. 
RTS,S/AS02 demonstrated to be safe, immunogenic, and partially protective in naïve 
U.S. volunteers and semi-immune adults living in malaria endemic regions,34 which 
required two to three standard 50 µg doses for best efficacy.35 Although thyromerosal 
has proven to be safe, concerns regarding potential neurotoxicity led to its removal from 
AS02 resulting in the new adjuvant AS02A, an oil-in-water emulsion containing the same 
immune stimulants MPL and QS21 but using lactose instead as cryopreservant.27   
In a Phase I trial, RTS,S/AS02A was evaluated for safety and immunogenicity at three 
different doses: 10 µg (10 µg RTS,S in 0.1 mL AS02A), 25 µg (25 µg RTS,S in 0.25 mL 
AS02A) and finally a 50 µg (50 µg RTS,S in 0.5 mL AS02A).36 One hundred and thirty 
five children were enrolled in this study. Based on the results obtained, the 10 µg dose 
displayed lower anti-CSP Ab response than the 50 µg and 25 µg doses. In addition, it 
was demonstrated that the higher the concentration, the lower the safety of the vaccine. 
Accordingly, the 25 µg dose was selected for posterior studies in the pediatric 
population. 
In a Phase IIb trial in Mozambique, children between 1-4 years old were divided in two 
cohorts: cohort 1 (C1) included 1,605 children from Manhiça who were followed by 
passive case detection (PCD), and cohort 2 (C2) constituted by 407 children from Ilha 
Josina followed during the first 6 months post vaccination (M8.5) by active case 
detection and subsequently by PCD.37 More than 92% of the children followed the entire 
protocol receiving all three doses. The results of this trial suggested that RTS,S/AS02A 
was safe and well tolerated, and that malaria transmission was higher in C2 than in C1. 
In addition, the anti-CSP Ab response increased after the third dose, but dropped to a 
quarter of the initial values after six months (M8.5) from the last vaccination, but still 
remaining above baseline values. In C1 RTS,S/AS02A conferred protection of 29.9% 
(95% confidence interval (CI), 11.0%–44.8%; P = 0.004) against the first clinical episode 
and 57.7% (95% CI, 16.2%–80.6%; P = 0.019) against severe malaria. In C2, vaccine 
efficacy was 45% (95%), 31.4%–55.9%; P = 0.001) against infection.37  
An extended follow-up showed that C1 continued to present anti-CSP Ab units 50% 
higher than in the control vaccine group at month 21 (M21).38 The prevalence of asexual 
Pf parasitemia in C2 was similar in the control vaccine group, in contrast with C1, where 
the prevalence of parasitemia was 29% lower than in the control vaccine group. 
However, C2 differs from C1, because C2 was drug-treated to clear parasitemia after the 
final dose, and children from C2 were given treatment if a new infection was detected 
from month 2.5 to M8.5. The latter could account for C2 interrupted exposure to the 
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malaria parasite, and consequently, affecting the development of NAI. The efficacy for 
the extended follow-up period from the third dose to M21 was 35.3% (95% CI, 21.6%–
48.6%; P = 0.001) against clinical malaria and 48.6% (95% CI, 12.3%–71.0%; P= 0.02) 
against severe malaria. 
Subsequently, the efficacy of the vaccine was evaluated at month 45 (M45).39 A limitation 
of the clinical trials is the difficulty to estimate the efficacy of a vaccine over time against 
malaria, when immunity is age and exposure dependent. From the 2,022 children, a total 
of 1,465 completed the follow-up to study month 45. The prevalence of parasitemia was 
lower in RTS,S/AS02A vaccinated children and vaccine efficacy over the entire follow-up 
was 30.5% (95% CI, 18.9%–40.4%) against clinical malaria and 38.3% (95% CI, 3.4%–
61.3%) against severe malaria.39 
In the Phase IIb trial, the difference in naturally acquired Ab responses between children 
vaccinated with RTS,S and control has been evaluated at M8.5 in C1 and C2;40 the time 
when waning efficacy was observed in C2 but not C1. Campo et al. hypothesized that 
since C1 children were exposed to low burden of blood stage parasitemia because they 
were not actively followed and treated, a higher difference of immune response against 
erythrocytic stage antigens between RTS,S and control group should be observed in C1 
compared to C2 at M8.5. However, at month M8.5 there was not a difference between 
groups against all the antigens tested in this study in children ≥ 2 years old (AMA-1-3D7, 
AMA-1-FVO, MSP-142-3D7, MSP-142-FVO, EBA-175) suggesting neither enhancement 
nor impairment of acquired immune response against these antigens. Results were 
unable to explain the waning efficacy in one cohort and not the other. Recent finding 
suggests that waning efficacy in C2 might be due to the fact that higher transmission 
regions presented the lowest RTS,S efficacy.41 Nonetheless, further longitudinal studies 
against blood stage malaria antigens might help to understand whether RTS,S 
vaccination might facilitate a more effective blood stage immune response, 
consequently, generating a long lasting protection against clinical malaria. 
Recently, RTS,S/AS01 is being evaluated in a Phase III trial. In this trial, 15,460 children 
were enrolled in two age categories: i) 6,537 infants between 6 to 12 week of age and ii) 
8,923 children between 5 to 17 months of age. Preliminary results during 12 months of 
follow-up in the first 6,000 children between 5 to 17 months of age who received the 
three RTS,S/AS01 doses demonstrated that the vaccine has an efficacy of 55.8% and 
47.3% against clinical and severe malaria, respectively.42 In this trial, further results,7 
using as  primary end point clinical malaria, suggests that the efficacy reported was 
lower for infants from 6 to 12 week of age than that previously found for children of 5-17 
months of age. WHO will review the results of the RTS,S/AS01 vaccine in 2015 and 
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make a policy recommendation depending on the complete data obtained in Phase III 
trial by 2014.43 
Up to now, it has been demonstrated that anti-CSP IgG response correlate with 
protection against Pf infection44 but not consistently with clinical40 or severe malaria. 
Vaccinated children are still partially protected against clinical and severe malaria after 
43 months of follow-up (with stable efficacy) in some studies37-39 but not in others.45 Also, 
it is known that strong acquired immunity against CSP is not naturally developed. 
However, the interaction between RTS,S vaccination and the development of naturally 
acquired immunity to malaria at different ages and under different transmission 
intensities remains to be established. 
 
5.3. Aim and Scope 
This work aimed to determine naturally acquired IgG Ab acquisition against seven Pf 
antigens in RTS,S-vaccinated and control-vaccinated children at seven different time 
points over a period of 60 months post-vaccination. For this study, 401 among 1,605 
children from Manhiça, Mozambique, who had completed the entire follow-up period (5 
years), were randomly selected from C1. Specifically, the study aims to: 
i. Estimate the rate of Ab acquisition in the RTS,S and control groups. 
ii. Describe the Ab kinetics after parasite exposure. 
iii. Describe the influence of age and transmission co-variates in the Ab responses. 
The antigens selected for this longitudinal study are well characterized and known to 
have important roles in parasite invasion and development in the human host. These 
antigens are being developed as potential vaccine candidates. The antigens are the 
following: 
i. AMA-1 (3D7 and FVO), the polymorphic form expressed in merozoites which is 
involved in erythrocyte invasion.46 
ii. MSP-142 (3D7 and FVO), the major merozoite surface protein which binds to 
erythrocyte and has a role in its invasion.47 
iii. EBA-175, promotes Pf binding to erythrocytes.48  
iv. DBL-alpha, involved in the formation of rosettes, or healthy erythrocytes 
surrounding infected erythrocytes.49    
v. SSP2, presents in the surface of the sporozoite.50 
vi. LSA-1, accumulates in the parasitophorous vacuole of infected hepatocytes 
around the merozoites.51 
vii. CelTOS, mediates malaria invasion into the host.52 
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viii. BSA (bovine serum albumin), a non-Pf malaria antigen used as negative control 
in this study. 
Children were divided into two age groups: < 2 years old and ≥ 2 years old since these 
two groups received different control vaccines. Older children received three doses of 
hepatitis B vaccine (Engerix; GSK) and younger children received 7-valent 
pneumococcal conjugate vaccine (Prevenar;Wyeth LederleVaccines) in the first and third 
vaccination, and in the second vaccination they were administered Haemophilus 
influenzae type B vaccine (Hiberix; GSK Biologicals). The seven different times points 
included for this study were pre-vaccine (D0), month 3 (M3), M8.5, M21, M33, M45, and 
M63, resulting in a total number of 2,807 samples analyzed by Luminex.  
 
5.4. Results and Discussion 
There were only 821 children out of the 1,605 from cohort 1 who had completed the 60 
months of follow-up. Therefore, to test whether a bias was introduced by randomly 
selecting 401 samples from the 821 children instead of making a random selection from 
the 1,605 of entire cohort, the baseline levels of Ab responses against the malaria 
parasite of the 401 children, were measured by immunofluorescence antibody test 
(IFAT), and analyzed at D0, pre-vaccination (Fig. 53). Accordingly, if there were bias in 
the sample selection, a significant difference (p < 0.05) will be observed between the Ab 
responses of RTS,S and control group at D0 meaning imbalance between the Ab 
responses among groups before vaccination. However, such a difference was not 
observed concluding that bias was not introduced in the sample selection.   
 
	  
Figure 53. IFAT titre at baseline for RTS,S (R) and control (C) groups. 	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The non-bias of the selection permitted further analysis of the samples by Luminex. 
Luminex was used for the study because it reduces labor and cost compared to ELISA 
assays.53 Luminex is a fluorescence-based assay using a flow cytometer, which allows 
the quantification of Ab responses against up to 100 proteins in one assay-plate. Since 
the microspheres, also known as beads, are coded with a fluorescent signature, it is 
possible to use a multiple suspension array technology (SAT) to distinguish Ab 
responses to multiple antigens at once.  
The multiplex SAT used included the 9 pre-erythrocytic and erythrocytic antigens and the 
BSA as a negative control. Initially, the beads were coupled to the respective antigens 
using EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) and Sulfo-NHS (N-
hydroxysulfosuccinimide) as coupling reagents (Scheme 16). Sulfo-NHS is a water 
soluble reagent which allows to run the reaction at physiological conditions and 
significantly increases the efficacy of amide bond formation/or coupling reaction since it 
generates a very amine-reactive intermediate which is stable and hydrolyzed relatively 
slowly in water.54 In contrast, EDC alone fails to quickly react, permitting the hydrolysis of 
the corresponding ester intermediate resulting isourea and the inactivation of EDC, and 
consequently, obtainment of the original carboxylic acid, in this case, the uncoupled 
bead. 
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Scheme 16. Microspheres coupling. 
 
The Luminex assay was designed to include in each plate the following: i) all time points 
(M0, M3, M8.5, M21, M33, M45, M63) on the same plate for a child; ii) duplicate 
readings; iii) 2 dilutions of serum or plasma samples (1:500 and 1:20000); iv) positive-
hyperimmune control plasma (adults who were exposed to the parasite and present a 
high Ab response) in two 2 dilutions (1:500 and 1:15000); and v) negative European 
adult control plasma samples. All samples were analyzed following the same protocol 
previously published,40 where the microspheres were initially incubated with the test 
plasma to allow the interaction of the IgG with the different antigens in the multiplex SAT, 
followed by an anti-IgG Ab conjugated to biotin. Finally, a streptavidin-conjugated 
fluorocrome (R-phycoerythrin) was incubated with the bead-antigen-Ab complexes to 
permit the detection and quantification of fluorescence intensity when read in the 
Luminex (Fig. 54).  
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Figure 54. Luminex assays to evaluate the IgG response of each selected child. PBS-BN: 1% BSA/0.05% 
sodium azide in PBS. 
 
A total of 138 Luminex assays were run, 4 of which were repeats, to analyze the 401 
children from C1 and each of the corresponding 7 time points of this longitudinal study. 
Accordingly, there were only four plates from the entire study whose positive control did 
not follow the same trends as the Ab response of positive-hyperimmune controls from 
the rest of the assays, since the Ab responses were lower. Those plates were repeated 
and the new results did follow the desired pattern of Ab response as seen in fig. 55; the 
results of the old 4 plates were discarded. Accordingly, the MFI (median fluorescence 
intensity) results for each sample were normalized using the positive hyperimmune 
control responses as a reference curve for MFI values. To do this, MFI for each analyte 
at each concentration were fit to expected concentrations using a 4-parameter logistic 
regression, as specified: 
 𝑦 = 𝐴 +    𝐷 − 𝐴(1 + 𝑥 𝐶 !) 
 
where A and D are the maximum and minimum asymptotes of the sigmoidal curve, 
respectively, C is the concentration at point of inflection, and B is the slope at point C. 
Using the fit of the positive controls in each plate, MFI values for test samples were 
interpolated and expressed as arbitrary units per mL. For each sample analyzed, there 
were two dilutions. Those MFI results that were too high or low and fell out of the range 
of the positive hyperimmune response were assigned a fixed value correspondingly 
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above or below the asymptotes. Those values where the duplicates resulted in a CV 
(coefficient of variation) greater than 30% were omitted from analysis.  
 
 
	  
Figure 55. Ab responses of positive hyperimmune controls: In the left are all initial assays Ab responses. In 
the right corner are the results once the four assays were repeated. 
 
Evaluation of the Ab units or MFI over time for RTS,S and control group allowed the 
validation of the study since it demonstrated: 
i) Both groups, RTS,S and control, presented low non-specific Ab response against the 
antigen BSA (Fig. 56) and these responses were not significantly different from one 
another. These Ab responses + 2 standard deviations (SD) were used as a threshold for 
seropositivity in this study (a child is considered seropositive if he/she presents Ab units 
over the threshold established using anti-BSA Ab units). 
 
	  
Figure 56. Geometric mean of anti-BSA Ab units of both control (C) and RTS,S (R) group. 
 
ii) Older children (≥ 2 years) presented higher level of Ab units than younger children as 
observed in the Ab breadth over time. Ab breadth is a score calculated by the sum of 
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seropositive antibody responses at the individual level (Fig. 57). These results are in 
agreement with previously reported data.40 
 
 
	  
Figure 57. Ab breadth representation by age. 
 
iii) Cross-strain recognition was evaluated by plotting Ab responses against 3D7 versus 
Ab responses against FVO for AMA-1 and MSP-142, correspondingly. Correlation of the 
Ab responses between strains was assessed using Pearson’s correlation coefficient (ρ), 
where values of ρ between 0.5 and 1 are considered strong correlation (the closer the 
ρ value is to one, the stronger the correlation). Accordingly, ρ values obtained of 0.945 
for AMA-1 and of 0.835 for MSP-142 show strong correlation between the anti-AMA-1 or 
anti-MSP-142 Ab response against the 3D7 and FVO strains. Therefore, high level of Ab 
units were observed against antigen AMA-1 and MSP-142 regardless of the strain tested 
(3D7 and FVO) demonstrating high level of cross-strain recognition which is in 
agreement with previously reported data (Fig. 58).40 
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Figure 58. Anti-AMA-1 (left) and anti-MSP-142 (Right) Ab responses against both strains 3D7 in the “Y” axis 
and FVO in the “X” axis, respectively. Dash lines defines the anti-BSA Ab units + 2SD. 
 
Analysis of the Ab units over time of all results together (Control and RTS,S group 
responses) by geographical area, high Ab units were identified as possible markers of 
areas with higher malaria exposure as observed in the Ab response against AMA-1 3D7 
and the prevalence of parasitemia (% of children with infection) by region (Fig. 59). 
Accordingly, regions 1, 4, 7, 9, 14, 15, and 21, 23, and 24 (See map of Manhiça, 
Mozambique divided by region in Appendix F) represent areas of high malaria 
transmission intensity. This finding might help to monitor trends of the prevalence of 
malaria in certain regions and, consequently, help in the obtainment of information 
regarding the effectiveness of malaria control programs in those areas. Also, these 
results confirm previous findings20, 55 that immunoepidemiology studies need to take into 
account prior exposure in order to better understand mechanism of immune protection. 
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Figure 59. Parasitemia, shown as proportion of children with Pf infection (left), and anti-AMA-1 3D7 Ab units 
(right). The red color indicated the highest prevalence or Ab responses and the yellow the lowest. 
 
5.4.1. Difference between RTS,S and control group 
The Pf parasitemia was examined in both groups (Control and RTS,S) from pre-
vaccination to M63 after vaccination. Data suggest that there is no difference between 
these two groups at M63 which may imply that the efficacy of RTS,S vaccine completely 
disappears after 5 years of the follow-up (Fig. 60). Although the anti-CSP Ab response 
for the 401 samples at M63 was not measured, these data was available for a subset of 
children from the entire cohort. Correspondingly, it could be estimated that at M63 Ab 
levels seemed to continue to drop over time, although the sample size at M63 (n= 220) 
might be too small to draw definite conclusions (Fig. 60). 
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Figure 60. RTS,S (R) and control (C) groups difference in terms of parasitemia (left) and anti-CSP Ab 
response (right). 
 
Furthermore, the difference between the RTS,S and control groups was examined using 
a reverse cumulative distribution of Ab units (See results summarized in table 19). In this 
type of graphic, the proportion of children in each group who presented Ab units at a 
given level are plotted versus Ab units. The difference previously observed in the Ab 
response of older and younger children should not impact the results of this analysis 
because age groups were equally divided between RTS,S and Control vaccinated 
children. Kolmogorov-Smirnov equality-of-distributions test, used to evaluate whether the 
distribution across the two groups of data set is the same, was used to compare 
distributions of Ab units between RTS,S and control group, and only P-values below 0.05 
representing a significant difference between groups are shown in Table 19. Accordingly, 
it was found that the control group seemed to present higher Ab response than the 
RTS,S group for tested antigens (except for AMA-1 FVO) at months 8.5, and/or 21, 
and/or 33, and/or 45.  
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Table 19. Statistically significant difference found (p values lower than 0.05). 
Antigen Month 
P values  
RandC 
(all) 
RandC 
(<2 years) 
RandC 
(≥2 years) 
AMA-1 3D7 33 0.0249 0.0226 0.4757 
AMA-1 FVO NO[a] 
CelTOS 
8.5 0.01 0.4196 0.0801 
33 0.0617 0.8617 0.0418 
DBL-alpha 45 0.0086 0.1064 0.1069 
EBA-175 8.5 0.0068 0.6393 0.0147 
LSA-1 33 0.047 0.5142 0.0212 
MSP-142 3D7 
21 0.0277 0.9904 0.0323 
33 0.0015 0.0126 0.0219 
45 0.0372 0.2094 0.0777 
MSP-142 
FVO 
8.5 0.0016 0.4119 0.014 
21 0.0243 0.77 0.0163 
33 0.0336 0.1841 0.0761 
SPP2 63 0.3406 0.0399 0.9327 
NO: No difference was observed for antigen AMA1-FVO at any time point. P 
values were estimated using Kolmogorov-Smirnov equality-of-distributions test. 
 
 
By examining the Ab responses stratified by age in the RTS,S and control groups, the 
difference becomes less obvious and in some cases it disappears. The latter can be 
observed in the Ab responses against CelTOS at M8.5, DBL-alpha at M45, MSP-142 3D7 
at M45, MSP-142 FVO at M33. These results could be explained by the fact that the total 
sample size including both age groups has higher statistical power than the sample sizes 
of each age group, separately. Ab response with group-wise differences in the younger 
children but not in the total cohort could be explained by the fact that the sample size of 
children ≥ 2 year-old (n=311) is bigger than the < 2 year-old children (n=90). Therefore, it 
could be inferred that older children should have more impact in the outcomes of the 
analysis (anti-SSP2 Ab responses at M63). Results reflecting differences in RTS,S and 
control groups as a whole and in age group <2 year-old, such as Ab responses against 
AMA-1 at M33, independent of strain, are mostly related to the <2 year-old age group. In 
contrast, data which shows difference between RTS,S and control vaccinated children as 
a whole and in group age >2 year-old, such as Ab responses against EBA-175 at M8.5 
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and LSA-1 at M33, are exclusively associated to children ≥ 2 year-old. These findings 
suggest: i) differences in Ab responses between RTS,S and control groups from month 
8.5 on, and ii) Ab responses to studied antigens are age-dependent. 
 
Ab kinetics after malaria exposure 
To estimate the time since last exposure to malaria at each study visit, the PCD follow-
up to identify cases occurring before sampling was used. The pattern of Ab levels 
against time since last exposure to the malaria parasite was evaluated using lowess 
regression, which produced a “smooth” set of predictions for Ab units at small windows 
(bandwidth) of time (since exposure). These graphics represent the Ab responses of 
children measured in one of the studied time points against a specific antigen vs the 
number of days between a scheduled visit (M3, M8.5, M21, M33, M45) and the last 
malaria episode or parasitemia reported before that visit (See fig. 61). Children who were 
parasitemic at time of sample collection were given a value of 0 for time since last 
documented exposure and M63 was not included in this study due to a break in follow-up 
for clinical malaria. As observed, in general, children show a high peak of Ab responses 
against all antigens immediately after a malaria case or parasitemia, especially for AMA-
1 and MSP-1. This high Ab response drops rapidly over time after a malaria event, 
largely disappearing within a 90-days range. After about 180 days had passed from the 
last malaria episode or parasitemia, Ab units continued to decrease, but at a lower rate 
compared to the beginning. In addition, examining the other Ab responses against the 
other antigens from this study, it is possible to notice that most Ab responses stay close 
to the seropositivity threshold.  
 
 
 
 	  
Figure 61. Anti-AMA-1 Ab response (3D7 and FVO) versus time since last exposure (in days) to a malaria 
episode or parasitemia by lowess smoothing analysis. Dot line represents the seropositivity threshold. 
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In addition, when analyzing Ab units over time (in days) until month 43 of the follow-up 
after the third vaccine dose (M45), there seems to be no difference between RTS,S and 
control, as observed in Fig. 62 where the blue and the dark-red dots representing the 
control and RTS,S group, respectively, are equally distributed through time.  
 
 
	  
Figure 62. Anti-AMA-1 and anti-MSP-1 ab responses, respectively, vs time since last exposure (in days). 
Control (C) and RTS,S (R) group. 
 
Qualitative analysis 
Further qualitative analyses were carried and different patterns at the individual level 
were identified. In this analysis, M63 was not considered also due to a break in follow-up 
for clinical malaria. After M33, some children who have previously presented a malaria 
episode later present only parasitemia and high Ab response, but no symptomatic 
malaria, regardless of age and of being from the control or RTS,S group, suggesting a 
level of clinical immunity and maintenance of immune response (ID 347 and 1654 in the 
lattice plot shown below, fig. 63). These children were generally from higher transmission 
regions previously identified (Regions 1,4, 9, 15, 21, 23, 24). Other children did not 
present any Ab responses or malaria episodes during the entire follow up, as in the case 
of subject 1,604, likely due to lack of exposure, which could be justified by the fact that 
Manhiça started with a moderate transmission rate that dropped over time. In addition, a 
small group of children who presented intermediate Ab responses, but one or no malaria 
episodes during the entire follow up, as in subject 928, could indicate low/non-detected 
parasitemia exposure but protection from disease, and/or possible control of parasitemia 
at subpatent levels. Furthermore, some children such as subject 1,371 presented with 
only Ab units against SSP2, which could represent false positives or parasites that never 
made it to the liver. Finally, some other children, probably immune to the disease, 
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presented high Ab units after one malaria episode at the beginning of the follow up but 
no parasitemia or malaria clinical thereafter (ID 318). These data highlight the 
heterogeneity of malaria exposure in Manhiça, Mozambique. 
 
 
	  
Figure 63. Lattice plot of individuals’ antibody levels over time. Each subplot represents a randomly selected 
individual. The title box contains the subject ID for this study, his/her age in years, and which vaccination 
group the individual belongs to (RTS,S or Control). The Ab response against specific antigens is represented 
in colored lines: AMA-1 3D7, black; AMA-1 FVO, maroon; MSP-142 3D7, navy; MSP-142 FVO, green; EBA-
175, orange; LSA-1, purple; SSP2, olive; CelTOS, red; DBL-alpha, blue. Each point represents a cross-
sectional survey sampling. White diamonds represent documented clinical episodes of malaria, and black 
diamonds represent parasitemia at cross-sectional timepoints. The x-axis scale is in days, ranging from 1st 
June 2003 to 1st June 2007 which includes time points from D0 to M45.  
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5.5. Experimental Section 
 
5.5.1. Recombinant proteins 
Recombinant proteins were either bought or previously produced in a research center: 
• BSA: bought from Sigma Aldrich (Tres Cantos, Spain); 
• AMA-1 3D7: produced at International Centre for Genetic Engineering and 
Biotechnology, New Delhi, India (ICGEB); 
• AMA-1 FVO: produced at U.S. Military Malaria Vaccine Program, Walter 
Reed Army Institute of Research, Silver Spring, Maryland, U.S.A. 
(WRAIR); 
• MSP-142 3D7 and FVO: produced at WRAIR; 
• EBA-175 and DBL-alpha: produced at ICGEB; 
• SSP2, LSA-1, and CelTOS: produced at Protein Potential, LLC, Rockville, 
Maryland, U.S.A.. 
5.5.2. Microsphere Coupling 
Microsphere coupling was carried out by a methodology previously described.40 Briefly, a 
SAT panel was prepared to detect the IgG response to a total of 9 pre-erythrocytic and 
erythrocytic Pf antigens and the negative control BSA antigen using Luminex xMAPTMP 
and the Bio-Plex 100 Platform. xMAP regions (35-38, 42-44, 46-47, and 51) were 
selected for each antigen. Microsphere activation was done using 50mg/mL Sulfo-NHS 
(N-hydroxysulfosuccinimide) and 50 mg/mL of EDC (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride) in 80 µL 100 mM of bead activation 
buffer at room temperature for 20 min in reaction tubes protected from light. 
Subsequently, 1 to 5 µg of the corresponding recombinant proteins per million 
microspheres were added and the volume of the resulted solution was increased to 250 
µL using the respective buffer (table 20). Following, the reaction tubes were incubated at 
4oC in a shaker overnight. Finally, microspheres were blocked using 250 µL of 1% BSA 
(w/v) in phosphate-buffered saline (PBS) for 30 min in a shaker. The reaction tubes were 
place into a magnetic separator for 60 sec and the supernatant was removed and the 
microsphere were re-suspended in 500µL of a PBS with 0.05% (w/v) sodium azide 
(PBS-BN), filtered buffer. A Guava PCA desktop cytometer was used to quantify the 
microspheres coupled, and equal amount of each analyte were combined in multiplex 
tubes and stored at 1,000 microspheres/µL at 4oC protected from light. 
. 
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Table 20. Microsphere coupling. 
Antigen 
Antigen 
µg/106 beads 
Protein stock 
concentration 
(mg/mL) 
Antigen 
(µL) 
Buffer 
(µL) 
Region 
AMA-1 3D7 2 0.63 7.94 MES (242) 36 
AMA-1 FVO 2 0.235 21.28 MES (229) 37 
MSP-142 3D7 2 0.58 8.62 MES (241) 38 
MSP-142 FVO 2 0.25 20 MES (230) 42 
EBA-175 2 0.6 8.33 MES (241) 43 
DBL-alpha 2 0.4 12.5 PBS (238) 47 
SPP2 1 2.56 1 PBS (249) 46 
LSA-1 2 1.07 4.7 PBS (245) 44 
CelTOS 5 1.23 10.16 PBS (240) 51 
Each region tube contains 1mL of 2.5x106 beads/tube. BSA was coupled to region 35 using a solution of 
1%BSA in 250µL of PBS. 
 
 
5.5.3. Luminex Assay 
The assay consisted on adding 50 µL of a solution of 1,000 microspheres of the SAT 
previously prepared in PBS-BN to a 96-well plate per well. Following 50 µL of test 
plasmas (1:500 and 1:20000 in PBS-BN) were respectively added to the wells and 
incubated for 1 h with agitation and protected from light. The plates were later washed 
using 0.05% Tween 20 (v/v) in PBS buffer (PBS-T) three times on a Bio-Plex Pro II 
Wash Station and later re-suspended. 100 µL of biotinylated anti-human IgG diluted at 
1:2500 in PBS-BN was applied to all wells and incubated at room temperature for 45 min 
with agitation and protection from light. Subsequently, the plates were washed as before, 
and 100 µL of streptavidin-conjugated R-phycoerythrin diluted 1:1000 in PBS-BN was 
added to each well and incubated for 25 min with agitation and protection from light. 
After plated were washed as explained before, 100 µL of PBS-BN was added to each 
well and the plates were immediately read on the Bio-Plex 100 Luminex machine using 
Bio-Plex Manager software, version 4.0. The panel was designed to include all time 
points (D0, M3, M8.5, M21, M33, M45, M63) for a child, positive hyperimmune control 
(1:500 and 1:15,000), two dilutions 1/500 and 1/20,000 of negative control European 
adults, and duplicate reading for each dilution. 
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6.1. Conclusions 
This doctoral project mainly involved the design, synthesis, and evaluation of two 
generations of compounds as inhibitors Pf malaria growth. First generation of 
compounds, HE[DI]CINs, presented activity in the micromolar range against CQ-
resistant (W2) strain of Pf (IC50 = 0.83- > 10 µM). Results suggested that the MOA of 
HEDICINs was neither inhibition of falcipains’ action or hemozoin formation. For 
instance, the most active compound of the series, 1c, against the parasite development, 
which displayed an IC50 of 830 nM, did not inhibit falcipain action or hemozoin formation. 
The p-NH2 cinnamoyl derivative 1e, was the compound which best reached the goal of 
dual action inhibitors since the latter was very active against β-H formation, presented 
activity against falcipain (IC50 (FP2) = 20.3 µM) and showed antiplasmodial activity (IC50 
(Pf W2) = 3.28 µM). HE[DI]CINs’ results demonstrated the essential role of the: i) 
chloroquinoline core, ii) hydrophobic link, and iii) cinnamoyl moiety in the antiplasmodial 
activity of the compounds. 
In addition, HE[DI]CINs showed to be more efficient inhibitors of babesipain-1 (bbspn-1) 
from B. bigemina than of FP2. In silico studies carried in order to understand the 
interaction of this generation of compounds against bbspn-1 included i) building of a 3D 
structure of bbspn-1 by homology model, ii) detailed assessment of the model obtained 
using ProQ, ProSA, QMEAN, and PROCHECK as validation tools, and iii) docking 
HEDICINs and HECINs against the well validated model built for bbspn-1 to explain the 
in vitro data obtained. Results suggested the chloroquinoline moiety in HECINs 
establishes stronger hydrophobic interactions with S2 site residues, explaining their 
higher efficiency as bbspn-1 inhibitors as compared to results presented against FP2. 
Further in vitro assays need to be carried in order to understand whether the activity of 
HE[DI]CINs against bbspn-1 correlates with the inhibition of the parasite, B. bigemina, 
development. Results in this study could be employed in the development of new leads 
to inhibit bbspn-1. 
Second generation of compounds, HEFLECINs, was designed based on antiplasmodial 
results previously found for HE[DI]CINs. HEFLECINs resulted dual-stage inhibitors since 
they presented activity against blood stage parasite and liver stage parasite, higher or 
comparable to the reference drug, CQ and PQ, respectively. The SAR of the 
HEFLECINs demonstrated the essential roles of i) the 4-amino-7-chloroquinoline, ii) the 
chlorine in position seven of the chloroquinoline ring, iii) the butyl link, and iv) the amide 
bond for the potent antiplasmodial activity of the compounds against both stages. Two of 
the most active HEFLECINs, namely, the p-iPr and the p-Cl cinnamoyl derivatives 13c 
and 13h presented in vitro activity against CQ-resistant W2 strain (IC50 = 11.0-11.6 nM) 
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comparable to artemisinin (IC50 = 9.5 nM), the base compound of ACT. Furthermore, in 
this series, compound 13h and the most potent compound, 13d (IC50 = 20 nM), which 
also complied with Veber, Lipinski, and Leadlikeness filters, displayed activity in vivo 
against P. berghei in rodents. However, these compounds did not inhibit falcipains’ 
action and HEFLECINs’ antiplasmodial activities did not correlate with the ability of the 
compounds to inhibit β-H formation. This lack of correlation could be explained by the 
absence of the tertiary amine at the end of the butyl chain which have been 
demonstrated to also promote accumulation of CQ in the FV.1 Nonetheless, in general, 
compounds displayed higher antiplasmodial activities than their parent drug, CQ. The 
latter demonstrates the existence of an alternative MOA, yet to be elucidated, through 
which these derivatives exert their activity. Preliminary results suggest NPP inhibition 
since compound 13c, one of the best inhibitors of Pf growth, was clearly able to inhibit 
NPP in Plasmodium-infected RBC. Still, alternative mechanisms of action such as CQ-
chemosensitizing activity should not be discarded. In addition, the p-OMe and p-Cl 
derivatives 13d, 28d and 13h were evaluated in vivo against liver stage parasite. 
However, none of the tested derivatives display in vivo activity. This could be explained 
by the fact that most drugs are generally converted into less active or inactive 
compounds when they enter the liver.2 
Since malaria is known to affect mainly low-income/developing countries, significant 
efforts have been made in order to expand access to ACT by supplying this 
chemotherapy at an affordable price to the public and private sectors.3, 4 However, this 
strategy is an unsustainable approach against malaria, thus the need to develop new 
inexpensive drugs which target malaria. All synthetic pathways here developed 
constituted straightforward procedures and involved low cost reagents. Therefore, 
HEFLECINs are not only active against dual-stage forms of the malaria parasite but are 
also affordable. Thus HEFLECINs constitute new antimalarial leads.5 Furthermore, we 
were able to demonstrate that the cinnamoylation boosting effect is also observed on 
other heterocyclic antimalarials such as PQ and AQ, as PRIMACINs 28 were highly 
active against liver stage (IC50 = 1.4-2.4 µM) and AQ-based HEFLECINs 29 displayed 
higher activity against both blood (IC50 = 126-842 nM) and liver stage parasite (IC50 = 
3.2- < 10 µM). Moreover, the second generation of compounds, namely, compounds 13 
and 28 also displayed potent activity against L. infantum. Furthermore, activity of 
HEFLECINs as anti-leishmanial agents suggests that these compounds should be 
evaluated against a broader panel of protozoans. Results obtained so far demonstrated 
cinnamoyl/quinoline derivatives to be new candidate in medicinal chemistry to develop 
novel antiprotozoan agents. 
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This doctoral project further included a longitudinal analysis on the acquisition of IgG 
response to P. falciparum antigens in 401 African children who completed a 60 month 
follow-up after three doses of RTS,S vaccination. Results demonstrated: 
• According to the reverse cumulative distribution of the Ab-responses against the 
antigens included in this study, there seems to be a difference between the 
RTS,S vaccine and control groups which drops over the follow up time.  
• Data from this study contribute to the understanding of the immune response in 
association with intensity of exposure to malaria. High Ab levels against blood 
stage antigens studied could represent markers of malaria exposure.  
• Examining time since last parasite exposure, Ab units drop to low values for each 
evaluated antigen in less than 90 days.  
Moreover, the longitudinal study, carried in the area of malaria prevention, contributes to 
the understanding of the naturally-acquired Ab responses after immunization with the 
partially efficacious RTS,S vaccine in children younger than 5 years old. However, the 
mechanism underlying RTS,S protection is yet to be elucidated. Further studies need to 
be done in order to understand the mode of action of the vaccine and help to develop 
future attempts to improve the efficacy of RTS,S vaccination. Results obtained in this 
three and a half months study contributes to gain insight into the complex immune 
responses against malaria in children under age five vaccinated and exposed to the 
disease. 
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6.2. Future Perspectives 
Further studies needs to be carried to understand the MOA of the compounds 
synthesized in this doctoral project. Most heterocyclic-cinnamic conjugates were already 
sent for their evaluation as inhibitors of NPP in order to assess whether the 
antiplasmodial SAR presented by the compounds correlated with activities against NPP. 
Preclinical studies need to be done to investigate the absorption, distribution, 
metabolism, and excretion (ADME) properties of the compounds. The latter will 
determine which of these properties should be improved and taken into account in 
further structural modifications in order to enhance the in vivo activity displayed by the N-
cinnamoylated derivatives. 
The influence on the substitution of the cinnamoyl moiety by other functionalities should 
also be studied. Preliminary studies suggest that the absence of the cinnamoyl is not 
detrimental for the antiplasmodial activity of the compounds but the substitution of the 
cinnamoyl aromatic ring by alkyl functionalities seems to have a negative impact on the 
stability of the compounds. 
Future studies should be conducted to improve the solubility of the compounds in 
aqueous media. Synthesizing new derivatives with an additional protonable amine, such 
as compounds displayed in Fig. 64, should increase the water solubility and 
consequently the in vivo activity displayed against blood stage by the cinnamoyl 
derivatives. Furthermore, such structural modification might promote compound’s ability 
to inhibit β-H, since the additional protonable amine will also improve accumulation of the 
corresponding compounds in the FV, consequently increasing the antiplasmodial activity 
displayed by the compounds. In fact, Cornut et al recently demonstrated that introduction 
of a basic nitrogen in the spacer of CQ analogues significantly improve the antimalarial 
activity of the respective compounds against CQ-resistant (W2) and CQ-sensitive 
parasite (3D7).6 
 
	  
Figure 64. General structure of the cinnamoyl derivatives including an additional protonable amine. 
 
Preliminary cytotoxic studies against human cell (MKN-28, Caco-2, and MCF-7) have 
been carried. Accordingly, HEFLECINS are only cytotoxic in the micromolar range (IC50 = 
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5.1-59.3 µM). Moreover, compounds demonstrated to be selective for MKN-28, Caco-2, 
and MCF-7 tumor cells over normal HFF-1 cells (IC50 > 100 µM). These results suggest 
HEFLECINs to be a promising start towards the development of new leads to discover 
novel affordable antitumor agents. 
With regards to the longitudinal analysis carried to measure antibody responses to P. 
falciparum antigens in RTS,S-vaccinated children, further analysis of the data and 
additional studies need to be performed in order to draw detailed conclusions regarding 
the influence of RTS,S vaccination on the immune response of children exposed to 
malaria. Moreover, future work includes analyzing the IgG Ab response for C2 against 
these antigens to compare both cohorts (C1 and C2) to better understand why C1 
maintains RTS,S efficacy for 43 months after vaccination, while C2 efficacy disappears 
after 6 months. Other types of Ab response such as IgM and IgG subclasses should be 
also evaluated. Finally, other antigens thought to induce protection should be included in 
future studies, as well as the evaluation of the effect of IgG levels in malaria risk. 
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